US20110015222A1 - Benzoquinolizinium salt derivatives as anticancer agents - Google Patents
Benzoquinolizinium salt derivatives as anticancer agents Download PDFInfo
- Publication number
- US20110015222A1 US20110015222A1 US12/458,657 US45865709A US2011015222A1 US 20110015222 A1 US20110015222 A1 US 20110015222A1 US 45865709 A US45865709 A US 45865709A US 2011015222 A1 US2011015222 A1 US 2011015222A1
- Authority
- US
- United States
- Prior art keywords
- benzodioxolo
- dimethoxy
- dihydrobenzo
- quinolizinium iodide
- ethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- XYIUTVDOILVALE-UHFFFAOYSA-N benzo[a]quinolizin-5-ium Chemical class C1=CC=C2C3=CC=CC=C3C=C[N+]2=C1 XYIUTVDOILVALE-UHFFFAOYSA-N 0.000 title description 4
- 239000002246 antineoplastic agent Substances 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 104
- -1 13-substituted 5,6-dihydrodibenzo[a,g]quinolizinium salt compounds Chemical class 0.000 claims abstract description 78
- 238000000034 method Methods 0.000 claims abstract description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 claims abstract description 6
- 238000004519 manufacturing process Methods 0.000 claims abstract description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 32
- 239000002253 acid Substances 0.000 claims description 24
- BRLDZKPJJNASGG-UHFFFAOYSA-N berbine Chemical class C1=CC=C2CN3CCC4=CC=CC=C4C3CC2=C1 BRLDZKPJJNASGG-UHFFFAOYSA-N 0.000 claims description 17
- DVGXMBLNKPLSPU-UHFFFAOYSA-M quinolizin-5-ium;iodide Chemical compound [I-].C1=CC=CC2=CC=CC=[N+]21 DVGXMBLNKPLSPU-UHFFFAOYSA-M 0.000 claims description 17
- 125000001424 substituent group Chemical group 0.000 claims description 17
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 15
- 229910052757 nitrogen Inorganic materials 0.000 claims description 14
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 12
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 9
- 229920000858 Cyclodextrin Polymers 0.000 claims description 9
- 125000005842 heteroatom Chemical group 0.000 claims description 9
- 229910052740 iodine Inorganic materials 0.000 claims description 9
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 125000005843 halogen group Chemical group 0.000 claims description 8
- 125000000623 heterocyclic group Chemical group 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 8
- 238000007112 amidation reaction Methods 0.000 claims description 7
- 229910052794 bromium Inorganic materials 0.000 claims description 7
- 150000004820 halides Chemical group 0.000 claims description 7
- 125000003118 aryl group Chemical group 0.000 claims description 6
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 6
- 150000002148 esters Chemical class 0.000 claims description 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 6
- KAJSGIRPCBIXMP-UHFFFAOYSA-M 16,17-dimethoxy-21-(3-phenylpropyl)-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene iodide Chemical compound [I-].C=12C3=CC=4OCOC=4C=C3CC[N+]2=CC2=C(OC)C(OC)=CC=C2C=1CCCC1=CC=CC=C1 KAJSGIRPCBIXMP-UHFFFAOYSA-M 0.000 claims description 5
- 125000001246 bromo group Chemical group Br* 0.000 claims description 5
- 229910052801 chlorine Inorganic materials 0.000 claims description 5
- 239000000460 chlorine Substances 0.000 claims description 5
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 150000002367 halogens Chemical class 0.000 claims description 5
- 239000007800 oxidant agent Substances 0.000 claims description 5
- PVWAENUYGVRIAX-UHFFFAOYSA-M 1-(5-chloroindol-1-yl)-2-(16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaen-21-yl)ethanone iodide Chemical compound [I-].C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C(CC(=O)N4C5=CC=C(Cl)C=C5C=C4)=C3C2=CC2=C1OCO2 PVWAENUYGVRIAX-UHFFFAOYSA-M 0.000 claims description 4
- OAVNNXSLMIXUIY-UHFFFAOYSA-M 16,17-dimethoxy-21-[2-(4-methoxyphenyl)ethyl]-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene iodide Chemical compound [I-].C1=CC(OC)=CC=C1CCC1=C(C=2C(=CC=3OCOC=3C=2)CC2)[N+]2=CC2=C(OC)C(OC)=CC=C12 OAVNNXSLMIXUIY-UHFFFAOYSA-M 0.000 claims description 4
- XBPFOEWVPYEKMP-UHFFFAOYSA-M 21-(3,3-diphenylpropyl)-16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene iodide Chemical compound [I-].C=12C3=CC=4OCOC=4C=C3CC[N+]2=CC2=C(OC)C(OC)=CC=C2C=1CCC(C=1C=CC=CC=1)C1=CC=CC=C1 XBPFOEWVPYEKMP-UHFFFAOYSA-M 0.000 claims description 4
- BWWPULJWRSBJOD-UHFFFAOYSA-M 21-[2-(1H-indol-3-yl)ethyl]-16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene iodide Chemical compound [I-].C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C(CCC=4C5=CC=CC=C5NC=4)=C3C2=CC2=C1OCO2 BWWPULJWRSBJOD-UHFFFAOYSA-M 0.000 claims description 4
- XTFBOPGCYNRRPI-UHFFFAOYSA-M 21-[2-(4-chlorophenyl)ethyl]-16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene iodide Chemical compound [I-].C=12C3=CC=4OCOC=4C=C3CC[N+]2=CC2=C(OC)C(OC)=CC=C2C=1CCC1=CC=C(Cl)C=C1 XTFBOPGCYNRRPI-UHFFFAOYSA-M 0.000 claims description 4
- 125000003143 4-hydroxybenzyl group Chemical group [H]C([*])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 claims description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 4
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 claims description 4
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 4
- 229960004853 betadex Drugs 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 claims description 4
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 claims description 4
- 229940080345 gamma-cyclodextrin Drugs 0.000 claims description 4
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 4
- 125000000335 thiazolyl group Chemical group 0.000 claims description 4
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 3
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 3
- WMBPMMINQFZICQ-UHFFFAOYSA-M 16,17-dimethoxy-21-(2-naphthalen-1-ylethyl)-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene iodide Chemical compound [I-].C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C(CCC=4C5=CC=CC=C5C=CC=4)=C3C2=CC2=C1OCO2 WMBPMMINQFZICQ-UHFFFAOYSA-M 0.000 claims description 3
- ONFXUOGUFBPBQY-UHFFFAOYSA-M 16,17-dimethoxy-21-(2-phenoxyethyl)-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene iodide Chemical compound [I-].C=12C3=CC=4OCOC=4C=C3CC[N+]2=CC2=C(OC)C(OC)=CC=C2C=1CCOC1=CC=CC=C1 ONFXUOGUFBPBQY-UHFFFAOYSA-M 0.000 claims description 3
- ZSERCDNBKZIAJK-UHFFFAOYSA-M 16,17-dimethoxy-21-(2-phenylethyl)-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene iodide Chemical compound [I-].C=12C3=CC=4OCOC=4C=C3CC[N+]2=CC2=C(OC)C(OC)=CC=C2C=1CCC1=CC=CC=C1 ZSERCDNBKZIAJK-UHFFFAOYSA-M 0.000 claims description 3
- AXSGYZODTREFAT-UHFFFAOYSA-M 16,17-dimethoxy-21-(2-phenylmethoxyethyl)-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene iodide Chemical compound [I-].C=12C3=CC=4OCOC=4C=C3CC[N+]2=CC2=C(OC)C(OC)=CC=C2C=1CCOCC1=CC=CC=C1 AXSGYZODTREFAT-UHFFFAOYSA-M 0.000 claims description 3
- JABTTWZTZQFHRP-UHFFFAOYSA-M 16,17-dimethoxy-21-(phenylmethoxymethyl)-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene iodide Chemical compound [I-].C=12C3=CC=4OCOC=4C=C3CC[N+]2=CC2=C(OC)C(OC)=CC=C2C=1COCC1=CC=CC=C1 JABTTWZTZQFHRP-UHFFFAOYSA-M 0.000 claims description 3
- NXEAKTAYNNMSFU-UHFFFAOYSA-M 16,17-dimethoxy-21-[(4-methoxyphenyl)methoxymethyl]-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene iodide Chemical compound [I-].C1=CC(OC)=CC=C1COCC1=C(C=2C(=CC=3OCOC=3C=2)CC2)[N+]2=CC2=C(OC)C(OC)=CC=C12 NXEAKTAYNNMSFU-UHFFFAOYSA-M 0.000 claims description 3
- YKTLIUGQIVJGPT-UHFFFAOYSA-M 16,17-dimethoxy-21-[2-(4-methoxynaphthalen-1-yl)ethyl]-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene iodide Chemical compound [I-].C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C(CCC=4C5=CC=CC=C5C(OC)=CC=4)=C3C2=CC2=C1OCO2 YKTLIUGQIVJGPT-UHFFFAOYSA-M 0.000 claims description 3
- MUMGFVVVKVWKJG-UHFFFAOYSA-M 16,17-dimethoxy-21-[2-(4-methoxyphenoxy)ethyl]-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene iodide Chemical compound [I-].C1=CC(OC)=CC=C1OCCC1=C(C=2C(=CC=3OCOC=3C=2)CC2)[N+]2=CC2=C(OC)C(OC)=CC=C12 MUMGFVVVKVWKJG-UHFFFAOYSA-M 0.000 claims description 3
- TZWSCWZEEZGCOC-UHFFFAOYSA-M 16,17-dimethoxy-21-[2-(4-methylphenyl)ethyl]-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene iodide Chemical compound [I-].C=12C3=CC=4OCOC=4C=C3CC[N+]2=CC2=C(OC)C(OC)=CC=C2C=1CCC1=CC=C(C)C=C1 TZWSCWZEEZGCOC-UHFFFAOYSA-M 0.000 claims description 3
- QRJGZVGDRYGCDD-UHFFFAOYSA-M 16,17-dimethoxy-21-[2-(4-nitronaphthalen-1-yl)ethyl]-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene iodide Chemical compound [I-].C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C(CCC=4C5=CC=CC=C5C([N+]([O-])=O)=CC=4)=C3C2=CC2=C1OCO2 QRJGZVGDRYGCDD-UHFFFAOYSA-M 0.000 claims description 3
- DYMKLSFXKMHDPQ-UHFFFAOYSA-M 16,17-dimethoxy-21-[2-(4-nitrophenyl)ethyl]-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene iodide Chemical compound [I-].C=12C3=CC=4OCOC=4C=C3CC[N+]2=CC2=C(OC)C(OC)=CC=C2C=1CCC1=CC=C([N+]([O-])=O)C=C1 DYMKLSFXKMHDPQ-UHFFFAOYSA-M 0.000 claims description 3
- FECTUTZJFASEFV-UHFFFAOYSA-M 16,17-dimethoxy-21-[2-(5-methoxy-1H-indol-3-yl)ethyl]-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene iodide Chemical compound [I-].COC1=CC=C2C(CCC3=CNC4=CC=C(C=C43)OC)=C(C=3C(=CC=4OCOC=4C=3)CC3)[N+]3=CC2=C1OC FECTUTZJFASEFV-UHFFFAOYSA-M 0.000 claims description 3
- GGPWXVDGWUCDSF-UHFFFAOYSA-M 16,17-dimethoxy-21-[2-(5-nitro-1H-indol-3-yl)ethyl]-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene iodide Chemical compound [I-].C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C(CCC=4C5=CC(=CC=C5NC=4)[N+]([O-])=O)=C3C2=CC2=C1OCO2 GGPWXVDGWUCDSF-UHFFFAOYSA-M 0.000 claims description 3
- JLWPXPQVBWQVPV-UHFFFAOYSA-M 16,17-dimethoxy-21-[2-[(4-methoxyphenyl)methoxy]ethyl]-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene iodide Chemical compound [I-].C1=CC(OC)=CC=C1COCCC1=C(C=2C(=CC=3OCOC=3C=2)CC2)[N+]2=CC2=C(OC)C(OC)=CC=C12 JLWPXPQVBWQVPV-UHFFFAOYSA-M 0.000 claims description 3
- SAMXRJPOOXZABY-UHFFFAOYSA-M 16,17-dimethoxy-21-[2-[4-(trifluoromethoxy)phenyl]ethyl]-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene iodide Chemical compound [I-].C=12C3=CC=4OCOC=4C=C3CC[N+]2=CC2=C(OC)C(OC)=CC=C2C=1CCC1=CC=C(OC(F)(F)F)C=C1 SAMXRJPOOXZABY-UHFFFAOYSA-M 0.000 claims description 3
- LMXGLYVIZWTMAZ-UHFFFAOYSA-M 16,17-dimethoxy-21-[2-[4-(trifluoromethyl)phenyl]ethyl]-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene iodide Chemical compound [I-].C=12C3=CC=4OCOC=4C=C3CC[N+]2=CC2=C(OC)C(OC)=CC=C2C=1CCC1=CC=C(C(F)(F)F)C=C1 LMXGLYVIZWTMAZ-UHFFFAOYSA-M 0.000 claims description 3
- WDWCKAZTAJIZJI-UHFFFAOYSA-M 16,17-dimethoxy-21-[3-(4-methoxynaphthalen-1-yl)propyl]-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene iodide Chemical compound [I-].C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C(CCCC=4C5=CC=CC=C5C(OC)=CC=4)=C3C2=CC2=C1OCO2 WDWCKAZTAJIZJI-UHFFFAOYSA-M 0.000 claims description 3
- UFCYTOPVEQBMMP-UHFFFAOYSA-M 16,17-dimethoxy-21-[3-(4-methoxyphenoxy)propyl]-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene iodide Chemical compound [I-].C1=CC(OC)=CC=C1OCCCC1=C(C=2C(=CC=3OCOC=3C=2)CC2)[N+]2=CC2=C(OC)C(OC)=CC=C12 UFCYTOPVEQBMMP-UHFFFAOYSA-M 0.000 claims description 3
- CCMYROBIVBKDGF-UHFFFAOYSA-M 16,17-dimethoxy-21-[3-(4-methoxyphenyl)propyl]-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene iodide Chemical compound [I-].C1=CC(OC)=CC=C1CCCC1=C(C=2C(=CC=3OCOC=3C=2)CC2)[N+]2=CC2=C(OC)C(OC)=CC=C12 CCMYROBIVBKDGF-UHFFFAOYSA-M 0.000 claims description 3
- IDXYTSGEXWWPPE-UHFFFAOYSA-M 16,17-dimethoxy-21-[3-(4-methylphenyl)propyl]-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene iodide Chemical compound [I-].C=12C3=CC=4OCOC=4C=C3CC[N+]2=CC2=C(OC)C(OC)=CC=C2C=1CCCC1=CC=C(C)C=C1 IDXYTSGEXWWPPE-UHFFFAOYSA-M 0.000 claims description 3
- HMYLESWJBNUHMY-UHFFFAOYSA-M 16,17-dimethoxy-21-[3-(4-nitrophenyl)propyl]-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene iodide Chemical compound [I-].C=12C3=CC=4OCOC=4C=C3CC[N+]2=CC2=C(OC)C(OC)=CC=C2C=1CCCC1=CC=C([N+]([O-])=O)C=C1 HMYLESWJBNUHMY-UHFFFAOYSA-M 0.000 claims description 3
- TUYXJCWZLLJQCJ-UHFFFAOYSA-M 16,17-dimethoxy-21-[3-(4-phenoxyphenyl)propyl]-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene iodide Chemical compound [I-].C=12C3=CC=4OCOC=4C=C3CC[N+]2=CC2=C(OC)C(OC)=CC=C2C=1CCCC(C=C1)=CC=C1OC1=CC=CC=C1 TUYXJCWZLLJQCJ-UHFFFAOYSA-M 0.000 claims description 3
- FCVMMFOFCFAESH-UHFFFAOYSA-M 16,17-dimethoxy-21-[3-(5-methoxy-1H-indol-3-yl)propyl]-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene iodide Chemical compound [I-].COC1=CC=C2C(CCCC3=CNC4=CC=C(C=C43)OC)=C(C=3C(=CC=4OCOC=4C=3)CC3)[N+]3=CC2=C1OC FCVMMFOFCFAESH-UHFFFAOYSA-M 0.000 claims description 3
- HHXDANHHPFJPOK-UHFFFAOYSA-M 16,17-dimethoxy-21-[3-(5-nitro-1H-indol-3-yl)propyl]-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene iodide Chemical compound [I-].C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C(CCCC=4C5=CC(=CC=C5NC=4)[N+]([O-])=O)=C3C2=CC2=C1OCO2 HHXDANHHPFJPOK-UHFFFAOYSA-M 0.000 claims description 3
- VSTALBGPJQRBOM-UHFFFAOYSA-M 16,17-dimethoxy-21-[3-[4-(trifluoromethoxy)phenyl]propyl]-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene iodide Chemical compound [I-].C=12C3=CC=4OCOC=4C=C3CC[N+]2=CC2=C(OC)C(OC)=CC=C2C=1CCCC1=CC=C(OC(F)(F)F)C=C1 VSTALBGPJQRBOM-UHFFFAOYSA-M 0.000 claims description 3
- BFGIYKNMNBOLEZ-UHFFFAOYSA-M 16,17-dimethoxy-21-[3-[4-(trifluoromethyl)phenyl]propyl]-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene iodide Chemical compound [I-].C=12C3=CC=4OCOC=4C=C3CC[N+]2=CC2=C(OC)C(OC)=CC=C2C=1CCCC1=CC=C(C(F)(F)F)C=C1 BFGIYKNMNBOLEZ-UHFFFAOYSA-M 0.000 claims description 3
- VPHRLTRQJKRWHM-UHFFFAOYSA-N 2-(16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaen-21-yl)-1-(5-hydroxyindol-1-yl)ethanone iodide Chemical compound [I-].C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C(CC(=O)N4C5=CC=C(O)C=C5C=C4)=C3C2=CC2=C1OCO2 VPHRLTRQJKRWHM-UHFFFAOYSA-N 0.000 claims description 3
- TZCIUYPCXAYSKZ-UHFFFAOYSA-M 2-(16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaen-21-yl)-1-[5-(dimethylamino)indol-1-yl]ethanone iodide Chemical compound [I-].C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C(CC(=O)N4C5=CC=C(C=C5C=C4)N(C)C)=C3C2=CC2=C1OCO2 TZCIUYPCXAYSKZ-UHFFFAOYSA-M 0.000 claims description 3
- BMFRGDJAPJIVID-UHFFFAOYSA-N 2-(16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaen-21-yl)-N-(4-hydroxyphenyl)acetamide iodide Chemical compound [I-].C=12C3=CC=4OCOC=4C=C3CC[N+]2=CC2=C(OC)C(OC)=CC=C2C=1CC(=O)NC1=CC=C(O)C=C1 BMFRGDJAPJIVID-UHFFFAOYSA-N 0.000 claims description 3
- UOEIDOCWAHACIA-UHFFFAOYSA-N 2-(16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaen-21-yl)-N-(4-methoxyphenyl)acetamide iodide Chemical compound [I-].C1=CC(OC)=CC=C1NC(=O)CC1=C(C=2C(=CC=3OCOC=3C=2)CC2)[N+]2=CC2=C(OC)C(OC)=CC=C12 UOEIDOCWAHACIA-UHFFFAOYSA-N 0.000 claims description 3
- FQTPMWFIVQNKJP-UHFFFAOYSA-N 2-(16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaen-21-yl)-N-[(4-methoxyphenyl)methyl]acetamide iodide Chemical compound [I-].C1=CC(OC)=CC=C1CNC(=O)CC1=C(C=2C(=CC=3OCOC=3C=2)CC2)[N+]2=CC2=C(OC)C(OC)=CC=C12 FQTPMWFIVQNKJP-UHFFFAOYSA-N 0.000 claims description 3
- YWACJRVZPOROIH-UHFFFAOYSA-N 2-(16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaen-21-yl)-N-[4-(dimethylamino)phenyl]acetamide iodide Chemical compound [I-].C=12C3=CC=4OCOC=4C=C3CC[N+]2=CC2=C(OC)C(OC)=CC=C2C=1CC(=O)NC1=CC=C(N(C)C)C=C1 YWACJRVZPOROIH-UHFFFAOYSA-N 0.000 claims description 3
- FAKNMNUUTNHJTR-UHFFFAOYSA-N 2-(16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaen-21-yl)-N-[[4-(dimethylamino)phenyl]methyl]acetamide iodide Chemical compound [I-].C=12C3=CC=4OCOC=4C=C3CC[N+]2=CC2=C(OC)C(OC)=CC=C2C=1CC(=O)NCC1=CC=C(N(C)C)C=C1 FAKNMNUUTNHJTR-UHFFFAOYSA-N 0.000 claims description 3
- WUCPVDNCAPPRTH-UHFFFAOYSA-N 2-(16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaen-21-yl)-N-phenylacetamide iodide Chemical compound [I-].C=12C3=CC=4OCOC=4C=C3CC[N+]2=CC2=C(OC)C(OC)=CC=C2C=1CC(=O)NC1=CC=CC=C1 WUCPVDNCAPPRTH-UHFFFAOYSA-N 0.000 claims description 3
- OVXSAVDAYHMIID-UHFFFAOYSA-N 2-(16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaen-21-yl)-N-pyridin-4-ylacetamide iodide Chemical compound [I-].C=12C3=CC=4OCOC=4C=C3CC[N+]2=CC2=C(OC)C(OC)=CC=C2C=1CC(=O)NC1=CC=NC=C1 OVXSAVDAYHMIID-UHFFFAOYSA-N 0.000 claims description 3
- ZSCPHBCBJMDTQB-UHFFFAOYSA-N 2-(4-chlorophenyl)-N-[(16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaen-21-yl)methyl]acetamide iodide Chemical compound [I-].C=12C3=CC=4OCOC=4C=C3CC[N+]2=CC2=C(OC)C(OC)=CC=C2C=1CNC(=O)CC1=CC=C(Cl)C=C1 ZSCPHBCBJMDTQB-UHFFFAOYSA-N 0.000 claims description 3
- BTUJKYJTNKWRCK-UHFFFAOYSA-M 21-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)-16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene chloride Chemical compound [Cl-].C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C(CC4OC5=CC=CC=C5OC4)=C3C2=CC2=C1OCO2 BTUJKYJTNKWRCK-UHFFFAOYSA-M 0.000 claims description 3
- DMDYOMMOIBSSOF-UHFFFAOYSA-M 21-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)-16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene iodide Chemical compound [I-].C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C(CC4OC5=CC=CC=C5OC4)=C3C2=CC2=C1OCO2 DMDYOMMOIBSSOF-UHFFFAOYSA-M 0.000 claims description 3
- ZMLHQLWLPSYQFK-UHFFFAOYSA-M 21-(2-benzhydryloxyethyl)-16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene iodide Chemical compound [I-].C=12C3=CC=4OCOC=4C=C3CC[N+]2=CC2=C(OC)C(OC)=CC=C2C=1CCOC(C=1C=CC=CC=1)C1=CC=CC=C1 ZMLHQLWLPSYQFK-UHFFFAOYSA-M 0.000 claims description 3
- GYKGOLOMIQOSOW-UHFFFAOYSA-M 21-[(4-chlorophenyl)methoxymethyl]-16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene iodide Chemical compound [I-].C=12C3=CC=4OCOC=4C=C3CC[N+]2=CC2=C(OC)C(OC)=CC=C2C=1COCC1=CC=C(Cl)C=C1 GYKGOLOMIQOSOW-UHFFFAOYSA-M 0.000 claims description 3
- ILEVQKUXELABQT-UHFFFAOYSA-M 21-[2,2-bis(4-bromophenyl)ethyl]-16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene iodide Chemical compound [I-].C=12C3=CC=4OCOC=4C=C3CC[N+]2=CC2=C(OC)C(OC)=CC=C2C=1CC(C=1C=CC(Br)=CC=1)C1=CC=C(Br)C=C1 ILEVQKUXELABQT-UHFFFAOYSA-M 0.000 claims description 3
- AHPQWRLZXNYMDC-UHFFFAOYSA-M 21-[2,2-bis(4-chlorophenyl)ethyl]-16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene iodide Chemical compound [I-].C=12C3=CC=4OCOC=4C=C3CC[N+]2=CC2=C(OC)C(OC)=CC=C2C=1CC(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 AHPQWRLZXNYMDC-UHFFFAOYSA-M 0.000 claims description 3
- WNXTXIBWPACRDB-UHFFFAOYSA-M 21-[2,2-bis(4-fluorophenyl)ethyl]-16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene iodide Chemical compound [I-].C=12C3=CC=4OCOC=4C=C3CC[N+]2=CC2=C(OC)C(OC)=CC=C2C=1CC(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 WNXTXIBWPACRDB-UHFFFAOYSA-M 0.000 claims description 3
- GAEUKZCVAYGLRA-UHFFFAOYSA-M 21-[2,2-bis(4-methoxyphenyl)ethyl]-16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene iodide Chemical compound [I-].C1=CC(OC)=CC=C1C(C=1C=CC(OC)=CC=1)CC1=C(C=2C(=CC=3OCOC=3C=2)CC2)[N+]2=CC2=C(OC)C(OC)=CC=C12 GAEUKZCVAYGLRA-UHFFFAOYSA-M 0.000 claims description 3
- VPEKNORIKSCGRU-UHFFFAOYSA-M 21-[2,2-bis(4-methylphenyl)ethyl]-16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene iodide Chemical compound [I-].C=12C3=CC=4OCOC=4C=C3CC[N+]2=CC2=C(OC)C(OC)=CC=C2C=1CC(C=1C=CC(C)=CC=1)C1=CC=C(C)C=C1 VPEKNORIKSCGRU-UHFFFAOYSA-M 0.000 claims description 3
- PSPUHEZMYLJIII-UHFFFAOYSA-M 21-[2-(4-bromophenyl)ethyl]-16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene iodide Chemical compound [I-].C=12C3=CC=4OCOC=4C=C3CC[N+]2=CC2=C(OC)C(OC)=CC=C2C=1CCC1=CC=C(Br)C=C1 PSPUHEZMYLJIII-UHFFFAOYSA-M 0.000 claims description 3
- LROCCZLRRFTPTR-UHFFFAOYSA-M 21-[2-(4-chloronaphthalen-1-yl)ethyl]-16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene iodide Chemical compound [I-].C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C(CCC=4C5=CC=CC=C5C(Cl)=CC=4)=C3C2=CC2=C1OCO2 LROCCZLRRFTPTR-UHFFFAOYSA-M 0.000 claims description 3
- LJICYPLWCYNWDC-UHFFFAOYSA-M 21-[2-(4-chlorophenoxy)ethyl]-16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene iodide Chemical compound [I-].C=12C3=CC=4OCOC=4C=C3CC[N+]2=CC2=C(OC)C(OC)=CC=C2C=1CCOC1=CC=C(Cl)C=C1 LJICYPLWCYNWDC-UHFFFAOYSA-M 0.000 claims description 3
- XKRSIFUWUZTKEO-UHFFFAOYSA-M 21-[2-(4-fluorophenyl)ethyl]-16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene iodide Chemical compound [I-].C=12C3=CC=4OCOC=4C=C3CC[N+]2=CC2=C(OC)C(OC)=CC=C2C=1CCC1=CC=C(F)C=C1 XKRSIFUWUZTKEO-UHFFFAOYSA-M 0.000 claims description 3
- STIYOOVBLJOEDQ-UHFFFAOYSA-M 21-[2-[(4-chlorophenyl)methoxy]ethyl]-16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene iodide Chemical compound [I-].C=12C3=CC=4OCOC=4C=C3CC[N+]2=CC2=C(OC)C(OC)=CC=C2C=1CCOCC1=CC=C(Cl)C=C1 STIYOOVBLJOEDQ-UHFFFAOYSA-M 0.000 claims description 3
- NUHVXGLSFHEWIM-UHFFFAOYSA-M 21-[3,3-bis(4-bromophenyl)propyl]-16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene iodide Chemical compound [I-].C=12C3=CC=4OCOC=4C=C3CC[N+]2=CC2=C(OC)C(OC)=CC=C2C=1CCC(C=1C=CC(Br)=CC=1)C1=CC=C(Br)C=C1 NUHVXGLSFHEWIM-UHFFFAOYSA-M 0.000 claims description 3
- MOMFATHKUBOYNA-UHFFFAOYSA-M 21-[3,3-bis(4-chlorophenyl)propyl]-16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene iodide Chemical compound [I-].C=12C3=CC=4OCOC=4C=C3CC[N+]2=CC2=C(OC)C(OC)=CC=C2C=1CCC(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 MOMFATHKUBOYNA-UHFFFAOYSA-M 0.000 claims description 3
- XKAQZRLVUKDSDO-UHFFFAOYSA-M 21-[3,3-bis(4-fluorophenyl)propyl]-16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene iodide Chemical compound [I-].C=12C3=CC=4OCOC=4C=C3CC[N+]2=CC2=C(OC)C(OC)=CC=C2C=1CCC(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 XKAQZRLVUKDSDO-UHFFFAOYSA-M 0.000 claims description 3
- MYCGJSGNKWWRGW-UHFFFAOYSA-M 21-[3,3-bis(4-methoxyphenyl)propyl]-16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene iodide Chemical compound [I-].C1=CC(OC)=CC=C1C(C=1C=CC(OC)=CC=1)CCC1=C(C=2C(=CC=3OCOC=3C=2)CC2)[N+]2=CC2=C(OC)C(OC)=CC=C12 MYCGJSGNKWWRGW-UHFFFAOYSA-M 0.000 claims description 3
- SPTKMSRDHDBVFZ-UHFFFAOYSA-M 21-[3,3-bis(4-methylphenyl)propyl]-16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene iodide Chemical compound [I-].C=12C3=CC=4OCOC=4C=C3CC[N+]2=CC2=C(OC)C(OC)=CC=C2C=1CCC(C=1C=CC(C)=CC=1)C1=CC=C(C)C=C1 SPTKMSRDHDBVFZ-UHFFFAOYSA-M 0.000 claims description 3
- CGPKBZYCVCYPGL-UHFFFAOYSA-M 21-[3-(4-bromophenyl)propyl]-16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene iodide Chemical compound [I-].C=12C3=CC=4OCOC=4C=C3CC[N+]2=CC2=C(OC)C(OC)=CC=C2C=1CCCC1=CC=C(Br)C=C1 CGPKBZYCVCYPGL-UHFFFAOYSA-M 0.000 claims description 3
- YRULCDYLASMHEF-UHFFFAOYSA-M 21-[3-(4-chlorophenoxy)propyl]-16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene iodide Chemical compound [I-].C=12C3=CC=4OCOC=4C=C3CC[N+]2=CC2=C(OC)C(OC)=CC=C2C=1CCCOC1=CC=C(Cl)C=C1 YRULCDYLASMHEF-UHFFFAOYSA-M 0.000 claims description 3
- OOHNYJZROJCTJX-UHFFFAOYSA-M 21-[3-(4-chlorophenyl)propyl]-16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene iodide Chemical compound [I-].C=12C3=CC=4OCOC=4C=C3CC[N+]2=CC2=C(OC)C(OC)=CC=C2C=1CCCC1=CC=C(Cl)C=C1 OOHNYJZROJCTJX-UHFFFAOYSA-M 0.000 claims description 3
- OGQKODUEFJNFLY-UHFFFAOYSA-M 21-[3-(4-fluorophenyl)propyl]-16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene iodide Chemical compound [I-].C=12C3=CC=4OCOC=4C=C3CC[N+]2=CC2=C(OC)C(OC)=CC=C2C=1CCCC1=CC=C(F)C=C1 OGQKODUEFJNFLY-UHFFFAOYSA-M 0.000 claims description 3
- NIKLPNKJRGVLNA-UHFFFAOYSA-M 21-[3-(5-chloro-1H-indol-3-yl)propyl]-16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene iodide Chemical compound [I-].C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C(CCCC=4C5=CC(Cl)=CC=C5NC=4)=C3C2=CC2=C1OCO2 NIKLPNKJRGVLNA-UHFFFAOYSA-M 0.000 claims description 3
- MGLPYWKWXWYUDM-UHFFFAOYSA-M 4-[(16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaen-21-yl)methoxymethyl]-N,N-dimethylaniline iodide Chemical compound [I-].C=12C3=CC=4OCOC=4C=C3CC[N+]2=CC2=C(OC)C(OC)=CC=C2C=1COCC1=CC=C(N(C)C)C=C1 MGLPYWKWXWYUDM-UHFFFAOYSA-M 0.000 claims description 3
- GHXYOCZSPAYDJQ-UHFFFAOYSA-N 4-[(16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaen-21-yl)methoxymethyl]phenol iodide Chemical compound [I-].C=12C3=CC=4OCOC=4C=C3CC[N+]2=CC2=C(OC)C(OC)=CC=C2C=1COCC1=CC=C(O)C=C1 GHXYOCZSPAYDJQ-UHFFFAOYSA-N 0.000 claims description 3
- AGDKPGXACURWOE-UHFFFAOYSA-N 4-[2-(16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaen-21-yl)ethoxy]phenol iodide Chemical compound [I-].C=12C3=CC=4OCOC=4C=C3CC[N+]2=CC2=C(OC)C(OC)=CC=C2C=1CCOC1=CC=C(O)C=C1 AGDKPGXACURWOE-UHFFFAOYSA-N 0.000 claims description 3
- WFNFXEHHOXXIQS-UHFFFAOYSA-N 4-[2-(16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaen-21-yl)ethoxymethyl]phenol iodide Chemical compound [I-].C=12C3=CC=4OCOC=4C=C3CC[N+]2=CC2=C(OC)C(OC)=CC=C2C=1CCOCC1=CC=C(O)C=C1 WFNFXEHHOXXIQS-UHFFFAOYSA-N 0.000 claims description 3
- DKGAVSYLKJJODX-UHFFFAOYSA-M 4-[2-(16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaen-21-yl)ethyl]-N,N-dimethylaniline iodide Chemical compound [I-].C=12C3=CC=4OCOC=4C=C3CC[N+]2=CC2=C(OC)C(OC)=CC=C2C=1CCC1=CC=C(N(C)C)C=C1 DKGAVSYLKJJODX-UHFFFAOYSA-M 0.000 claims description 3
- CFWGLBGEPUEIAR-UHFFFAOYSA-N 4-[3-(16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaen-21-yl)propoxy]phenol iodide Chemical compound [I-].C=12C3=CC=4OCOC=4C=C3CC[N+]2=CC2=C(OC)C(OC)=CC=C2C=1CCCOC1=CC=C(O)C=C1 CFWGLBGEPUEIAR-UHFFFAOYSA-N 0.000 claims description 3
- VJFKLCWTNRNWJX-UHFFFAOYSA-M 4-[3-(16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaen-21-yl)propyl]-N,N-dimethylaniline iodide Chemical compound [I-].C=12C3=CC=4OCOC=4C=C3CC[N+]2=CC2=C(OC)C(OC)=CC=C2C=1CCCC1=CC=C(N(C)C)C=C1 VJFKLCWTNRNWJX-UHFFFAOYSA-M 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 3
- KVJMSZCYUKGMSK-UHFFFAOYSA-N N-(4-chlorophenyl)-2-(16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaen-21-yl)acetamide iodide Chemical compound [I-].C=12C3=CC=4OCOC=4C=C3CC[N+]2=CC2=C(OC)C(OC)=CC=C2C=1CC(=O)NC1=CC=C(Cl)C=C1 KVJMSZCYUKGMSK-UHFFFAOYSA-N 0.000 claims description 3
- SSEHMDOSMVRKGQ-UHFFFAOYSA-N N-[(16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaen-21-yl)methyl]-2-(4-hydroxyphenyl)acetamide iodide Chemical compound [I-].C=12C3=CC=4OCOC=4C=C3CC[N+]2=CC2=C(OC)C(OC)=CC=C2C=1CNC(=O)CC1=CC=C(O)C=C1 SSEHMDOSMVRKGQ-UHFFFAOYSA-N 0.000 claims description 3
- GDAFKNMODOIQMK-UHFFFAOYSA-N N-[(16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaen-21-yl)methyl]-2-(4-methoxyphenyl)acetamide iodide Chemical compound [I-].C1=CC(OC)=CC=C1CC(=O)NCC1=C(C=2C(=CC=3OCOC=3C=2)CC2)[N+]2=CC2=C(OC)C(OC)=CC=C12 GDAFKNMODOIQMK-UHFFFAOYSA-N 0.000 claims description 3
- SOZCGMVTSWHHLP-UHFFFAOYSA-N N-[(16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaen-21-yl)methyl]-2-phenylacetamide iodide Chemical compound [I-].C=12C3=CC=4OCOC=4C=C3CC[N+]2=CC2=C(OC)C(OC)=CC=C2C=1CNC(=O)CC1=CC=CC=C1 SOZCGMVTSWHHLP-UHFFFAOYSA-N 0.000 claims description 3
- DYTCTKYSIOGCCD-UHFFFAOYSA-N N-[(16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaen-21-yl)methyl]benzamide iodide Chemical compound [I-].C=12C3=CC=4OCOC=4C=C3CC[N+]2=CC2=C(OC)C(OC)=CC=C2C=1CNC(=O)C1=CC=CC=C1 DYTCTKYSIOGCCD-UHFFFAOYSA-N 0.000 claims description 3
- PAONSCXXNIKBPN-UHFFFAOYSA-N N-[(16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaen-21-yl)methyl]pyridine-4-carboxamide iodide Chemical compound [I-].C=12C3=CC=4OCOC=4C=C3CC[N+]2=CC2=C(OC)C(OC)=CC=C2C=1CNC(=O)C1=CC=NC=C1 PAONSCXXNIKBPN-UHFFFAOYSA-N 0.000 claims description 3
- WPVKRJUFELRZNX-UHFFFAOYSA-N N-[(4-chlorophenyl)methyl]-2-(16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaen-21-yl)acetamide iodide Chemical compound [I-].C=12C3=CC=4OCOC=4C=C3CC[N+]2=CC2=C(OC)C(OC)=CC=C2C=1CC(=O)NCC1=CC=C(Cl)C=C1 WPVKRJUFELRZNX-UHFFFAOYSA-N 0.000 claims description 3
- BXKZLRRTUOYRLI-UHFFFAOYSA-N N-[4-[2-(16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaen-21-yl)ethyl]phenyl]acetamide iodide Chemical compound [I-].C=12C3=CC=4OCOC=4C=C3CC[N+]2=CC2=C(OC)C(OC)=CC=C2C=1CCC1=CC=C(NC(C)=O)C=C1 BXKZLRRTUOYRLI-UHFFFAOYSA-N 0.000 claims description 3
- RADRLUFDNLODKF-UHFFFAOYSA-N N-[4-[3-(16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaen-21-yl)propyl]phenyl]acetamide iodide Chemical compound [I-].C=12C3=CC=4OCOC=4C=C3CC[N+]2=CC2=C(OC)C(OC)=CC=C2C=1CCCC1=CC=C(NC(C)=O)C=C1 RADRLUFDNLODKF-UHFFFAOYSA-N 0.000 claims description 3
- DIZDWWXDMUFYCA-UHFFFAOYSA-N N-benzyl-2-(16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaen-21-yl)acetamide iodide Chemical compound [I-].C=12C3=CC=4OCOC=4C=C3CC[N+]2=CC2=C(OC)C(OC)=CC=C2C=1CC(=O)NCC1=CC=CC=C1 DIZDWWXDMUFYCA-UHFFFAOYSA-N 0.000 claims description 3
- LAVLGCRBWJDPQP-UHFFFAOYSA-M [I-].C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C(CCCC=4NC5=CC=CC=C5C=4)=C3C2=CC2=C1OCO2 Chemical compound [I-].C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C(CCCC=4NC5=CC=CC=C5C=4)=C3C2=CC2=C1OCO2 LAVLGCRBWJDPQP-UHFFFAOYSA-M 0.000 claims description 3
- LKJUKOHYIYBMQM-UHFFFAOYSA-N [I-].C1=CC(OC)=CC=C1C(=O)NCC1=C(C=2C(=CC=3OCOC=3C=2)CC2)[N+]2=CC2=C(OC)C(OC)=CC=C12 Chemical compound [I-].C1=CC(OC)=CC=C1C(=O)NCC1=C(C=2C(=CC=3OCOC=3C=2)CC2)[N+]2=CC2=C(OC)C(OC)=CC=C12 LKJUKOHYIYBMQM-UHFFFAOYSA-N 0.000 claims description 3
- FRQAFFAWJPIRLE-UHFFFAOYSA-M [I-].C=12C3=CC=4OCOC=4C=C3CC[N+]2=CC2=C(OC)C(OC)=CC=C2C=1CCCOC1=CC=CC=C1 Chemical compound [I-].C=12C3=CC=4OCOC=4C=C3CC[N+]2=CC2=C(OC)C(OC)=CC=C2C=1CCCOC1=CC=CC=C1 FRQAFFAWJPIRLE-UHFFFAOYSA-M 0.000 claims description 3
- ODVOGXONTSDFJR-UHFFFAOYSA-N [I-].C=12C3=CC=4OCOC=4C=C3CC[N+]2=CC2=C(OC)C(OC)=CC=C2C=1CNC(=O)C1=CC=C(Cl)C=C1 Chemical compound [I-].C=12C3=CC=4OCOC=4C=C3CC[N+]2=CC2=C(OC)C(OC)=CC=C2C=1CNC(=O)C1=CC=C(Cl)C=C1 ODVOGXONTSDFJR-UHFFFAOYSA-N 0.000 claims description 3
- UCZHAMFWYGEESM-UHFFFAOYSA-N [I-].C=12C3=CC=4OCOC=4C=C3CC[N+]2=CC2=C(OC)C(OC)=CC=C2C=1CNC(=O)C1=CC=C(O)C=C1 Chemical compound [I-].C=12C3=CC=4OCOC=4C=C3CC[N+]2=CC2=C(OC)C(OC)=CC=C2C=1CNC(=O)C1=CC=C(O)C=C1 UCZHAMFWYGEESM-UHFFFAOYSA-N 0.000 claims description 3
- FYFWFJHTTMELBS-UHFFFAOYSA-M [I-].C=12C3=CC=4OCOC=4C=C3CC[N+]2=CC2=C(OC)C(OC)=CC=C2C=1COC(C=1C=CC=CC=1)C1=CC=CC=C1 Chemical compound [I-].C=12C3=CC=4OCOC=4C=C3CC[N+]2=CC2=C(OC)C(OC)=CC=C2C=1COC(C=1C=CC=CC=1)C1=CC=CC=C1 FYFWFJHTTMELBS-UHFFFAOYSA-M 0.000 claims description 3
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims description 3
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 claims description 3
- 125000004122 cyclic group Chemical group 0.000 claims description 3
- 125000004185 ester group Chemical group 0.000 claims description 3
- WLGGEGZVNSKYPM-UHFFFAOYSA-N ethyl 3-[2-(16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaen-21-yl)ethyl]-1H-indole-5-carboxylate iodide Chemical compound [I-].COC1=CC=C2C(CCC3=CNC4=CC=C(C=C43)C(=O)OCC)=C(C=3C(=CC=4OCOC=4C=3)CC3)[N+]3=CC2=C1OC WLGGEGZVNSKYPM-UHFFFAOYSA-N 0.000 claims description 3
- GCAKJVHPJAKSOR-UHFFFAOYSA-M ethyl 4-[2-(16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaen-21-yl)ethyl]benzoate iodide Chemical compound [I-].C1=CC(C(=O)OCC)=CC=C1CCC1=C(C=2C(=CC=3OCOC=3C=2)CC2)[N+]2=CC2=C(OC)C(OC)=CC=C12 GCAKJVHPJAKSOR-UHFFFAOYSA-M 0.000 claims description 3
- FICKPXCEUZQULX-UHFFFAOYSA-M ethyl 4-[2-(16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaen-21-yl)ethyl]naphthalene-1-carboxylate iodide Chemical compound [I-].C12=CC=CC=C2C(C(=O)OCC)=CC=C1CCC1=C(C=2C(=CC=3OCOC=3C=2)CC2)[N+]2=CC2=C(OC)C(OC)=CC=C12 FICKPXCEUZQULX-UHFFFAOYSA-M 0.000 claims description 3
- DEKMEGNJILRSIW-UHFFFAOYSA-M ethyl 4-[3-(16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaen-21-yl)propyl]benzoate iodide Chemical compound [I-].C1=CC(C(=O)OCC)=CC=C1CCCC1=C(C=2C(=CC=3OCOC=3C=2)CC2)[N+]2=CC2=C(OC)C(OC)=CC=C12 DEKMEGNJILRSIW-UHFFFAOYSA-M 0.000 claims description 3
- OUWNRXWBIKYICM-UHFFFAOYSA-M ethyl 4-[3-(16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaen-21-yl)propyl]naphthalene-1-carboxylate iodide Chemical compound [I-].C12=CC=CC=C2C(C(=O)OCC)=CC=C1CCCC1=C(C=2C(=CC=3OCOC=3C=2)CC2)[N+]2=CC2=C(OC)C(OC)=CC=C12 OUWNRXWBIKYICM-UHFFFAOYSA-M 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- 125000000165 tricyclic carbocycle group Chemical group 0.000 claims description 3
- AACDLRPYTKUBOQ-UHFFFAOYSA-M 16,17-dimethoxy-21-[3-(4-nitronaphthalen-1-yl)propyl]-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene iodide Chemical compound [I-].C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C(CCCC=4C5=CC=CC=C5C([N+]([O-])=O)=CC=4)=C3C2=CC2=C1OCO2 AACDLRPYTKUBOQ-UHFFFAOYSA-M 0.000 claims description 2
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 claims description 2
- SAMYHVFRLAXLBC-UHFFFAOYSA-N 3-(16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaen-21-yl)-N-phenylpropanamide iodide Chemical compound [I-].C=12C3=CC=4OCOC=4C=C3CC[N+]2=CC2=C(OC)C(OC)=CC=C2C=1CCC(=O)NC1=CC=CC=C1 SAMYHVFRLAXLBC-UHFFFAOYSA-N 0.000 claims description 2
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 claims description 2
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical group OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 claims description 2
- 229940043377 alpha-cyclodextrin Drugs 0.000 claims description 2
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 claims description 2
- 125000003828 azulenyl group Chemical group 0.000 claims description 2
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 claims description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 2
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 claims description 2
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims description 2
- 125000002541 furyl group Chemical group 0.000 claims description 2
- 230000003301 hydrolyzing effect Effects 0.000 claims description 2
- 125000002883 imidazolyl group Chemical group 0.000 claims description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 2
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000001041 indolyl group Chemical group 0.000 claims description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 2
- 125000005956 isoquinolyl group Chemical group 0.000 claims description 2
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 2
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- 125000002971 oxazolyl group Chemical group 0.000 claims description 2
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 claims description 2
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 2
- 125000005495 pyridazyl group Chemical group 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 2
- 125000005493 quinolyl group Chemical group 0.000 claims description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 2
- 125000001544 thienyl group Chemical group 0.000 claims description 2
- 125000001425 triazolyl group Chemical group 0.000 claims description 2
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 claims description 2
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 claims 3
- 239000002671 adjuvant Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000003981 vehicle Substances 0.000 claims 2
- 238000002360 preparation method Methods 0.000 abstract description 9
- 238000011282 treatment Methods 0.000 abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 46
- 0 [1*]C1=C([2*])C=C2C(=C1)CC[N+]1=CC3=C(C=CC([4*])=C3[3*])C(CC)=C21 Chemical compound [1*]C1=C([2*])C=C2C(=C1)CC[N+]1=CC3=C(C=CC([4*])=C3[3*])C(CC)=C21 0.000 description 30
- 210000004027 cell Anatomy 0.000 description 26
- 239000000203 mixture Substances 0.000 description 25
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 24
- 239000000243 solution Substances 0.000 description 23
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 11
- 239000012279 sodium borohydride Substances 0.000 description 11
- 229910000033 sodium borohydride Inorganic materials 0.000 description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 9
- 229940093265 berberine Drugs 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 8
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 8
- 230000000259 anti-tumor effect Effects 0.000 description 8
- 150000003250 quinolizines Chemical class 0.000 description 8
- 238000010992 reflux Methods 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 7
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 7
- 150000007975 iminium salts Chemical class 0.000 description 7
- 239000012074 organic phase Substances 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- UICBHOXXGLYZJH-UHFFFAOYSA-N 5,6-dihydroisoquinolino[2,1-b]isoquinolin-7-ium Chemical class C1=CC=C2CC[N+]3=CC4=CC=CC=C4C=C3C2=C1 UICBHOXXGLYZJH-UHFFFAOYSA-N 0.000 description 6
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- FZAGOOYMTPGPGF-UHFFFAOYSA-N Lambertine Chemical compound C1=C2C3=CC4=CC=C(OC)C(OC)=C4CN3CCC2=CC2=C1OCO2 FZAGOOYMTPGPGF-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 229960004316 cisplatin Drugs 0.000 description 6
- 229960002949 fluorouracil Drugs 0.000 description 6
- 239000011630 iodine Substances 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Natural products CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
- 229960005420 etoposide Drugs 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 235000009518 sodium iodide Nutrition 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 4
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 4
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 4
- 229960000485 methotrexate Drugs 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 4
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- VKJGBAJNNALVAV-UHFFFAOYSA-M Berberine chloride (TN) Chemical compound [Cl-].C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 VKJGBAJNNALVAV-UHFFFAOYSA-M 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- SORGEQQSQGNZFI-UHFFFAOYSA-N [azido(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(N=[N+]=[N-])OC1=CC=CC=C1 SORGEQQSQGNZFI-UHFFFAOYSA-N 0.000 description 3
- 230000029936 alkylation Effects 0.000 description 3
- 238000005804 alkylation reaction Methods 0.000 description 3
- GLYPKDKODVRYGP-UHFFFAOYSA-O berberrubine Chemical compound C1=C2CC[N+]3=CC4=C(O)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 GLYPKDKODVRYGP-UHFFFAOYSA-O 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 3
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 2
- HAPDBNYNWAAHOU-UHFFFAOYSA-M 16,17-dimethoxy-21-(3-naphthalen-1-ylpropyl)-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene iodide Chemical compound [I-].C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C(CCCC=4C5=CC=CC=C5C=CC=4)=C3C2=CC2=C1OCO2 HAPDBNYNWAAHOU-UHFFFAOYSA-M 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical class Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 2
- 108010006654 Bleomycin Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- GLOBSZURDZPNNA-UHFFFAOYSA-N C1=C2C3C(CC(O)=O)C4=CC=C(OC)C(OC)=C4CN3CCC2=CC2=C1OCO2 Chemical compound C1=C2C3C(CC(O)=O)C4=CC=C(OC)C(OC)=C4CN3CCC2=CC2=C1OCO2 GLOBSZURDZPNNA-UHFFFAOYSA-N 0.000 description 2
- AQZQOZOWCQCWEV-UHFFFAOYSA-N C1=C2C3C(CC4OC5=CC=CC=C5OC4)C4=CC=C(OC)C(OC)=C4CN3CCC2=CC2=C1OCO2 Chemical compound C1=C2C3C(CC4OC5=CC=CC=C5OC4)C4=CC=C(OC)C(OC)=C4CN3CCC2=CC2=C1OCO2 AQZQOZOWCQCWEV-UHFFFAOYSA-N 0.000 description 2
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 108010092160 Dactinomycin Proteins 0.000 description 2
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 2
- 239000001116 FEMA 4028 Substances 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- 230000027311 M phase Effects 0.000 description 2
- 241000204031 Mycoplasma Species 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 230000018199 S phase Effects 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
- RDXDCIUYJJVYHC-UHFFFAOYSA-M [I-].C=12C3=CC=4OCOC=4C=C3CC[N+]2=CC2=C(OC)C(OC)=CC=C2C=1CC1=CC=CC=C1 Chemical compound [I-].C=12C3=CC=4OCOC=4C=C3CC[N+]2=CC2=C(OC)C(OC)=CC=C2C=1CC1=CC=CC=C1 RDXDCIUYJJVYHC-UHFFFAOYSA-M 0.000 description 2
- IQAAFJAVCBUASB-UHFFFAOYSA-M [I-].COC1=CC=C2C(CC(=O)N3C4=CC=C(C=C4C=C3)OC)=C(C=3C(=CC=4OCOC=4C=3)CC3)[N+]3=CC2=C1OC Chemical compound [I-].COC1=CC=C2C(CC(=O)N3C4=CC=C(C=C4C=C3)OC)=C(C=3C(=CC=4OCOC=4C=3)CC3)[N+]3=CC2=C1OC IQAAFJAVCBUASB-UHFFFAOYSA-M 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- BRLDZKPJJNASGG-KRWDZBQOSA-N alpha-berbine Chemical compound C1=CC=C2CN3CCC4=CC=CC=C4[C@@H]3CC2=C1 BRLDZKPJJNASGG-KRWDZBQOSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 150000003832 berberine derivatives Chemical group 0.000 description 2
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical class N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 229960004630 chlorambucil Drugs 0.000 description 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 229960003901 dacarbazine Drugs 0.000 description 2
- 229960000975 daunorubicin Drugs 0.000 description 2
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- VLCYCQAOQCDTCN-UHFFFAOYSA-N eflornithine Chemical compound NCCCC(N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-UHFFFAOYSA-N 0.000 description 2
- 150000002081 enamines Chemical class 0.000 description 2
- 229960001904 epirubicin Drugs 0.000 description 2
- XQDBMXLNDRBRKK-UHFFFAOYSA-N ethyl 3-[3-(16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaen-21-yl)propyl]-1H-indole-5-carboxylate iodide Chemical compound [I-].COC1=CC=C2C(CCCC3=CNC4=CC=C(C=C43)C(=O)OCC)=C(C=3C(=CC=4OCOC=4C=3)CC3)[N+]3=CC2=C1OC XQDBMXLNDRBRKK-UHFFFAOYSA-N 0.000 description 2
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- CHPZKNULDCNCBW-UHFFFAOYSA-N gallium nitrate Chemical compound [Ga+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O CHPZKNULDCNCBW-UHFFFAOYSA-N 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 229960001101 ifosfamide Drugs 0.000 description 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 2
- 229960004961 mechlorethamine Drugs 0.000 description 2
- 229960001428 mercaptopurine Drugs 0.000 description 2
- 238000005649 metathesis reaction Methods 0.000 description 2
- 229960001156 mitoxantrone Drugs 0.000 description 2
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- QUCQEUCGKKTEBI-UHFFFAOYSA-N palmatine Chemical compound COC1=CC=C2C=C(C3=C(C=C(C(=C3)OC)OC)CC3)[N+]3=CC2=C1OC QUCQEUCGKKTEBI-UHFFFAOYSA-N 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 229960004622 raloxifene Drugs 0.000 description 2
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- PVYJZLYGTZKPJE-UHFFFAOYSA-N streptonigrin Chemical compound C=1C=C2C(=O)C(OC)=C(N)C(=O)C2=NC=1C(C=1N)=NC(C(O)=O)=C(C)C=1C1=CC=C(OC)C(OC)=C1O PVYJZLYGTZKPJE-UHFFFAOYSA-N 0.000 description 2
- 229960001603 tamoxifen Drugs 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229960001196 thiotepa Drugs 0.000 description 2
- 229960003087 tioguanine Drugs 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 229960003048 vinblastine Drugs 0.000 description 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
- 229960004528 vincristine Drugs 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- NNJPGOLRFBJNIW-HNNXBMFYSA-N (-)-demecolcine Chemical compound C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 description 1
- WDQLRUYAYXDIFW-RWKIJVEZSA-N (2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-4-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1 WDQLRUYAYXDIFW-RWKIJVEZSA-N 0.000 description 1
- FLWWDYNPWOSLEO-HQVZTVAUSA-N (2s)-2-[[4-[1-(2-amino-4-oxo-1h-pteridin-6-yl)ethyl-methylamino]benzoyl]amino]pentanedioic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1C(C)N(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FLWWDYNPWOSLEO-HQVZTVAUSA-N 0.000 description 1
- CGMTUJFWROPELF-YPAAEMCBSA-N (3E,5S)-5-[(2S)-butan-2-yl]-3-(1-hydroxyethylidene)pyrrolidine-2,4-dione Chemical compound CC[C@H](C)[C@@H]1NC(=O)\C(=C(/C)O)C1=O CGMTUJFWROPELF-YPAAEMCBSA-N 0.000 description 1
- XRBSKUSTLXISAB-XVVDYKMHSA-N (5r,6r,7r,8r)-8-hydroxy-7-(hydroxymethyl)-5-(3,4,5-trimethoxyphenyl)-5,6,7,8-tetrahydrobenzo[f][1,3]benzodioxole-6-carboxylic acid Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H](CO)[C@@H]2C(O)=O)=C1 XRBSKUSTLXISAB-XVVDYKMHSA-N 0.000 description 1
- XRBSKUSTLXISAB-UHFFFAOYSA-N (7R,7'R,8R,8'R)-form-Podophyllic acid Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C(CO)C2C(O)=O)=C1 XRBSKUSTLXISAB-UHFFFAOYSA-N 0.000 description 1
- AESVUZLWRXEGEX-DKCAWCKPSA-N (7S,9R)-7-[(2S,4R,5R,6R)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione iron(3+) Chemical compound [Fe+3].COc1cccc2C(=O)c3c(O)c4C[C@@](O)(C[C@H](O[C@@H]5C[C@@H](N)[C@@H](O)[C@@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO AESVUZLWRXEGEX-DKCAWCKPSA-N 0.000 description 1
- JXVAMODRWBNUSF-KZQKBALLSA-N (7s,9r,10r)-7-[(2r,4s,5s,6s)-5-[[(2s,4as,5as,7s,9s,9ar,10ar)-2,9-dimethyl-3-oxo-4,4a,5a,6,7,9,9a,10a-octahydrodipyrano[4,2-a:4',3'-e][1,4]dioxin-7-yl]oxy]-4-(dimethylamino)-6-methyloxan-2-yl]oxy-10-[(2s,4s,5s,6s)-4-(dimethylamino)-5-hydroxy-6-methyloxan-2 Chemical compound O([C@@H]1C2=C(O)C=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C2[C@@H](O[C@@H]2O[C@@H](C)[C@@H](O[C@@H]3O[C@@H](C)[C@H]4O[C@@H]5O[C@@H](C)C(=O)C[C@@H]5O[C@H]4C3)[C@H](C2)N(C)C)C[C@]1(O)CC)[C@H]1C[C@H](N(C)C)[C@H](O)[C@H](C)O1 JXVAMODRWBNUSF-KZQKBALLSA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- IEXUMDBQLIVNHZ-YOUGDJEHSA-N (8s,11r,13r,14s,17s)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(3-hydroxypropyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(O)CCCO)[C@@]2(C)C1 IEXUMDBQLIVNHZ-YOUGDJEHSA-N 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- LYFPBWOBIJJASK-INIZCTEOSA-N (S)-(-)-Canadine Natural products O(C)c1c(OC)ccc2c1C[N+]1[C@H](c3c(cc4OCOc4c3)CC1)C2 LYFPBWOBIJJASK-INIZCTEOSA-N 0.000 description 1
- AGNGYMCLFWQVGX-AGFFZDDWSA-N (e)-1-[(2s)-2-amino-2-carboxyethoxy]-2-diazonioethenolate Chemical compound OC(=O)[C@@H](N)CO\C([O-])=C\[N+]#N AGNGYMCLFWQVGX-AGFFZDDWSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- FLVXBEZGSZBQKD-UHFFFAOYSA-N 13-benzyl-5,6-dihydroisoquinolino[2,1-b]isoquinolin-7-ium Chemical class C=12C3=CC=CC=C3CC[N+]2=CC2=CC=CC=C2C=1CC1=CC=CC=C1 FLVXBEZGSZBQKD-UHFFFAOYSA-N 0.000 description 1
- SKEWVUFDQGRLAZ-UHFFFAOYSA-N 16,17-dimethoxy-21-[2-(4-methoxyphenoxy)ethyl]-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-2,4(8),9,15(20),16,18-hexaene iodide Chemical compound [I-].C1=CC(OC)=CC=C1OCCC1C(C=CC(OC)=C2OC)=C2C[NH+]2C1C1=CC(OCO3)=C3C=C1CC2 SKEWVUFDQGRLAZ-UHFFFAOYSA-N 0.000 description 1
- 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- BTOTXLJHDSNXMW-POYBYMJQSA-N 2,3-dideoxyuridine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(=O)NC(=O)C=C1 BTOTXLJHDSNXMW-POYBYMJQSA-N 0.000 description 1
- BOMZMNZEXMAQQW-UHFFFAOYSA-N 2,5,11-trimethyl-6h-pyrido[4,3-b]carbazol-2-ium-9-ol;acetate Chemical compound CC([O-])=O.C[N+]1=CC=C2C(C)=C(NC=3C4=CC(O)=CC=3)C4=C(C)C2=C1 BOMZMNZEXMAQQW-UHFFFAOYSA-N 0.000 description 1
- NAQLRSXGEHOYHH-UHFFFAOYSA-N 2-(16,17-dimethoxy-5,7-dioxa-13-azapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-2,4(8),9,15(20),16,18-hexaen-21-yl)propanoic acid Chemical compound C1=C2C3C(C(C)C(O)=O)C4=CC=C(OC)C(OC)=C4CN3CCC2=CC2=C1OCO2 NAQLRSXGEHOYHH-UHFFFAOYSA-N 0.000 description 1
- QCXJFISCRQIYID-IAEPZHFASA-N 2-amino-1-n-[(3s,6s,7r,10s,16s)-3-[(2s)-butan-2-yl]-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-10-propan-2-yl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-4,6-dimethyl-3-oxo-9-n-[(3s,6s,7r,10s,16s)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propa Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N=C2C(C(=O)N[C@@H]3C(=O)N[C@H](C(N4CCC[C@H]4C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]3C)=O)[C@@H](C)CC)=C(N)C(=O)C(C)=C2O2)C2=C(C)C=C1 QCXJFISCRQIYID-IAEPZHFASA-N 0.000 description 1
- JJFOBACUIRKUPN-UHFFFAOYSA-N 2-bromoethoxybenzene Chemical compound BrCCOC1=CC=CC=C1 JJFOBACUIRKUPN-UHFFFAOYSA-N 0.000 description 1
- FDAYLTPAFBGXAB-UHFFFAOYSA-N 2-chloro-n,n-bis(2-chloroethyl)ethanamine Chemical compound ClCCN(CCCl)CCCl FDAYLTPAFBGXAB-UHFFFAOYSA-N 0.000 description 1
- VNBAOSVONFJBKP-UHFFFAOYSA-N 2-chloro-n,n-bis(2-chloroethyl)propan-1-amine;hydrochloride Chemical compound Cl.CC(Cl)CN(CCCl)CCCl VNBAOSVONFJBKP-UHFFFAOYSA-N 0.000 description 1
- WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical compound BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- WPISZVBOCVQFGW-UHFFFAOYSA-M 21-(2,2-diphenylethyl)-16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene iodide Chemical compound [I-].C=12C3=CC=4OCOC=4C=C3CC[N+]2=CC2=C(OC)C(OC)=CC=C2C=1CC(C=1C=CC=CC=1)C1=CC=CC=C1 WPISZVBOCVQFGW-UHFFFAOYSA-M 0.000 description 1
- JUVKIJKSUTVNCV-UHFFFAOYSA-N 21-[2,2-bis(4-methylphenyl)ethyl]-16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-2,4(8),9,15(20),16,18-hexaene iodide Chemical compound [I-].C1CC2=CC=3OCOC=3C=C2C2[NH+]1CC1=C(OC)C(OC)=CC=C1C2CC(C=1C=CC(C)=CC=1)C1=CC=C(C)C=C1 JUVKIJKSUTVNCV-UHFFFAOYSA-N 0.000 description 1
- ZLPRBKMWCLYUEO-UHFFFAOYSA-M 21-[3-(4-chloronaphthalen-1-yl)propyl]-16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene iodide Chemical compound [I-].C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C(CCCC=4C5=CC=CC=C5C(Cl)=CC=4)=C3C2=CC2=C1OCO2 ZLPRBKMWCLYUEO-UHFFFAOYSA-M 0.000 description 1
- OUSKTLWOQOMSKW-UHFFFAOYSA-N 21-[3-(4-chlorophenyl)propyl]-16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-2,4(8),9,15(20),16,18-hexaene iodide Chemical compound [I-].C1CC2=CC=3OCOC=3C=C2C2[NH+]1CC1=C(OC)C(OC)=CC=C1C2CCCC1=CC=C(Cl)C=C1 OUSKTLWOQOMSKW-UHFFFAOYSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- PWMYMKOUNYTVQN-UHFFFAOYSA-N 3-(8,8-diethyl-2-aza-8-germaspiro[4.5]decan-2-yl)-n,n-dimethylpropan-1-amine Chemical compound C1C[Ge](CC)(CC)CCC11CN(CCCN(C)C)CC1 PWMYMKOUNYTVQN-UHFFFAOYSA-N 0.000 description 1
- XMZQWZJMTBCUFT-UHFFFAOYSA-N 3-bromopropylbenzene Chemical compound BrCCCC1=CC=CC=C1 XMZQWZJMTBCUFT-UHFFFAOYSA-N 0.000 description 1
- DODQJNMQWMSYGS-QPLCGJKRSA-N 4-[(z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-phenylbut-1-en-2-yl]phenol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 DODQJNMQWMSYGS-QPLCGJKRSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- GDRVFDDBLLKWRI-UHFFFAOYSA-N 4H-quinolizine Chemical compound C1=CC=CN2CC=CC=C21 GDRVFDDBLLKWRI-UHFFFAOYSA-N 0.000 description 1
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- WYXSYVWAUAUWLD-SHUUEZRQSA-N 6-azauridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=N1 WYXSYVWAUAUWLD-SHUUEZRQSA-N 0.000 description 1
- 229960005538 6-diazo-5-oxo-L-norleucine Drugs 0.000 description 1
- YCWQAMGASJSUIP-YFKPBYRVSA-N 6-diazo-5-oxo-L-norleucine Chemical compound OC(=O)[C@@H](N)CCC(=O)C=[N+]=[N-] YCWQAMGASJSUIP-YFKPBYRVSA-N 0.000 description 1
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 1
- HDZZVAMISRMYHH-UHFFFAOYSA-N 9beta-Ribofuranosyl-7-deazaadenin Natural products C1=CC=2C(N)=NC=NC=2N1C1OC(CO)C(O)C1O HDZZVAMISRMYHH-UHFFFAOYSA-N 0.000 description 1
- CEIZFXOZIQNICU-UHFFFAOYSA-N Alternaria alternata Crofton-weed toxin Natural products CCC(C)C1NC(=O)C(C(C)=O)=C1O CEIZFXOZIQNICU-UHFFFAOYSA-N 0.000 description 1
- 102000014654 Aromatase Human genes 0.000 description 1
- 108010078554 Aromatase Proteins 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical class C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- YDTWAWPAHGZEHW-UHFFFAOYSA-N C12=CC=CC=C2C(C(=O)OCC)=CC=C1CCC1C(C=CC(OC)=C2OC)=C2CN2C1C1=CC(OCO3)=C3C=C1CC2 Chemical compound C12=CC=CC=C2C(C(=O)OCC)=CC=C1CCC1C(C=CC(OC)=C2OC)=C2CN2C1C1=CC(OCO3)=C3C=C1CC2 YDTWAWPAHGZEHW-UHFFFAOYSA-N 0.000 description 1
- MGIDQOGZTCNVTK-UHFFFAOYSA-N C12=CC=CC=C2C(C(=O)OCC)=CC=C1CCCC1C(C=CC(OC)=C2OC)=C2CN2C1C1=CC(OCO3)=C3C=C1CC2 Chemical compound C12=CC=CC=C2C(C(=O)OCC)=CC=C1CCCC1C(C=CC(OC)=C2OC)=C2CN2C1C1=CC(OCO3)=C3C=C1CC2 MGIDQOGZTCNVTK-UHFFFAOYSA-N 0.000 description 1
- OSUBGEFLHMQJJE-UHFFFAOYSA-N C1=C2C3C(CC(=O)N4C5=CC=C(C=C5C=C4)N(C)C)C4=CC=C(OC)C(OC)=C4CN3CCC2=CC2=C1OCO2 Chemical compound C1=C2C3C(CC(=O)N4C5=CC=C(C=C5C=C4)N(C)C)C4=CC=C(OC)C(OC)=C4CN3CCC2=CC2=C1OCO2 OSUBGEFLHMQJJE-UHFFFAOYSA-N 0.000 description 1
- DIWHSUNEGQDNCU-UHFFFAOYSA-N C1=C2C3C(CC(=O)N4C5=CC=C(Cl)C=C5C=C4)C4=CC=C(OC)C(OC)=C4CN3CCC2=CC2=C1OCO2 Chemical compound C1=C2C3C(CC(=O)N4C5=CC=C(Cl)C=C5C=C4)C4=CC=C(OC)C(OC)=C4CN3CCC2=CC2=C1OCO2 DIWHSUNEGQDNCU-UHFFFAOYSA-N 0.000 description 1
- XOIDALCMDKJDDI-UHFFFAOYSA-N C1=C2C3C(CC(=O)N4C5=CC=C(O)C=C5C=C4)C4=CC=C(OC)C(OC)=C4CN3CCC2=CC2=C1OCO2 Chemical compound C1=C2C3C(CC(=O)N4C5=CC=C(O)C=C5C=C4)C4=CC=C(OC)C(OC)=C4CN3CCC2=CC2=C1OCO2 XOIDALCMDKJDDI-UHFFFAOYSA-N 0.000 description 1
- GROAWBUKFBUWMA-UHFFFAOYSA-N C1=C2C3C(CCC=4C5=CC(=CC=C5NC=4)[N+]([O-])=O)C4=CC=C(OC)C(OC)=C4CN3CCC2=CC2=C1OCO2 Chemical compound C1=C2C3C(CCC=4C5=CC(=CC=C5NC=4)[N+]([O-])=O)C4=CC=C(OC)C(OC)=C4CN3CCC2=CC2=C1OCO2 GROAWBUKFBUWMA-UHFFFAOYSA-N 0.000 description 1
- FYNKYAWJJMBYCH-UHFFFAOYSA-N C1=C2C3C(CCC=4C5=CC=CC=C5C(Cl)=CC=4)C4=CC=C(OC)C(OC)=C4CN3CCC2=CC2=C1OCO2 Chemical compound C1=C2C3C(CCC=4C5=CC=CC=C5C(Cl)=CC=4)C4=CC=C(OC)C(OC)=C4CN3CCC2=CC2=C1OCO2 FYNKYAWJJMBYCH-UHFFFAOYSA-N 0.000 description 1
- APCIJSUSAWDALK-UHFFFAOYSA-N C1=C2C3C(CCC=4C5=CC=CC=C5C(OC)=CC=4)C4=CC=C(OC)C(OC)=C4CN3CCC2=CC2=C1OCO2 Chemical compound C1=C2C3C(CCC=4C5=CC=CC=C5C(OC)=CC=4)C4=CC=C(OC)C(OC)=C4CN3CCC2=CC2=C1OCO2 APCIJSUSAWDALK-UHFFFAOYSA-N 0.000 description 1
- WNMYARXVEXNOSE-UHFFFAOYSA-N C1=C2C3C(CCC=4C5=CC=CC=C5C([N+]([O-])=O)=CC=4)C4=CC=C(OC)C(OC)=C4CN3CCC2=CC2=C1OCO2 Chemical compound C1=C2C3C(CCC=4C5=CC=CC=C5C([N+]([O-])=O)=CC=4)C4=CC=C(OC)C(OC)=C4CN3CCC2=CC2=C1OCO2 WNMYARXVEXNOSE-UHFFFAOYSA-N 0.000 description 1
- CELCPMXBKMGRGF-UHFFFAOYSA-N C1=C2C3C(CCC=4C5=CC=CC=C5C=CC=4)C4=CC=C(OC)C(OC)=C4CN3CCC2=CC2=C1OCO2 Chemical compound C1=C2C3C(CCC=4C5=CC=CC=C5C=CC=4)C4=CC=C(OC)C(OC)=C4CN3CCC2=CC2=C1OCO2 CELCPMXBKMGRGF-UHFFFAOYSA-N 0.000 description 1
- GJURETZQNWBUJH-UHFFFAOYSA-N C1=C2C3C(CCC=4C5=CC=CC=C5NC=4)C4=CC=C(OC)C(OC)=C4CN3CCC2=CC2=C1OCO2 Chemical compound C1=C2C3C(CCC=4C5=CC=CC=C5NC=4)C4=CC=C(OC)C(OC)=C4CN3CCC2=CC2=C1OCO2 GJURETZQNWBUJH-UHFFFAOYSA-N 0.000 description 1
- MZTNAXFXNFDPLK-UHFFFAOYSA-N C1=C2C3C(CCCC=4C5=CC(=CC=C5NC=4)[N+]([O-])=O)C4=CC=C(OC)C(OC)=C4CN3CCC2=CC2=C1OCO2 Chemical compound C1=C2C3C(CCCC=4C5=CC(=CC=C5NC=4)[N+]([O-])=O)C4=CC=C(OC)C(OC)=C4CN3CCC2=CC2=C1OCO2 MZTNAXFXNFDPLK-UHFFFAOYSA-N 0.000 description 1
- OWSLQXCBXBLWCG-UHFFFAOYSA-N C1=C2C3C(CCCC=4C5=CC(Cl)=CC=C5NC=4)C4=CC=C(OC)C(OC)=C4CN3CCC2=CC2=C1OCO2 Chemical compound C1=C2C3C(CCCC=4C5=CC(Cl)=CC=C5NC=4)C4=CC=C(OC)C(OC)=C4CN3CCC2=CC2=C1OCO2 OWSLQXCBXBLWCG-UHFFFAOYSA-N 0.000 description 1
- MOKTUTUPVVCOGN-UHFFFAOYSA-N C1=C2C3C(CCCC=4C5=CC=CC=C5C(OC)=CC=4)C4=CC=C(OC)C(OC)=C4CN3CCC2=CC2=C1OCO2 Chemical compound C1=C2C3C(CCCC=4C5=CC=CC=C5C(OC)=CC=4)C4=CC=C(OC)C(OC)=C4CN3CCC2=CC2=C1OCO2 MOKTUTUPVVCOGN-UHFFFAOYSA-N 0.000 description 1
- XXZRYZGSLTUJHK-UHFFFAOYSA-N C1=C2C3C(CCCC=4C5=CC=CC=C5C([N+]([O-])=O)=CC=4)C4=CC=C(OC)C(OC)=C4CN3CCC2=CC2=C1OCO2 Chemical compound C1=C2C3C(CCCC=4C5=CC=CC=C5C([N+]([O-])=O)=CC=4)C4=CC=C(OC)C(OC)=C4CN3CCC2=CC2=C1OCO2 XXZRYZGSLTUJHK-UHFFFAOYSA-N 0.000 description 1
- JKWGCBJEJHGSKN-UHFFFAOYSA-N C1=C2C3C(CCCC=4C5=CC=CC=C5C=CC=4)C4=CC=C(OC)C(OC)=C4CN3CCC2=CC2=C1OCO2 Chemical compound C1=C2C3C(CCCC=4C5=CC=CC=C5C=CC=4)C4=CC=C(OC)C(OC)=C4CN3CCC2=CC2=C1OCO2 JKWGCBJEJHGSKN-UHFFFAOYSA-N 0.000 description 1
- PWSUVCZERSPFTN-UHFFFAOYSA-N C1=C2C3C(CCCC=4NC5=CC=CC=C5C=4)C4=CC=C(OC)C(OC)=C4CN3CCC2=CC2=C1OCO2 Chemical compound C1=C2C3C(CCCC=4NC5=CC=CC=C5C=4)C4=CC=C(OC)C(OC)=C4CN3CCC2=CC2=C1OCO2 PWSUVCZERSPFTN-UHFFFAOYSA-N 0.000 description 1
- IYAUDHOQBOARNC-UHFFFAOYSA-N C1=CC(C(=O)OCC)=CC=C1CCC1C(C=CC(OC)=C2OC)=C2CN2C1C1=CC(OCO3)=C3C=C1CC2 Chemical compound C1=CC(C(=O)OCC)=CC=C1CCC1C(C=CC(OC)=C2OC)=C2CN2C1C1=CC(OCO3)=C3C=C1CC2 IYAUDHOQBOARNC-UHFFFAOYSA-N 0.000 description 1
- RYACWLZONAESIJ-UHFFFAOYSA-N C1=CC(C(=O)OCC)=CC=C1CCCC1C(C=CC(OC)=C2OC)=C2CN2C1C1=CC(OCO3)=C3C=C1CC2 Chemical compound C1=CC(C(=O)OCC)=CC=C1CCCC1C(C=CC(OC)=C2OC)=C2CN2C1C1=CC(OCO3)=C3C=C1CC2 RYACWLZONAESIJ-UHFFFAOYSA-N 0.000 description 1
- KGVIIXOKIYFGOR-UHFFFAOYSA-N C1=CC(OC)=CC=C1C(=O)NCC1C2=CC=C(OC)C(OC)=C2CN2C1C1=CC(OCO3)=C3C=C1CC2 Chemical compound C1=CC(OC)=CC=C1C(=O)NCC1C2=CC=C(OC)C(OC)=C2CN2C1C1=CC(OCO3)=C3C=C1CC2 KGVIIXOKIYFGOR-UHFFFAOYSA-N 0.000 description 1
- SUJKOLXUCREVDO-UHFFFAOYSA-N C1=CC(OC)=CC=C1C(C=1C=CC(OC)=CC=1)CC1C(C=CC(OC)=C2OC)=C2CN2C1C1=CC(OCO3)=C3C=C1CC2 Chemical compound C1=CC(OC)=CC=C1C(C=1C=CC(OC)=CC=1)CC1C(C=CC(OC)=C2OC)=C2CN2C1C1=CC(OCO3)=C3C=C1CC2 SUJKOLXUCREVDO-UHFFFAOYSA-N 0.000 description 1
- AFZRYHZFAPFNKR-UHFFFAOYSA-N C1=CC(OC)=CC=C1C(C=1C=CC(OC)=CC=1)CCC1C(C=CC(OC)=C2OC)=C2CN2C1C1=CC(OCO3)=C3C=C1CC2 Chemical compound C1=CC(OC)=CC=C1C(C=1C=CC(OC)=CC=1)CCC1C(C=CC(OC)=C2OC)=C2CN2C1C1=CC(OCO3)=C3C=C1CC2 AFZRYHZFAPFNKR-UHFFFAOYSA-N 0.000 description 1
- RBZOJLCZEUXJOG-UHFFFAOYSA-N C1=CC(OC)=CC=C1CC(=O)NCC1C2=CC=C(OC)C(OC)=C2CN2C1C1=CC(OCO3)=C3C=C1CC2 Chemical compound C1=CC(OC)=CC=C1CC(=O)NCC1C2=CC=C(OC)C(OC)=C2CN2C1C1=CC(OCO3)=C3C=C1CC2 RBZOJLCZEUXJOG-UHFFFAOYSA-N 0.000 description 1
- FXWMZRLJLMTUAL-UHFFFAOYSA-N C1=CC(OC)=CC=C1CCC1C(C=CC(OC)=C2OC)=C2CN2C1C1=CC(OCO3)=C3C=C1CC2 Chemical compound C1=CC(OC)=CC=C1CCC1C(C=CC(OC)=C2OC)=C2CN2C1C1=CC(OCO3)=C3C=C1CC2 FXWMZRLJLMTUAL-UHFFFAOYSA-N 0.000 description 1
- QWPHFUVRJHAOLP-UHFFFAOYSA-N C1=CC(OC)=CC=C1CCCC1C(C=CC(OC)=C2OC)=C2CN2C1C1=CC(OCO3)=C3C=C1CC2 Chemical compound C1=CC(OC)=CC=C1CCCC1C(C=CC(OC)=C2OC)=C2CN2C1C1=CC(OCO3)=C3C=C1CC2 QWPHFUVRJHAOLP-UHFFFAOYSA-N 0.000 description 1
- AQXPZLNKXDIFHN-UHFFFAOYSA-N C1=CC(OC)=CC=C1CNC(=O)CC1C2=CC=C(OC)C(OC)=C2CN2C1C1=CC(OCO3)=C3C=C1CC2 Chemical compound C1=CC(OC)=CC=C1CNC(=O)CC1C2=CC=C(OC)C(OC)=C2CN2C1C1=CC(OCO3)=C3C=C1CC2 AQXPZLNKXDIFHN-UHFFFAOYSA-N 0.000 description 1
- GMWGLCPACMRURV-UHFFFAOYSA-N C1=CC(OC)=CC=C1COCC1C(C=CC(OC)=C2OC)=C2CN2C1C1=CC(OCO3)=C3C=C1CC2 Chemical compound C1=CC(OC)=CC=C1COCC1C(C=CC(OC)=C2OC)=C2CN2C1C1=CC(OCO3)=C3C=C1CC2 GMWGLCPACMRURV-UHFFFAOYSA-N 0.000 description 1
- ZFUSHVLDPMZLET-UHFFFAOYSA-N C1=CC(OC)=CC=C1OCCCC1C(C=CC(OC)=C2OC)=C2CN2C1C1=CC(OCO3)=C3C=C1CC2 Chemical compound C1=CC(OC)=CC=C1OCCCC1C(C=CC(OC)=C2OC)=C2CN2C1C1=CC(OCO3)=C3C=C1CC2 ZFUSHVLDPMZLET-UHFFFAOYSA-N 0.000 description 1
- GJWKOXGRAMSUAZ-UHFFFAOYSA-N C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CC(=O)N1C2=CC=C(OC)C=C2C=C1 Chemical compound C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CC(=O)N1C2=CC=C(OC)C=C2C=C1 GJWKOXGRAMSUAZ-UHFFFAOYSA-N 0.000 description 1
- VJEFMRHOYMGNKL-UHFFFAOYSA-N C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CC(=O)NC1=CC=C(Cl)C=C1 Chemical compound C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CC(=O)NC1=CC=C(Cl)C=C1 VJEFMRHOYMGNKL-UHFFFAOYSA-N 0.000 description 1
- OBCIGVYNBIGCIQ-UHFFFAOYSA-N C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CC(=O)NC1=CC=C(N(C)C)C=C1 Chemical compound C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CC(=O)NC1=CC=C(N(C)C)C=C1 OBCIGVYNBIGCIQ-UHFFFAOYSA-N 0.000 description 1
- OQQYNDBCQCFQKA-UHFFFAOYSA-N C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CC(=O)NC1=CC=C(O)C=C1 Chemical compound C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CC(=O)NC1=CC=C(O)C=C1 OQQYNDBCQCFQKA-UHFFFAOYSA-N 0.000 description 1
- DVYOPQCHSMBXCC-UHFFFAOYSA-N C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CC(=O)NC1=CC=NC=C1 Chemical compound C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CC(=O)NC1=CC=NC=C1 DVYOPQCHSMBXCC-UHFFFAOYSA-N 0.000 description 1
- QXVHVUPMMWYPMN-UHFFFAOYSA-N C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CC(=O)NCC1=CC=C(Cl)C=C1 Chemical compound C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CC(=O)NCC1=CC=C(Cl)C=C1 QXVHVUPMMWYPMN-UHFFFAOYSA-N 0.000 description 1
- MLGVPKIJMSHZGB-UHFFFAOYSA-N C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CC(=O)NCC1=CC=C(N(C)C)C=C1 Chemical compound C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CC(=O)NCC1=CC=C(N(C)C)C=C1 MLGVPKIJMSHZGB-UHFFFAOYSA-N 0.000 description 1
- NCFNHCDGOVIUCL-UHFFFAOYSA-N C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CC(=O)NCC1=CC=CC=C1 Chemical compound C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CC(=O)NCC1=CC=CC=C1 NCFNHCDGOVIUCL-UHFFFAOYSA-N 0.000 description 1
- KMLFFCLKZUTHMT-UHFFFAOYSA-N C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CC(C=1C=CC(Br)=CC=1)C1=CC=C(Br)C=C1 Chemical compound C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CC(C=1C=CC(Br)=CC=1)C1=CC=C(Br)C=C1 KMLFFCLKZUTHMT-UHFFFAOYSA-N 0.000 description 1
- DDZSAJZJGGSYEJ-UHFFFAOYSA-N C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CC(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 Chemical compound C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CC(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 DDZSAJZJGGSYEJ-UHFFFAOYSA-N 0.000 description 1
- JZSNNALMAAQXBN-UHFFFAOYSA-N C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CC(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 Chemical compound C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CC(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 JZSNNALMAAQXBN-UHFFFAOYSA-N 0.000 description 1
- MPNBGZPNAXRBGY-UHFFFAOYSA-N C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CCC(=O)NC1=CC=CC=C1 Chemical compound C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CCC(=O)NC1=CC=CC=C1 MPNBGZPNAXRBGY-UHFFFAOYSA-N 0.000 description 1
- IDFVSMDWKXUDRE-UHFFFAOYSA-N C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CCC(C=1C=CC(Br)=CC=1)C1=CC=C(Br)C=C1 Chemical compound C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CCC(C=1C=CC(Br)=CC=1)C1=CC=C(Br)C=C1 IDFVSMDWKXUDRE-UHFFFAOYSA-N 0.000 description 1
- ABAQEUPYIJBTGX-UHFFFAOYSA-N C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CCC(C=1C=CC(C)=CC=1)C1=CC=C(C)C=C1 Chemical compound C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CCC(C=1C=CC(C)=CC=1)C1=CC=C(C)C=C1 ABAQEUPYIJBTGX-UHFFFAOYSA-N 0.000 description 1
- ZYAITAIKUIUUFP-UHFFFAOYSA-N C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CCC(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 Chemical compound C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CCC(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 ZYAITAIKUIUUFP-UHFFFAOYSA-N 0.000 description 1
- KLTWKYFSUKMWJN-UHFFFAOYSA-N C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CCC(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 Chemical compound C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CCC(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 KLTWKYFSUKMWJN-UHFFFAOYSA-N 0.000 description 1
- NAZHRMPHAOUOQF-UHFFFAOYSA-N C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CCC(C=1C=CC=CC=1)C1=CC=CC=C1 Chemical compound C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CCC(C=1C=CC=CC=1)C1=CC=CC=C1 NAZHRMPHAOUOQF-UHFFFAOYSA-N 0.000 description 1
- TXKSDNLYNDVHJA-UHFFFAOYSA-N C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CCC1=CC=C(C(F)(F)F)C=C1 Chemical compound C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CCC1=CC=C(C(F)(F)F)C=C1 TXKSDNLYNDVHJA-UHFFFAOYSA-N 0.000 description 1
- LBWCGMKJBGONDF-UHFFFAOYSA-N C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CCC1=CC=C(C)C=C1 Chemical compound C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CCC1=CC=C(C)C=C1 LBWCGMKJBGONDF-UHFFFAOYSA-N 0.000 description 1
- SBKUPVKYGQVFIQ-UHFFFAOYSA-N C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CCC1=CC=C(Cl)C=C1 Chemical compound C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CCC1=CC=C(Cl)C=C1 SBKUPVKYGQVFIQ-UHFFFAOYSA-N 0.000 description 1
- JLYNMUCXWFCVLF-UHFFFAOYSA-N C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CCC1=CC=C(F)C=C1 Chemical compound C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CCC1=CC=C(F)C=C1 JLYNMUCXWFCVLF-UHFFFAOYSA-N 0.000 description 1
- KPQRLZUVOHJNGE-UHFFFAOYSA-N C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CCC1=CC=C(N(C)C)C=C1 Chemical compound C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CCC1=CC=C(N(C)C)C=C1 KPQRLZUVOHJNGE-UHFFFAOYSA-N 0.000 description 1
- ASRRVHYVLCFAHV-UHFFFAOYSA-N C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CCC1=CC=C(NC(C)=O)C=C1 Chemical compound C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CCC1=CC=C(NC(C)=O)C=C1 ASRRVHYVLCFAHV-UHFFFAOYSA-N 0.000 description 1
- ADXOGHQDKFLRLR-UHFFFAOYSA-N C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CCC1=CC=C([N+]([O-])=O)C=C1 Chemical compound C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CCC1=CC=C([N+]([O-])=O)C=C1 ADXOGHQDKFLRLR-UHFFFAOYSA-N 0.000 description 1
- XOVMXAIOWLYVBL-UHFFFAOYSA-N C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CCC1=CC=CC=C1 Chemical compound C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CCC1=CC=CC=C1 XOVMXAIOWLYVBL-UHFFFAOYSA-N 0.000 description 1
- DJFMFTCRNWWLCM-UHFFFAOYSA-N C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CCC1=CNC2=CC=C(C(=O)OCC)C=C21 Chemical compound C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CCC1=CNC2=CC=C(C(=O)OCC)C=C21 DJFMFTCRNWWLCM-UHFFFAOYSA-N 0.000 description 1
- GQAWQQCQHUATSU-UHFFFAOYSA-N C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CCC1=CNC2=CC=C(OC)C=C21 Chemical compound C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CCC1=CNC2=CC=C(OC)C=C21 GQAWQQCQHUATSU-UHFFFAOYSA-N 0.000 description 1
- UCQCLKQREHRGJC-UHFFFAOYSA-N C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CCCC(C=C1)=CC=C1OC1=CC=CC=C1 Chemical compound C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CCCC(C=C1)=CC=C1OC1=CC=CC=C1 UCQCLKQREHRGJC-UHFFFAOYSA-N 0.000 description 1
- LSCNAOPRGBPWLS-UHFFFAOYSA-N C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CCCC1=CC=C(Br)C=C1 Chemical compound C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CCCC1=CC=C(Br)C=C1 LSCNAOPRGBPWLS-UHFFFAOYSA-N 0.000 description 1
- NJTAZOJVXWAZLM-UHFFFAOYSA-N C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CCCC1=CC=C(C(F)(F)F)C=C1 Chemical compound C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CCCC1=CC=C(C(F)(F)F)C=C1 NJTAZOJVXWAZLM-UHFFFAOYSA-N 0.000 description 1
- MKEWMKYAMJFLHA-UHFFFAOYSA-N C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CCCC1=CC=C(C)C=C1 Chemical compound C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CCCC1=CC=C(C)C=C1 MKEWMKYAMJFLHA-UHFFFAOYSA-N 0.000 description 1
- BWCPHGXFVONULV-UHFFFAOYSA-N C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CCCC1=CC=C(F)C=C1 Chemical compound C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CCCC1=CC=C(F)C=C1 BWCPHGXFVONULV-UHFFFAOYSA-N 0.000 description 1
- CMPDAZAIXBZUPM-UHFFFAOYSA-N C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CCCC1=CC=C(N(C)C)C=C1 Chemical compound C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CCCC1=CC=C(N(C)C)C=C1 CMPDAZAIXBZUPM-UHFFFAOYSA-N 0.000 description 1
- JGHSBCYDRSPQLG-UHFFFAOYSA-N C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CCCC1=CC=C(NC(C)=O)C=C1 Chemical compound C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CCCC1=CC=C(NC(C)=O)C=C1 JGHSBCYDRSPQLG-UHFFFAOYSA-N 0.000 description 1
- GGBBGHZXSFTMGF-UHFFFAOYSA-N C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CCCC1=CC=C(OC(F)(F)F)C=C1 Chemical compound C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CCCC1=CC=C(OC(F)(F)F)C=C1 GGBBGHZXSFTMGF-UHFFFAOYSA-N 0.000 description 1
- BZAZHGBAESGMEY-UHFFFAOYSA-N C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CCCC1=CC=C([N+]([O-])=O)C=C1 Chemical compound C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CCCC1=CC=C([N+]([O-])=O)C=C1 BZAZHGBAESGMEY-UHFFFAOYSA-N 0.000 description 1
- ITEHYJHVACGCGC-UHFFFAOYSA-N C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CCCC1=CC=CC=C1 Chemical compound C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CCCC1=CC=CC=C1 ITEHYJHVACGCGC-UHFFFAOYSA-N 0.000 description 1
- XVWTVZDNCSQPOG-UHFFFAOYSA-N C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CCCC1=CNC2=CC=C(C(=O)OCC)C=C21 Chemical compound C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CCCC1=CNC2=CC=C(C(=O)OCC)C=C21 XVWTVZDNCSQPOG-UHFFFAOYSA-N 0.000 description 1
- MTHREFSFBZFYLH-UHFFFAOYSA-N C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CCCC1=CNC2=CC=C(OC)C=C21 Chemical compound C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CCCC1=CNC2=CC=C(OC)C=C21 MTHREFSFBZFYLH-UHFFFAOYSA-N 0.000 description 1
- BOPXMQKJIKDGPC-UHFFFAOYSA-N C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CCCOC1=CC=C(Cl)C=C1 Chemical compound C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CCCOC1=CC=C(Cl)C=C1 BOPXMQKJIKDGPC-UHFFFAOYSA-N 0.000 description 1
- CBKLTWJHMBKCSV-UHFFFAOYSA-N C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CCCOC1=CC=C(O)C=C1 Chemical compound C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CCCOC1=CC=C(O)C=C1 CBKLTWJHMBKCSV-UHFFFAOYSA-N 0.000 description 1
- XDJKVSYUCPBDMD-UHFFFAOYSA-N C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CCCOC1=CC=CC=C1 Chemical compound C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CCCOC1=CC=CC=C1 XDJKVSYUCPBDMD-UHFFFAOYSA-N 0.000 description 1
- BEGUXZSLVOVKMA-UHFFFAOYSA-N C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CCOC1=CC=C(Cl)C=C1 Chemical compound C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CCOC1=CC=C(Cl)C=C1 BEGUXZSLVOVKMA-UHFFFAOYSA-N 0.000 description 1
- BTXSVTBLLARHDS-UHFFFAOYSA-N C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CCOC1=CC=C(O)C=C1 Chemical compound C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CCOC1=CC=C(O)C=C1 BTXSVTBLLARHDS-UHFFFAOYSA-N 0.000 description 1
- AESQAAQDSJWVGA-UHFFFAOYSA-N C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CCOC1=CC=CC=C1 Chemical compound C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CCOC1=CC=CC=C1 AESQAAQDSJWVGA-UHFFFAOYSA-N 0.000 description 1
- JXUGHLADXLCHSM-UHFFFAOYSA-N C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CCOCC1=CC=CC=C1 Chemical compound C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CCOCC1=CC=CC=C1 JXUGHLADXLCHSM-UHFFFAOYSA-N 0.000 description 1
- VBDMXQTXNQJDMO-UHFFFAOYSA-N C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CNC(=O)C1=CC=C(Cl)C=C1 Chemical compound C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CNC(=O)C1=CC=C(Cl)C=C1 VBDMXQTXNQJDMO-UHFFFAOYSA-N 0.000 description 1
- HTQBEUCQRHYUFA-UHFFFAOYSA-N C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CNC(=O)C1=CC=C(O)C=C1 Chemical compound C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CNC(=O)C1=CC=C(O)C=C1 HTQBEUCQRHYUFA-UHFFFAOYSA-N 0.000 description 1
- UMWQRQZKHHGBHY-UHFFFAOYSA-N C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CNC(=O)C1=CC=CC=C1 Chemical compound C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CNC(=O)C1=CC=CC=C1 UMWQRQZKHHGBHY-UHFFFAOYSA-N 0.000 description 1
- IZQREDDQNGUUIG-UHFFFAOYSA-N C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CNC(=O)C1=CC=NC=C1 Chemical compound C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CNC(=O)C1=CC=NC=C1 IZQREDDQNGUUIG-UHFFFAOYSA-N 0.000 description 1
- QJIWTCFICKYWEM-UHFFFAOYSA-N C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CNC(=O)CC1=CC=C(Cl)C=C1 Chemical compound C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CNC(=O)CC1=CC=C(Cl)C=C1 QJIWTCFICKYWEM-UHFFFAOYSA-N 0.000 description 1
- CTZMTGIYRBCGCJ-UHFFFAOYSA-N C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CNC(=O)CC1=CC=C(O)C=C1 Chemical compound C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CNC(=O)CC1=CC=C(O)C=C1 CTZMTGIYRBCGCJ-UHFFFAOYSA-N 0.000 description 1
- JOUAFVICGFOPTM-UHFFFAOYSA-N C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CNC(=O)CC1=CC=CC=C1 Chemical compound C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2CNC(=O)CC1=CC=CC=C1 JOUAFVICGFOPTM-UHFFFAOYSA-N 0.000 description 1
- ITBTUOXVYBOFRV-UHFFFAOYSA-N C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2COCC1=CC=C(Cl)C=C1 Chemical compound C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2COCC1=CC=C(Cl)C=C1 ITBTUOXVYBOFRV-UHFFFAOYSA-N 0.000 description 1
- FOMIXJDJSPBVET-UHFFFAOYSA-N C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2COCC1=CC=C(N(C)C)C=C1 Chemical compound C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2COCC1=CC=C(N(C)C)C=C1 FOMIXJDJSPBVET-UHFFFAOYSA-N 0.000 description 1
- MLHRASIMVBMXML-UHFFFAOYSA-N C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2COCC1=CC=C(O)C=C1 Chemical compound C1CC2=CC=3OCOC=3C=C2C2N1CC1=C(OC)C(OC)=CC=C1C2COCC1=CC=C(O)C=C1 MLHRASIMVBMXML-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- SHHKQEUPHAENFK-UHFFFAOYSA-N Carboquone Chemical compound O=C1C(C)=C(N2CC2)C(=O)C(C(COC(N)=O)OC)=C1N1CC1 SHHKQEUPHAENFK-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- AOCCBINRVIKJHY-UHFFFAOYSA-N Carmofur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- MKQWTWSXVILIKJ-LXGUWJNJSA-N Chlorozotocin Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](C=O)NC(=O)N(N=O)CCCl MKQWTWSXVILIKJ-LXGUWJNJSA-N 0.000 description 1
- 238000006969 Curtius rearrangement reaction Methods 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 239000012624 DNA alkylating agent Substances 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- NNJPGOLRFBJNIW-UHFFFAOYSA-N Demecolcine Natural products C1=C(OC)C(=O)C=C2C(NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-UHFFFAOYSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- SAMRUMKYXPVKPA-VFKOLLTISA-N Enocitabine Chemical compound O=C1N=C(NC(=O)CCCCCCCCCCCCCCCCCCCCC)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 SAMRUMKYXPVKPA-VFKOLLTISA-N 0.000 description 1
- OBMLHUPNRURLOK-XGRAFVIBSA-N Epitiostanol Chemical compound C1[C@@H]2S[C@@H]2C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 OBMLHUPNRURLOK-XGRAFVIBSA-N 0.000 description 1
- 229930189413 Esperamicin Natural products 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 108091081406 G-quadruplex Proteins 0.000 description 1
- 230000037057 G1 phase arrest Effects 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000000853 LDL receptors Human genes 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- JLERVPBPJHKRBJ-UHFFFAOYSA-N LY 117018 Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCC3)=CC=2)C2=CC=C(O)C=C2S1 JLERVPBPJHKRBJ-UHFFFAOYSA-N 0.000 description 1
- 229920001491 Lentinan Polymers 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- VJRAUFKOOPNFIQ-UHFFFAOYSA-N Marcellomycin Natural products C12=C(O)C=3C(=O)C4=C(O)C=CC(O)=C4C(=O)C=3C=C2C(C(=O)OC)C(CC)(O)CC1OC(OC1C)CC(N(C)C)C1OC(OC1C)CC(O)C1OC1CC(O)C(O)C(C)O1 VJRAUFKOOPNFIQ-UHFFFAOYSA-N 0.000 description 1
- IVDYZAAPOLNZKG-KWHRADDSSA-N Mepitiostane Chemical compound O([C@@H]1[C@]2(CC[C@@H]3[C@@]4(C)C[C@H]5S[C@H]5C[C@@H]4CC[C@H]3[C@@H]2CC1)C)C1(OC)CCCC1 IVDYZAAPOLNZKG-KWHRADDSSA-N 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- SYNHCENRCUAUNM-UHFFFAOYSA-N Nitrogen mustard N-oxide hydrochloride Chemical compound Cl.ClCC[N+]([O-])(C)CCCl SYNHCENRCUAUNM-UHFFFAOYSA-N 0.000 description 1
- KGTDRFCXGRULNK-UHFFFAOYSA-N Nogalamycin Natural products COC1C(OC)(C)C(OC)C(C)OC1OC1C2=C(O)C(C(=O)C3=C(O)C=C4C5(C)OC(C(C(C5O)N(C)C)O)OC4=C3C3=O)=C3C=C2C(C(=O)OC)C(C)(O)C1 KGTDRFCXGRULNK-UHFFFAOYSA-N 0.000 description 1
- 229930187135 Olivomycin Natural products 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- PTPHDVKWAYIFRX-UHFFFAOYSA-N Palmatine Natural products C1C2=C(OC)C(OC)=CC=C2C=C2N1CCC1=C2C=C(OC)C(OC)=C1 PTPHDVKWAYIFRX-UHFFFAOYSA-N 0.000 description 1
- 241000218180 Papaveraceae Species 0.000 description 1
- 108010057150 Peplomycin Proteins 0.000 description 1
- KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- HFVNWDWLWUCIHC-GUPDPFMOSA-N Prednimustine Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 HFVNWDWLWUCIHC-GUPDPFMOSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 240000001987 Pyrus communis Species 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- AHHFEZNOXOZZQA-ZEBDFXRSSA-N Ranimustine Chemical compound CO[C@H]1O[C@H](CNC(=O)N(CCCl)N=O)[C@@H](O)[C@H](O)[C@H]1O AHHFEZNOXOZZQA-ZEBDFXRSSA-N 0.000 description 1
- 241000218201 Ranunculaceae Species 0.000 description 1
- 229910021607 Silver chloride Inorganic materials 0.000 description 1
- 229920000519 Sizofiran Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- CGMTUJFWROPELF-UHFFFAOYSA-N Tenuazonic acid Natural products CCC(C)C1NC(=O)C(=C(C)/O)C1=O CGMTUJFWROPELF-UHFFFAOYSA-N 0.000 description 1
- PQECCKIOFCWGRJ-UHFFFAOYSA-N Tetrahydro-berberine Natural products C1=C2C3CC4=CC=C(OC)C(O)=C4CN3CCC2=CC2=C1OCO2 PQECCKIOFCWGRJ-UHFFFAOYSA-N 0.000 description 1
- IWEQQRMGNVVKQW-OQKDUQJOSA-N Toremifene citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 IWEQQRMGNVVKQW-OQKDUQJOSA-N 0.000 description 1
- UMILHIMHKXVDGH-UHFFFAOYSA-N Triethylene glycol diglycidyl ether Chemical compound C1OC1COCCOCCOCCOCC1CO1 UMILHIMHKXVDGH-UHFFFAOYSA-N 0.000 description 1
- 241000863480 Vinca Species 0.000 description 1
- ZYVSOIYQKUDENJ-ASUJBHBQSA-N [(2R,3R,4R,6R)-6-[[(6S,7S)-6-[(2S,4R,5R,6R)-4-[(2R,4R,5R,6R)-4-[(2S,4S,5S,6S)-5-acetyloxy-4-hydroxy-4,6-dimethyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-7-[(3S,4R)-3,4-dihydroxy-1-methoxy-2-oxopentyl]-4,10-dihydroxy-3-methyl-5-oxo-7,8-dihydro-6H-anthracen-2-yl]oxy]-4-[(2R,4R,5R,6R)-4-hydroxy-5-methoxy-6-methyloxan-2-yl]oxy-2-methyloxan-3-yl] acetate Chemical class COC([C@@H]1Cc2cc3cc(O[C@@H]4C[C@@H](O[C@@H]5C[C@@H](O)[C@@H](OC)[C@@H](C)O5)[C@H](OC(C)=O)[C@@H](C)O4)c(C)c(O)c3c(O)c2C(=O)[C@H]1O[C@H]1C[C@@H](O[C@@H]2C[C@@H](O[C@H]3C[C@](C)(O)[C@@H](OC(C)=O)[C@H](C)O3)[C@H](O)[C@@H](C)O2)[C@H](O)[C@@H](C)O1)C(=O)[C@@H](O)[C@@H](C)O ZYVSOIYQKUDENJ-ASUJBHBQSA-N 0.000 description 1
- SPJCRMJCFSJKDE-ZWBUGVOYSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] 2-[4-[bis(2-chloroethyl)amino]phenyl]acetate Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)C(=O)CC1=CC=C(N(CCCl)CCCl)C=C1 SPJCRMJCFSJKDE-ZWBUGVOYSA-N 0.000 description 1
- IFJUINDAXYAPTO-UUBSBJJBSA-N [(8r,9s,13s,14s,17s)-17-[2-[4-[4-[bis(2-chloroethyl)amino]phenyl]butanoyloxy]acetyl]oxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] benzoate Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4OC(=O)COC(=O)CCCC=1C=CC(=CC=1)N(CCCl)CCCl)C)CC2=CC=3OC(=O)C1=CC=CC=C1 IFJUINDAXYAPTO-UUBSBJJBSA-N 0.000 description 1
- IHGLINDYFMDHJG-UHFFFAOYSA-N [2-(4-methoxyphenyl)-3,4-dihydronaphthalen-1-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]methanone Chemical compound C1=CC(OC)=CC=C1C(CCC1=CC=CC=C11)=C1C(=O)C(C=C1)=CC=C1OCCN1CCCC1 IHGLINDYFMDHJG-UHFFFAOYSA-N 0.000 description 1
- XZSRRNFBEIOBDA-CFNBKWCHSA-N [2-[(2s,4s)-4-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1h-tetracen-2-yl]-2-oxoethyl] 2,2-diethoxyacetate Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)C(OCC)OCC)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 XZSRRNFBEIOBDA-CFNBKWCHSA-N 0.000 description 1
- GLYOPNLBKCBTMI-UHFFFAOYSA-N [2-chloro-2-(1-chloro-2-phenylethoxy)ethyl]benzene Chemical compound C=1C=CC=CC=1CC(Cl)OC(Cl)CC1=CC=CC=C1 GLYOPNLBKCBTMI-UHFFFAOYSA-N 0.000 description 1
- RWWYTPCINPJDPE-UHFFFAOYSA-M [Cl-].C=12C3=CC=4OCOC=4C=C3CC[N+]2=CC2=C(OC)C(OC)=CC=C2C=1CCOC1=CC=CC=C1 Chemical compound [Cl-].C=12C3=CC=4OCOC=4C=C3CC[N+]2=CC2=C(OC)C(OC)=CC=C2C=1CCOC1=CC=CC=C1 RWWYTPCINPJDPE-UHFFFAOYSA-M 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- ZOZKYEHVNDEUCO-XUTVFYLZSA-N aceglatone Chemical compound O1C(=O)[C@H](OC(C)=O)[C@@H]2OC(=O)[C@@H](OC(=O)C)[C@@H]21 ZOZKYEHVNDEUCO-XUTVFYLZSA-N 0.000 description 1
- 229950002684 aceglatone Drugs 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- OVDMJDBIKMVRSN-UHFFFAOYSA-N acetoneberberine Chemical compound C1=C2C3=CC4=CC=C(OC)C(OC)=C4C(CC(C)=O)N3CCC2=CC2=C1OCO2 OVDMJDBIKMVRSN-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229910001516 alkali metal iodide Inorganic materials 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- 229960003437 aminoglutethimide Drugs 0.000 description 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
- 229960002749 aminolevulinic acid Drugs 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 229960001220 amsacrine Drugs 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- BBDAGFIXKZCXAH-CCXZUQQUSA-N ancitabine Chemical compound N=C1C=CN2[C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3OC2=N1 BBDAGFIXKZCXAH-CCXZUQQUSA-N 0.000 description 1
- 229950000242 ancitabine Drugs 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000013059 antihormonal agent Substances 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940045687 antimetabolites folic acid analogs Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000008209 arabinosides Chemical class 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 229950011321 azaserine Drugs 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- COKBTDHQMKTDCJ-UHFFFAOYSA-M berberine iodide Chemical compound [I-].C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 COKBTDHQMKTDCJ-UHFFFAOYSA-M 0.000 description 1
- OHXBMJJPRDNBSJ-UHFFFAOYSA-N berberine iodide Natural products COc1ccc2cc3c(NCc4cc5OCOc5cc34)c(O)c2c1OC OHXBMJJPRDNBSJ-UHFFFAOYSA-N 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229950008548 bisantrene Drugs 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- 208000024055 brain glioblastoma Diseases 0.000 description 1
- 201000011609 brain glioblastoma multiforme Diseases 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- GLYPKDKODVRYGP-UHFFFAOYSA-N burberrubine Natural products C12=CC=3OCOC=3C=C2CCN2C1=CC1=CC=C(OC)C(=O)C1=C2 GLYPKDKODVRYGP-UHFFFAOYSA-N 0.000 description 1
- 108700002839 cactinomycin Proteins 0.000 description 1
- 229950009908 cactinomycin Drugs 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229930195731 calicheamicin Natural products 0.000 description 1
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 1
- IVFYLRMMHVYGJH-PVPPCFLZSA-N calusterone Chemical compound C1C[C@]2(C)[C@](O)(C)CC[C@H]2[C@@H]2[C@@H](C)CC3=CC(=O)CC[C@]3(C)[C@H]21 IVFYLRMMHVYGJH-PVPPCFLZSA-N 0.000 description 1
- 229950009823 calusterone Drugs 0.000 description 1
- VZTUIEROBZXUFA-UHFFFAOYSA-N canadine Chemical compound C1=C2C3CC4=CC=C(OC)C(OC)=C4CN3CCC2=CC2=C1OCO2 VZTUIEROBZXUFA-UHFFFAOYSA-N 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 229960002115 carboquone Drugs 0.000 description 1
- 229930188550 carminomycin Natural products 0.000 description 1
- XREUEWVEMYWFFA-CSKJXFQVSA-N carminomycin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XREUEWVEMYWFFA-CSKJXFQVSA-N 0.000 description 1
- XREUEWVEMYWFFA-UHFFFAOYSA-N carminomycin I Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XREUEWVEMYWFFA-UHFFFAOYSA-N 0.000 description 1
- 229960003261 carmofur Drugs 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229950001725 carubicin Drugs 0.000 description 1
- 108010047060 carzinophilin Proteins 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 238000002701 cell growth assay Methods 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 229960001480 chlorozotocin Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 230000005574 cross-species transmission Effects 0.000 description 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 229960005052 demecolcine Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229950003913 detorubicin Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- WVYXNIXAMZOZFK-UHFFFAOYSA-N diaziquone Chemical compound O=C1C(NC(=O)OCC)=C(N2CC2)C(=O)C(NC(=O)OCC)=C1N1CC1 WVYXNIXAMZOZFK-UHFFFAOYSA-N 0.000 description 1
- 229950002389 diaziquone Drugs 0.000 description 1
- LHUZAYREVYDAGJ-UHFFFAOYSA-N dichloromethane;ethyl acetate;methanol Chemical compound OC.ClCCl.CCOC(C)=O LHUZAYREVYDAGJ-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 description 1
- 229950005454 doxifluridine Drugs 0.000 description 1
- NOTIQUSPUUHHEH-UXOVVSIBSA-N dromostanolone propionate Chemical compound C([C@@H]1CC2)C(=O)[C@H](C)C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](OC(=O)CC)[C@@]2(C)CC1 NOTIQUSPUUHHEH-UXOVVSIBSA-N 0.000 description 1
- 229950004683 drostanolone propionate Drugs 0.000 description 1
- 229960002759 eflornithine Drugs 0.000 description 1
- 229950000549 elliptinium acetate Drugs 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 229950011487 enocitabine Drugs 0.000 description 1
- 229950002973 epitiostanol Drugs 0.000 description 1
- 229950002017 esorubicin Drugs 0.000 description 1
- ITSGNOIFAJAQHJ-BMFNZSJVSA-N esorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)C[C@H](C)O1 ITSGNOIFAJAQHJ-BMFNZSJVSA-N 0.000 description 1
- 229960001842 estramustine Drugs 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- QSRLNKCNOLVZIR-KRWDZBQOSA-N ethyl (2s)-2-[[2-[4-[bis(2-chloroethyl)amino]phenyl]acetyl]amino]-4-methylsulfanylbutanoate Chemical compound CCOC(=O)[C@H](CCSC)NC(=O)CC1=CC=C(N(CCCl)CCCl)C=C1 QSRLNKCNOLVZIR-KRWDZBQOSA-N 0.000 description 1
- VEGCUWVZNBYXFC-UHFFFAOYSA-N ethyl 2-(16,17-dimethoxy-5,7-dioxa-13-azapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-2,4(8),9,15(20),16,18-hexaen-21-yl)acetate Chemical compound C1=CC(OC)=C(OC)C2=C1C(CC(=O)OCC)C1C3=CC(OCO4)=C4C=C3CCN1C2 VEGCUWVZNBYXFC-UHFFFAOYSA-N 0.000 description 1
- LTRWLJBMKWQIBE-UHFFFAOYSA-N ethyl 2-(16,17-dimethoxy-5,7-dioxa-13-azapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-2,4(8),9,15(20),16,18-hexaen-21-yl)propanoate Chemical compound COC1=CC=C2C(C(C)C(=O)OCC)C3C4=CC(OCO5)=C5C=C4CCN3CC2=C1OC LTRWLJBMKWQIBE-UHFFFAOYSA-N 0.000 description 1
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
- 229960005237 etoglucid Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229940043168 fareston Drugs 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 150000002224 folic acids Chemical class 0.000 description 1
- 229960004783 fotemustine Drugs 0.000 description 1
- YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 1
- 229940044658 gallium nitrate Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 229940015872 ibandronate Drugs 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 229940115286 lentinan Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 229960003538 lonidamine Drugs 0.000 description 1
- WDRYRZXSPDWGEB-UHFFFAOYSA-N lonidamine Chemical compound C12=CC=CC=C2C(C(=O)O)=NN1CC1=CC=C(Cl)C=C1Cl WDRYRZXSPDWGEB-UHFFFAOYSA-N 0.000 description 1
- MQXVYODZCMMZEM-ZYUZMQFOSA-N mannomustine Chemical compound ClCCNC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CNCCCl MQXVYODZCMMZEM-ZYUZMQFOSA-N 0.000 description 1
- 229950008612 mannomustine Drugs 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229950009246 mepitiostane Drugs 0.000 description 1
- VJRAUFKOOPNFIQ-TVEKBUMESA-N methyl (1r,2r,4s)-4-[(2r,4s,5s,6s)-5-[(2s,4s,5s,6s)-5-[(2s,4s,5s,6s)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-4-(dimethylamino)-6-methyloxan-2-yl]oxy-2-ethyl-2,5,7,10-tetrahydroxy-6,11-dioxo-3,4-dihydro-1h-tetracene-1-carboxylat Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=C(O)C=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1C[C@H](O)[C@H](O)[C@H](C)O1 VJRAUFKOOPNFIQ-TVEKBUMESA-N 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 229960005485 mitobronitol Drugs 0.000 description 1
- 229960003539 mitoguazone Drugs 0.000 description 1
- MXWHMTNPTTVWDM-NXOFHUPFSA-N mitoguazone Chemical compound NC(N)=N\N=C(/C)\C=N\N=C(N)N MXWHMTNPTTVWDM-NXOFHUPFSA-N 0.000 description 1
- VFKZTMPDYBFSTM-GUCUJZIJSA-N mitolactol Chemical compound BrC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-GUCUJZIJSA-N 0.000 description 1
- 229950010913 mitolactol Drugs 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229960000350 mitotane Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- FOYWNSCCNCUEPU-UHFFFAOYSA-N mopidamol Chemical compound C12=NC(N(CCO)CCO)=NC=C2N=C(N(CCO)CCO)N=C1N1CCCCC1 FOYWNSCCNCUEPU-UHFFFAOYSA-N 0.000 description 1
- 229950010718 mopidamol Drugs 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- NJSMWLQOCQIOPE-OCHFTUDZSA-N n-[(e)-[10-[(e)-(4,5-dihydro-1h-imidazol-2-ylhydrazinylidene)methyl]anthracen-9-yl]methylideneamino]-4,5-dihydro-1h-imidazol-2-amine Chemical compound N1CCN=C1N\N=C\C(C1=CC=CC=C11)=C(C=CC=C2)C2=C1\C=N\NC1=NCCN1 NJSMWLQOCQIOPE-OCHFTUDZSA-N 0.000 description 1
- GUWFOESQKSFAFF-UHFFFAOYSA-N n-ethylethanamine;hexane Chemical compound CCNCC.CCCCCC GUWFOESQKSFAFF-UHFFFAOYSA-N 0.000 description 1
- 229940086322 navelbine Drugs 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- QZGIWPZCWHMVQL-UIYAJPBUSA-N neocarzinostatin chromophore Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1O[C@@H]1C/2=C/C#C[C@H]3O[C@@]3([C@@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(O)C=CC2=C(C)C=C(OC)C=C12 QZGIWPZCWHMVQL-UIYAJPBUSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960002653 nilutamide Drugs 0.000 description 1
- XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
- 229960001420 nimustine Drugs 0.000 description 1
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 description 1
- YMVWGSQGCWCDGW-UHFFFAOYSA-N nitracrine Chemical compound C1=CC([N+]([O-])=O)=C2C(NCCCN(C)C)=C(C=CC=C3)C3=NC2=C1 YMVWGSQGCWCDGW-UHFFFAOYSA-N 0.000 description 1
- 229950008607 nitracrine Drugs 0.000 description 1
- 229950009266 nogalamycin Drugs 0.000 description 1
- KGTDRFCXGRULNK-JYOBTZKQSA-N nogalamycin Chemical compound CO[C@@H]1[C@@](OC)(C)[C@@H](OC)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=C4[C@@]5(C)O[C@H]([C@H]([C@@H]([C@H]5O)N(C)C)O)OC4=C3C3=O)=C3C=C2[C@@H](C(=O)OC)[C@@](C)(O)C1 KGTDRFCXGRULNK-JYOBTZKQSA-N 0.000 description 1
- CZDBNBLGZNWKMC-MWQNXGTOSA-N olivomycin Chemical class O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1)O[C@H]1O[C@@H](C)[C@H](O)[C@@H](OC2O[C@@H](C)[C@H](O)[C@@H](O)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@H](O)[C@H](OC)[C@H](C)O1 CZDBNBLGZNWKMC-MWQNXGTOSA-N 0.000 description 1
- 229950011093 onapristone Drugs 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- QIMGFXOHTOXMQP-GFAGFCTOSA-N peplomycin Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCN[C@@H](C)C=1C=CC=CC=1)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C QIMGFXOHTOXMQP-GFAGFCTOSA-N 0.000 description 1
- 229950003180 peplomycin Drugs 0.000 description 1
- 229960003424 phenylacetic acid Drugs 0.000 description 1
- 239000003279 phenylacetic acid Substances 0.000 description 1
- 125000003884 phenylalkyl group Chemical group 0.000 description 1
- 229960000952 pipobroman Drugs 0.000 description 1
- NJBFOOCLYDNZJN-UHFFFAOYSA-N pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 description 1
- 229960001221 pirarubicin Drugs 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229960004694 prednimustine Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- WOLQREOUPKZMEX-UHFFFAOYSA-N pteroyltriglutamic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(=O)NC(CCC(=O)NC(CCC(O)=O)C(O)=O)C(O)=O)C(O)=O)C=C1 WOLQREOUPKZMEX-UHFFFAOYSA-N 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 229960002185 ranimustine Drugs 0.000 description 1
- BMKDZUISNHGIBY-UHFFFAOYSA-N razoxane Chemical compound C1C(=O)NC(=O)CN1C(C)CN1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-UHFFFAOYSA-N 0.000 description 1
- 229960000460 razoxane Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 229950004892 rodorubicin Drugs 0.000 description 1
- VHXNKPBCCMUMSW-FQEVSTJZSA-N rubitecan Chemical compound C1=CC([N+]([O-])=O)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VHXNKPBCCMUMSW-FQEVSTJZSA-N 0.000 description 1
- 208000004548 serous cystadenocarcinoma Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 1
- 229950001403 sizofiran Drugs 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 229950006315 spirogermanium Drugs 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 229960005353 testolactone Drugs 0.000 description 1
- BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 description 1
- YFTWHEBLORWGNI-UHFFFAOYSA-N tiamiprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC(N)=NC2=C1NC=N2 YFTWHEBLORWGNI-UHFFFAOYSA-N 0.000 description 1
- 229950011457 tiamiprine Drugs 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- 229950001353 tretamine Drugs 0.000 description 1
- IUCJMVBFZDHPDX-UHFFFAOYSA-N tretamine Chemical compound C1CN1C1=NC(N2CC2)=NC(N2CC2)=N1 IUCJMVBFZDHPDX-UHFFFAOYSA-N 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- PXSOHRWMIRDKMP-UHFFFAOYSA-N triaziquone Chemical compound O=C1C(N2CC2)=C(N2CC2)C(=O)C=C1N1CC1 PXSOHRWMIRDKMP-UHFFFAOYSA-N 0.000 description 1
- 229960004560 triaziquone Drugs 0.000 description 1
- 125000006000 trichloroethyl group Chemical group 0.000 description 1
- 229960001670 trilostane Drugs 0.000 description 1
- KVJXBPDAXMEYOA-CXANFOAXSA-N trilostane Chemical compound OC1=C(C#N)C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@@]32O[C@@H]31 KVJXBPDAXMEYOA-CXANFOAXSA-N 0.000 description 1
- NOYPYLRCIDNJJB-UHFFFAOYSA-N trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 description 1
- 229960001099 trimetrexate Drugs 0.000 description 1
- 229950000212 trioxifene Drugs 0.000 description 1
- 229960000875 trofosfamide Drugs 0.000 description 1
- UMKFEPPTGMDVMI-UHFFFAOYSA-N trofosfamide Chemical compound ClCCN(CCCl)P1(=O)OCCCN1CCCl UMKFEPPTGMDVMI-UHFFFAOYSA-N 0.000 description 1
- HDZZVAMISRMYHH-LITAXDCLSA-N tubercidin Chemical compound C1=CC=2C(N)=NC=NC=2N1[C@@H]1O[C@@H](CO)[C@H](O)[C@H]1O HDZZVAMISRMYHH-LITAXDCLSA-N 0.000 description 1
- 229950009811 ubenimex Drugs 0.000 description 1
- 229960001055 uracil mustard Drugs 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- CILBMBUYJCWATM-PYGJLNRPSA-N vinorelbine ditartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC CILBMBUYJCWATM-PYGJLNRPSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229940053867 xeloda Drugs 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
- 229950009268 zinostatin Drugs 0.000 description 1
- 229960000641 zorubicin Drugs 0.000 description 1
- FBTUMDXHSRTGRV-ALTNURHMSA-N zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the present invention relates to benzoquinolizinium salt derivatives and to processes for the preparation of said compounds.
- the invention also encompass pharmaceutical compositions containing said derivatives and the use of said compounds for the manufacture of medicaments suitable for the treatment of cancerous diseases.
- Protoberberines constitute a family of naturally occurring benzoquinolizinium alkaloids found in plants such as, for instance, Anonaceae, Berbiridaceae, Papaveraceae, Ranunculaceae.
- Relevant examples of protoberberines are Berberine or 9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium; Berberrubine (or Berbine) or 9-hydroxy-10-methoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium; and Palmatine or 2,3,9,10-tetramethoxy-5,6-dihydrodibenzo[a,g]quinolizinium.
- inventive benzoquinolizinium salt derivatives may be also considered and commonly termed as protoberberine derivatives. Both the scientific, IUPAC-recommended and the trivial, common
- U.S. Pat. No. b 3 , 910 , 938 and U.S. Pat. No. 3,920,665 disclose berbine compounds carrying alkyl, allyl or alkoxy substituents in position 13 as inhibitors of the growth of transplanted sarcoma strains in mice. There is no mention about additional (hetero)aromatic moieties linked to the substituents in position 13.
- U.S. Pat. No. 6,008,356 and U.S. Pat. No. 6,030,978 disclose protoberberine derivatives substituted in position 13 by phenylmethyl (benzyl) and pyridylmethyl groups as antifungal agents, and pharmaceutical compositions containing them. Said patent specifications are completely silent in mentioning anything about an anticancer activity, and there is no reference about 13-(di)arylalkyl substituted compounds, even no disclosure or mention about phenylalkyl and pyridylalkyl substituents.
- Example 1 (13-benzyl) of said US patents was comparatively tested with the novel compounds of our specification, resulting in a much lower antitumour activity.
- U.S. Pat. No. 6,239,139 and U.S. Pat. No. 6,255,317 disclose berberine derivatives bearing alkyl, alkenyl, cycloalkylalkyl, haloalkyl, ethoxycarbonyl, ethoxycarbonylmethyl, hydroxycarbonylmethyl, ethoxycarbonylethyl, and 2-valerolactonyl groups in position 13, as inhibitors of cholesterol biosynthesis. There is no mention about an antitumour activity and/or additional (hetero)aromatic moieties linked to the substituents in position 13.
- WO 2008/040192 discloses berberine derivatives bearing lower alkyl, lower alkoxy and acetic acid lower alkyl esters in position 13.
- the said derivatives are glucose sorbefacient to muscle cells and have medical effects for improving glucose-tolerance and insulin-resistance, and can be used for treating diabetes mellitus, adiposity, fatty liver and their complications caused by insulin resistance.
- Life Sciences 73, 1401, 2003 describes the effects of 13-methyl and 13-ethyl berberine on the expression of certain proteins in connection with a reported antibacterial activity.
- the present invention is concerned with 13-substituted 5,6-dihydrodibenzo [a,g]quinolizinium salt compounds of the general formula (I):
- Ar represents a 5-15 membered unsaturated or aromatic mono-, bi- or tricyclic carbocyclic or heterocyclic ring system, wherein any of said heterocyclic ring systems, for each occurrence, contains one o more heteroatoms selected from O, N, or S; and wherein any of said ring systems, for each occurrence, optionally contains from 1 to 4 substituents independently selected from halogen, cyano, nitro, hydroxy, amino, (di)(C 1 -C 6 )alkylamino, (C 1 -C 6 )alkylcarbonylamino, (C 1 -C 6 )alkoxy, (C 1 -C 6 )alkylcarbonyloxy, (C 1 -C 6 )alkoxycarbonyl, (C 1 -C 6 )alkyl; and wherein any of said (C 1 -C 6 )alk* moieties, for each occurrence, contains from 1 to 4 halogen atoms independently chosen from F, Cl,
- R 1 and R 2 which may be the same or different, represent independently a hydroxy or a (C 1 -C 6 )alkoxy group, or, taken together, a methylenedioxy group;
- R 3 and R 4 which may be the same or different, represent independently a hydroxy or a (C 1 -C 6 )alkoxy group
- Ar represents a 5-15 membered unsaturated or aromatic mono-, bi- or tricyclic carbocyclic or heterocyclic ring system, wherein any of said heterocyclic ring systems, for each occurrence, contains one o more heteroatoms selected from O, N, or S; and wherein any of said ring systems, for each occurrence, optionally contains from 1 to 4 substituents independently selected from halogen, cyano, nitro, hydroxy, amino, (di)(C 1 -C 6 )alkylamino, (C 1 -C 6 )alkylcarbonylamino, (C 1 -C 6 )alkoxy, (C 1 -C 6 )alkylcarbonyloxy, (C 1 -C 6 )alkoxycarbonyl, (C 1 -C 6 )alkyl; and wherein any of said (C 1 -C 6 )alk* moieties, for each occurrence, contains from 1 to 4 halogen atoms independently chosen from F, Cl,
- a first aspect of the invention relates to such compounds of formula (I), wherein:
- the invention relates to such compounds wherein:
- the invention relates to such compounds wherein:
- the invention relates to such compounds wherein:
- the invention relates to such compounds of formula (I), wherein:
- the invention relates to such compounds wherein:
- the invention relates to such compounds wherein:
- the invention relates to such compounds wherein:
- the invention relates to such compounds wherein:
- Ar can represent an unsaturated or aromatic mono- or bicyclic carbocyclic ring system radical chosen from phenyl, naphthyl, indenyl, azulenyl, optionally containing from 1 to 4 substituents.
- Ar can also represent an unsaturated or aromatic mono- or bicyclic heterocyclic ring system radical chosen from imidazolyl, quinolyl, isoquinolyl, indolyl, indazolyl, pyridazyl, pyridyl, pyrrolyl, pyrazolyl, pyrazinyl, quinoxalyl, pyrimidinyl, pyridazinyl, furyl, thienyl, triazolyl, thiazolyl, tetrazolyl, benzofuranoyl, oxazolyl, benzoxazolyl, isoxazolyl, isothiazolyl, thiazolyl, thiadiazoyl, benzodioxolyl, optionally containing from 1 to 4 substituents.
- an unsaturated or aromatic mono- or bicyclic heterocyclic ring system radical chosen from imidazolyl, quinolyl, isoquinolyl, indoly
- Ar can also represent an unsaturated or aromatic tricyclic carbocyclic or heterocyclic ring system radical chosen from fluorenyl, anthracenyl, 5H-dibenzocycloheptenyl, 10,11-dihydro-5H-dibenzocycloheptenyl, xanthenyl, acridinyl, phenothiazinyl, phenoxazinyl, carbazolyl, optionally containing from 1 to 4 substituents.
- the substituents of the Ar moiety can be independently selected from, but not limited to, groups such as methyl, ethyl, propyl, and the like; trifluoromethyl, trichloromethyl, tribromomethyl, 2,2,2-trifluoroethyl, 2,2,2-trichloroethyl, and the like; hydroxy, methoxy, ethoxy, 2,2,2-trichloroethoxy, acetoxy, trifluoroacetoxy, trichloroacetoxy, and the like; amino, (di)methylamino, (di)ethylamino, acetamido, trifluoroacetamido and the like; cyano, nitro, fluoro, chloro, iodo and bromo.
- the compounds of the following list are preferred.
- the indicated meaning of the anion X should not be construed as limiting the specific compound claimed, since a definite X can be easily converted into a different X simply by carrying out metathesis reactions, e.g. the iodide of a compound of the general formula (I) may be converted into the chloride of the same compound of the general formula (I) by treatment with silver chloride (see e.g., J. Nat. Prod. 61, 1150, 1998).
- the present invention encompass also any other salt of that specific 13-substituted 5,6-dihydrodibenzo[a,g]quinolizinium which can be obtained by the above mentioned metathesis reaction.
- a first process comprises reacting a 13-substituted tetrahydroprotoberberine of general formula (II)
- R 1 , R 2 , R 3 , R 4 , G and n are as previously defined, with such oxidizing agents as represented by halogens, e.g. Br 2 or I 2 , or haloamides and haloimides, e.g N-chloro-, N-bromo- or N-iodosuccinimide to give a compound of the general formula (I) wherein R 1 , R 2 , R 3 , R 4 , G and n are as previously defined, and X represents the halogen atom derived from the above oxidizing agent used, being said 13-substituted tetrahydroprotoberberines of the general formula (II) obtained as follow:
- halogens e.g. Br 2 or I 2
- haloamides and haloimides e.g N-chloro-, N-bromo- or N-iodosuccinimide
- R 1 , R 2 , R 3 , R 4 , Ar, n and m are as previously defined, Z and Y are as herein above stated, and Hal is an halogen atom such as chlorine, bromine and iodine, to give a 13-substituted iminiumprotoberberine derivative of formula (V)
- R 1 , R 2 , R 3 , R 4 , n are as previously defined, and G is as herein above stated, and
- R 1 , R 2 , R 3 , R 4 , n are as previously defined, and G is as herein above stated;
- R 5 represents such radicals as methyl, ethyl, t-butyl, benzyl, 2,2,2-trichloethyl and the like, to obtain an 13-alkylcarboxy acid ester iminiumprotoberberine derivative of formula (VII),
- R 1 , R 2 , R 3 , R 4 , n are as previously defined, and G is as herein above stated;
- R 1 , R 2 , R 3 , R 4 , n are as previously defined, and G is as herein above stated.
- the oxidation of a 13-substituted tetrahydroprotoberberine of general formula (II) to give the compounds of the invention may be carried out according to known methods, for instance as described in U.S. Pat. No. 6,030,978 or in J. Nat. Prod. 6, 115 (1998).
- the reaction may be performed in an organic solvent such as chloroform, ethanol or acetic acid at temperatures ranging from 0 to about 100° C.
- the reaction is carried out in chloroform at reflux when N-chlorosuccinimide or N-bromosuccinimide is used.
- the preferred solvent is ethanol at reflux.
- the preferred solvent is acetic acid when bromine is used as oxidizing agent.
- the oxidation is carried out with N-chlorosuccinimide or iodine.
- reaction of a dihydroprotoberberine of general formula (III) with a halide of general formulae (IVa) or (IVb) to give a 13-substituted iminiumprotoberberine derivative of formula (V), wherein G stands for -Z—Ar, wherein Z is a bond or O(CH 2 ) m , or for —Y ⁇ (Ar) 2 , wherein Y is CH or O(CH 2 ) m —CH, and the similar reaction of a dihydroprotoberberine of general formula (III) with a haloalkanoic acid ester of formula (VI) to give a 13-alkylcarboxy acid ester iminiumprotoberberine derivative of formula (VII), may be carried out as generally reported for enamine alkylations.
- the enamine alkylation herebelow described, is an analogy process, for example as reported in Bioorganic & Medicinal Chemistry Letters 16, 3913 (2006).
- the alkylation may be performed in inert organic solvent, for instance acetonitrile, chloroform, dichloromethane or dioxane.
- the reaction is carried out in hot acetonitrile in the presence of sodium iodide.
- the halogen atom is preferably bromine or iodine.
- Suitable reaction conditions for the reduction of the iminium compounds of formula (V) and (VII) to obtain the corresponding 13-substituted tetrahydroprotoberberine of formula (II-i) and (VIII), respectively are sodium or potassium borohydride in a protic solvent, such as methanol, ethanol or isopropanol.
- a protic solvent such as methanol, ethanol or isopropanol.
- the reduction is carried out in ethanol solution at room temperature using an excess of sodium borohydride.
- the hydrolysis or the cleavage of the ester group of the ester compound of formula (VII) to obtain a 13-alkylcarboxy acid tetrahydroprotoberberine derivative of formula (IX) may be performed following usual methods and procedures known in organic chemistry for the hydrolysis of methyl, ethyl, t-butyl esters or for the cleavage of benzyl and trichloroethyl esters, respectively.
- acyl azido derivative of formula (XIII) is obtained by the corresponding acid of formula (IX) with methods known in organic chemistry.
- a preferred method is by the use of diphenyl phosphorazidate (DPPA), as described in Tetrahedron, 30, 2151, 1974.
- compositions containing, as active ingredient, a compound of formula (I) combined with a pharmaceutically acceptable diluent or carrier. Accordingly, a therapeutically effective dose of a compound of formula (I) is combined with an inert carrier.
- the compositions may be formulated in a conventional manner using common carriers as known to a person skilled in the pharmaceutical art.
- a preferred carrier is alpha-, beta- or gamma-cyclodextrin.
- the invention is based on the surprising recognition that the 13-substituted protoberberines of formula (I), in contrast to the prior art compounds derived from protoberberine structure, show a considerable antitumour activities in relevant cancer cell lines.
- Such a unique anticancer profile has not so far been described in the patent and scientific literature in connection with any one of the prior art protoberberine derivatives.
- the compounds of the invention were assayed in a panel of sensible, resistant and refractary tumour cell lines, which are only exemplary for the antitumour activity of the inventive compounds, and are not to be construed as limiting their antitumour activities only to the cell lines set forth herein.
- the 2008 cell line was established from a patient with serous cystadenocarcinoma of the ovary and the cDDP-resistant C13* subline, about 15-fold resistant to cDDP, was derived from the parent 2008 cell line by monthly exposure to cDDP, followed by chronic exposure to step-wise increases in cDDP concentration ( Cancer Research 52, 1895, 1992).
- the cell lines were grown as monolayers in RPMI 1640 medium containing 10% heat-inactivated fetal bovine serum and 50 ⁇ g/mL gentamycin sulfate. All cell media and serum were purchased from (Lonza, Verviers, Belgium). Cultures were equilibrated with humidified 5% CO 2 in air at 37° C. All studies were performed in Mycoplasma negative cells, as routinely determined with the MycoAlert Mycoplasma detection kit (Lonza, Walkersville, Md., USA).
- the human ovarian cancer cell line A2780 and a platinum-resistant subline selected in vitro by stepwise increases of cisplatin concentration in the medium were from University of Modena and Reggio Emilia.
- the cisplatin resistant A2780 cells were challenged weekly with 50 uM cisplatin for 1 hr. Both cell lines were maintained in RPMI 1640 medium with 10% (vol/vol) fetal calf serum, penicillin (62.9 mg/L), and streptomycin (100 mg/L) (GIBCO).
- Cell growth assay Cell growth was determined by a modification of the crystal violet dye assay ( Analytical biochemistry, 182, 16 1989). On selected days, after removal of the tissue culture medium, the cell monolayer was fixed with methanol prior to staining with 0.2% crystal violet solution in 20% methanol for at least 30 minutes. After washing several times with distilled water to remove the dye excess, the cells were let to dry. The incorporated dye was solubilized in acidic isopropanol (1N HCl : 2-propanol, 1:10). After appropriate dilution, dye was determined spectrophotometrically at 540 nm. The extracted dye was proportional to cell number.
- Percentage of cytotoxicity was calculated by comparing the absorbance of cultures exposed to the compounds of the invention to non-exposed (control) cultures. The data are shown in the following Tables 1a and 1b. Percentage of cytotoxicity is here reported as the half maximal inhibitory concentration (IC50), which is a measure of the effectiveness of a compound of the invention in inhibiting cell growth by half with respect to control (100%).
- IC50 half maximal inhibitory concentration
- Human tumor cells (HeLa from uterin cervix and HCT116 from colon carcinoma) were grown at 37° C. in humidified atmosphere containing 5% CO 2 in D-MEM supplemented with 10% FCS, 4 mM glutamine, 2 mM Na pyruvate, 100 U/mL penicillin and 0.1 mg/mL streptomycin (all reagents were from Celbio, Pero, Italy). HeLa cells are the most widely used human tumor cell line; HCT 116 colon carcinoma cell line has proven to be extremely resistant to conventional chemotherapy. Cells were treated with the compounds of the invention at a fixed dose of 10 uM for 24 h, eventually followed by 24 of recovery in drug free medium. As a positive control of growth inhibition, cells were treated with 10 uM etoposide. Some of the inventive were also assayed at a dose of 1 uM.
- MTT assay Cell proliferation assays.
- Cells are seeded in 96 multiwell-plates at the density of 10 3 /100 ⁇ l (except fibroblasts that are seeded at the density of 1.5 ⁇ 10 3 /100 ⁇ l). Cells are treated 24 h later with the drug for 24 h eventually followed by 24 h of recovery in drug-free medium. At the end of the treatments, 20 ⁇ l of CellTiter 96 Non - Radioactive Cell Proliferation Assay ( MTT ; Promega, Milano, Italy) are added to each well. Plates are then incubated for 4 h at 37° C. in the dark and analyzed with a reader of microplates (Gio. De Vita, Roma, Italy) at 492 nm. Experiments are performed in quadruplicate and repeated three times. Data are expressed in the following Tables 2a-c as the percentage compared to control cells considered as 100%.
- the claimed compounds are useful for the therapeutic treatments of tumour diseases in humans and other mammals by administration of therapeutically effective quantities of the compound of formula (I) to a subject under treatment for, e. g., leukemias, lymphomas, solid tumours such as sarcomas, breast, ovarian, and cervical carcinomas, bladder and prostate carcinomas, bronchogenic, gastric and hepatic carcinomas, mesotheliomas, brain tumours, glioblastoma and the like.
- the claimed compounds and compositions and may be administered alone or in combination with one or more additional chemotherapeutic or growth inhibitory agents.
- chemotherapeutic agents include alkylating agents such as thiotepa and cyclosphosphamide; alkyl sulfonates such as busulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelamines including altretamine, triethylenemelamine, trietylenephosphoramide, triethylenethiophosphaoramide and trimethylolomelamine; nitrogen mustards such as chlorambucil, chlomaphazine, cholophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard; nitrosureas such as carmustine, chlorozotocin, fotemustine, lomustine, n
- paclitaxel and docetaxel chlorambucil; gemcitabine; 6-thioguanine; mercaptopurine; methotrexate; platinum analogs such as cisplatin and carboplatin; vinblastine; platinum; etoposide (VP-16); ifosfamide; mitomycin C; mitoxantrone; vincristine; vinorelbine; navelbine; novantrone; teniposide; daunomycin; aminopterin; xeloda; ibandronate; CPT-11; topoisomerase inhibitor RFS 2000; difluoromethylornithine (DMFO); retinoic acid; esperamicins; capecitabine; and pharmaceutically acceptable salts, acids or derivatives of any of the above.
- platinum analogs such as cisplatin and carboplatin; vinblastine; platinum; etoposide (VP-16); ifosfamide; mitomycin C; mitoxantron
- anti-hormonal agents that act to regulate or inhibit hormone action on tumors
- anti-estrogens including for example tamoxifen, raloxifene, aromatase inhibiting 4(5)-imidazoles, 4-hydroxytamoxifen, trioxifene, keoxifene, LY117018, onapristone, and toremifene (Fareston); and anti-androgens such as flutamide, nilutamide, bicalutamide, leuprolide, and goserelin.
- growth inhibitory agents include agents that block cell cycle progression (at a place other than S phase), such as agents that induce G1 arrest and M-phase arrest.
- Classical M-phase blockers include the vincas (vincristine and vinblastine), taxol, and topo II inhibitors such as doxorubicin, epirubicin, daunorubicin, etoposide, and bleomycin.
- Those agents that arrest G1 also spill over into S-phase arrest, for example, DNA alkylating agents such as tamoxifen, prednisone, dacarbazine, mechlorethamine, cisplatin, methotrexate, 5-fluorouracil, and ara-C.
- Various delivery systems are known and can be used to administer an agent of the invention, e.g., encapsulation in liposomes, microparticles, microcapsules.
- Methods of introduction can be enteral or parenteral and include but are not limited to intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, intraocular, and oral routes.
- the compounds may be administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents. Administration can be systemic or local.
- Administration can be daily, weekly, or monthly, or in combination with other agents. Pulmonary administration can also be employed, e.g., by use of an inhaler or nebulizer, and formulation with an aerosolizing agent.
- the amount of the inventive compound that will be effective for its intended therapeutic use can be determined by standard clinical techniques based on the present description.
- in vitro assays may optionally be employed to help identify optimal dosage ranges.
- suitable dosage ranges for intravenous administration are generally about 1-50 mg/kg body weight, preferably about 5-40 mg/kg body weight, most preferably about 10-20 mg/kg body weight.
- the title compound was obtained by reacting 8-acetonyl-tetrahydroberberine with benzylbromide as described in Example 1 of U.S. Pat. No. 6,008,356 and U.S. Pat. No. 6,030,978.
- the iminium salt was dissolved in absolute ethanol (20 mL), then sodium borohydride (378 mg, 10 mmol) was added and the resulting suspension stirred for 30 min at room temperature. More sodium borohydride (378 mg, 10 mmol) was added and the mixture stirred for further 1 h at room temperature. The solvent was evaporated under vacuum, then water (60 mL) was added and the mixture extracted with ethyl acetate (3 ⁇ 100 mL). The combined organic phases were dried and evaporated to dryness. The residue was submitted to column chromatography using hexane-ethyl acetate (10-25%) as eluant to obtain the title compound.
- Triethylamine (1.02 g, 1.02 mmol) and diphenylphosphorylazide (2.75 g, 10 mmol) were added under stirring at room temperature to a suspension of 13-(carboxymethyl)-tetrahydroberberine (3.972 g, 10 mmol) in acetonitrile (30 mL). After 2 h additional stirring at room temperature the mixture was partitioned between chloroform and 5% aqueous sodium bicarbonate. The combined organic phases were dried and evaporated to give 13-(azidocarbonylmethyl)-tetrahydroberberine (3.80 g, 90% yield).
- Mixtures of a compound of formula (I) and of different amounts of beta-cyclodextrin, or gamma-cyclodextrin are prepared by grinding, followed by sieving ( ⁇ 0.375 mm) and 10 minute of mixing in a turbo-mixer.
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
- The present invention relates to benzoquinolizinium salt derivatives and to processes for the preparation of said compounds. The invention also encompass pharmaceutical compositions containing said derivatives and the use of said compounds for the manufacture of medicaments suitable for the treatment of cancerous diseases.
- Protoberberines constitute a family of naturally occurring benzoquinolizinium alkaloids found in plants such as, for instance, Anonaceae, Berbiridaceae, Papaveraceae, Ranunculaceae. Relevant examples of protoberberines are Berberine or 9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium; Berberrubine (or Berbine) or 9-hydroxy-10-methoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium; and Palmatine or 2,3,9,10-tetramethoxy-5,6-dihydrodibenzo[a,g]quinolizinium. The inventive benzoquinolizinium salt derivatives may be also considered and commonly termed as protoberberine derivatives. Both the scientific, IUPAC-recommended and the trivial, common nomenclatures will be used throughout the present specification interchangeably.
- U.S. Pat. No. b 3,910,938 and U.S. Pat. No. 3,920,665 disclose berbine compounds carrying alkyl, allyl or alkoxy substituents in position 13 as inhibitors of the growth of transplanted sarcoma strains in mice. There is no mention about additional (hetero)aromatic moieties linked to the substituents in position 13.
- U.S. Pat. No. 6,008,356 and U.S. Pat. No. 6,030,978 disclose protoberberine derivatives substituted in position 13 by phenylmethyl (benzyl) and pyridylmethyl groups as antifungal agents, and pharmaceutical compositions containing them. Said patent specifications are completely silent in mentioning anything about an anticancer activity, and there is no reference about 13-(di)arylalkyl substituted compounds, even no disclosure or mention about phenylalkyl and pyridylalkyl substituents. Example 1 (13-benzyl) of said US patents was comparatively tested with the novel compounds of our specification, resulting in a much lower antitumour activity.
- U.S. Pat. No. 6,239,139 and U.S. Pat. No. 6,255,317 disclose berberine derivatives bearing alkyl, alkenyl, cycloalkylalkyl, haloalkyl, ethoxycarbonyl, ethoxycarbonylmethyl, hydroxycarbonylmethyl, ethoxycarbonylethyl, and 2-valerolactonyl groups in position 13, as inhibitors of cholesterol biosynthesis. There is no mention about an antitumour activity and/or additional (hetero)aromatic moieties linked to the substituents in position 13.
- WO 2008/040192 discloses berberine derivatives bearing lower alkyl, lower alkoxy and acetic acid lower alkyl esters in position 13. The said derivatives are glucose sorbefacient to muscle cells and have medical effects for improving glucose-tolerance and insulin-resistance, and can be used for treating diabetes mellitus, adiposity, fatty liver and their complications caused by insulin resistance. There is no mention about an antitumour activity and/or additional (hetero)aromatic moieties linked to the substituents in position 13.
- Eur. J. Med. Chem., 31, 469, 1996 reports berberine analogues substituted in position 13 by solely unsubstituted lower alkyl groups as antibacterial agents.
- Life Sciences 73, 1401, 2003 describes the effects of 13-methyl and 13-ethyl berberine on the expression of certain proteins in connection with a reported antibacterial activity.
- Bioorg. Med. Chem. Lett. 16, 1707, 2006, discloses the compound 13-(piperidinopropyl) berberine and its binding to natural and synthetic G-quadruplex DNA structures.
- Bioorg. Med. Chem. Lett. 19, 954, 2009, discloses various 13-alkyl and 13-benzyl 5,6-dihydrodibenzo[a,g]quinolizinium compounds as P2X7 receptor antagonists as potential anti-inflammatory and immunomodulating agents.
- J. Med. Chem, 52, 492, 2009 reports berberine analogues substituted in position 13 by solely lower alkyl and benzyl groups as LDL receptor up-regulators.
- The present invention is concerned with 13-substituted 5,6-dihydrodibenzo [a,g]quinolizinium salt compounds of the general formula (I):
- wherein
-
- R1 and R2, which may be the same or different, represent independently a hydroxy or a (C1-C6)alkoxy group, or, taken together, a methylenedioxy group;
- R3 and R4, which may be the same or different, represent independently a hydroxy or a (C1-C6)alkoxy group;
- X represents inorganic acid ion, organic acid ion or halide;
- n is an integer from 1 to 5 inclusive; and
- G stands for
- (a) -Z—Ar; or
- (b) —Y═(Ar)2
- in which
-
- Z is a bond, or O(CH2)m, CO—NH(CH2)m, or NH—CO(CH2)m;
- Y is CH, O(CH2)m—CH, CO—N, CO—NH(CH2)m—CH, or NH—CO(CH2)m—CH;
- m is an integer from 0 to 3 inclusive; and
- Ar represents a 5-15 membered unsaturated or aromatic mono-, bi- or tricyclic carbocyclic or heterocyclic ring system, wherein any of said heterocyclic ring systems, for each occurrence, contains one o more heteroatoms selected from O, N, or S; and wherein any of said ring systems, for each occurrence, optionally contains from 1 to 4 substituents independently selected from halogen, cyano, nitro, hydroxy, amino, (di)(C1-C6)alkylamino, (C1-C6)alkylcarbonylamino, (C1-C6)alkoxy, (C1-C6)alkylcarbonyloxy, (C1-C6)alkoxycarbonyl, (C1-C6)alkyl; and wherein any of said (C1-C6)alk* moieties, for each occurrence, contains from 1 to 4 halogen atoms independently chosen from F, Cl, Br and I.
- It was surprisingly found, and that is a fundamental characteristic of the present invention, that the 13-substituted protoberberines of formula (I), in contrast to the prior art compounds derived from protoberberine structure, show a remarkable antitumour activities in relevant cancer cell lines. Accordingly, it can be expected that their applicability will encompass the treatment of several cancerous disorders, including cancers which are resistant to currently used anticancer agents.
- According to a first object of the present invention there are provided 13-substituted 5,6-dihydrodibenzo[a,g]quinolizinium salt compounds (13-substituted protoberberines) of the general formula (I):
- wherein
- R1 and R2, which may be the same or different, represent independently a hydroxy or a (C1-C6)alkoxy group, or, taken together, a methylenedioxy group;
- R3 and R4, which may be the same or different, represent independently a hydroxy or a (C1-C6)alkoxy group;
-
- X represents inorganic acid ion, organic acid ion or halide;
- n is an integer from 1 to 5 inclusive; and
- G stands for
- (a) -Z—Ar; or
- (b) —Y═(Ar)2
- in which
-
- Z is a bond, or O(CH2)m, CO—NH(CH2)m, or NH—CO(CH2)m;
- Y is CH, O(CH2)m—CH, CO—N, CO—NH(CH2)m—CH, or NH—CO(CH2)m—CH;
- m is an integer from 0 to 3 inclusive; and
- Ar represents a 5-15 membered unsaturated or aromatic mono-, bi- or tricyclic carbocyclic or heterocyclic ring system, wherein any of said heterocyclic ring systems, for each occurrence, contains one o more heteroatoms selected from O, N, or S; and wherein any of said ring systems, for each occurrence, optionally contains from 1 to 4 substituents independently selected from halogen, cyano, nitro, hydroxy, amino, (di)(C1-C6)alkylamino, (C1-C6)alkylcarbonylamino, (C1-C6)alkoxy, (C1-C6)alkylcarbonyloxy, (C1-C6)alkoxycarbonyl, (C1-C6)alkyl; and wherein any of said (C1-C6)alk* moieties, for each occurrence, contains from 1 to 4 halogen atoms independently chosen from F, Cl, Br and I.
- Particularly, the invention relates to compounds of formula (I), wherein:
-
- R1 and R2 are methoxy groups, or, taken together, represent a methylenedioxy group;
- R3 is hydroxy or methoxy;
- R4 is methoxy; and
- X, n, and G are as defined above.
- A first aspect of the invention relates to such compounds of formula (I), wherein:
-
- G stands for -Z—Ar; and
- Z and Ar are as defined above.
- In one embodiment of the first aspect, the invention relates to such compounds wherein:
-
- Z is a bond; and
- n is 1, 2, 3, 4, or 5
- In another embodiment of the first aspect, the invention relates to such compounds wherein:
-
- Z is O(CH2)m;
- m is 0, 1,or 2; and
- n is 1, 2, or 3.
- In yet another embodiment of the first aspect, the invention relates to such compounds wherein:
-
- Z is CO—NH(CH2)m, or NH—CO(CH2)m;
- m is 0, 1, or 2; and
- n is 1.
- In a second aspect, the invention relates to such compounds of formula (I), wherein:
-
- G stands for —Y═(Ar)2; and
- Y and Ar are as defined above.
- In one embodiment of the second aspect, the invention relates to such compounds wherein:
-
- Y is CH; and
- n is 1, 2, 3,or 4.
- In another embodiment of the second aspect, the invention relates to such compounds wherein:
-
- Y is O(CH2)m—CH;
- m is 0 or 1; and
- n is 1,2or 3.
- In yet another embodiment of the second aspect, the invention relates to such compounds wherein:
-
- Y is CO—N; and
- n is 1.
- In yet another embodiment of the second aspect, the invention relates to such compounds wherein:
-
- Y is CO—NH(CH2)m—CH, or NH—CO(CH2)m—CH;
- m is 0 or 1; and
- n is 1.
- In the compounds of formula (I), Ar can represent an unsaturated or aromatic mono- or bicyclic carbocyclic ring system radical chosen from phenyl, naphthyl, indenyl, azulenyl, optionally containing from 1 to 4 substituents.
- In the compounds of formula (I), Ar can also represent an unsaturated or aromatic mono- or bicyclic heterocyclic ring system radical chosen from imidazolyl, quinolyl, isoquinolyl, indolyl, indazolyl, pyridazyl, pyridyl, pyrrolyl, pyrazolyl, pyrazinyl, quinoxalyl, pyrimidinyl, pyridazinyl, furyl, thienyl, triazolyl, thiazolyl, tetrazolyl, benzofuranoyl, oxazolyl, benzoxazolyl, isoxazolyl, isothiazolyl, thiazolyl, thiadiazoyl, benzodioxolyl, optionally containing from 1 to 4 substituents.
- In the compounds of formula (I), when G stands for -Z—Ar, Ar can also represent an unsaturated or aromatic tricyclic carbocyclic or heterocyclic ring system radical chosen from fluorenyl, anthracenyl, 5H-dibenzocycloheptenyl, 10,11-dihydro-5H-dibenzocycloheptenyl, xanthenyl, acridinyl, phenothiazinyl, phenoxazinyl, carbazolyl, optionally containing from 1 to 4 substituents.
- The substituents of the Ar moiety can be independently selected from, but not limited to, groups such as methyl, ethyl, propyl, and the like; trifluoromethyl, trichloromethyl, tribromomethyl, 2,2,2-trifluoroethyl, 2,2,2-trichloroethyl, and the like; hydroxy, methoxy, ethoxy, 2,2,2-trichloroethoxy, acetoxy, trifluoroacetoxy, trichloroacetoxy, and the like; amino, (di)methylamino, (di)ethylamino, acetamido, trifluoroacetamido and the like; cyano, nitro, fluoro, chloro, iodo and bromo.
- The compounds of the following list are preferred. The indicated meaning of the anion X should not be construed as limiting the specific compound claimed, since a definite X can be easily converted into a different X simply by carrying out metathesis reactions, e.g. the iodide of a compound of the general formula (I) may be converted into the chloride of the same compound of the general formula (I) by treatment with silver chloride (see e.g., J. Nat. Prod. 61, 1150, 1998). Therefore, by referring, for instance, to the chloride (or bromide, or iodide, etc.) salt of a specific 13-substituted 5,6-dihydrodibenzo[a,g]quinolizinium, the present invention encompass also any other salt of that specific 13-substituted 5,6-dihydrodibenzo[a,g]quinolizinium which can be obtained by the above mentioned metathesis reaction.
- 13-[2-(phenyl)ethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[2-(4-chlorophenyl)ethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[2-(4-methoxyphenyl)ethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[2-(4-methylphenyl)ethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[2-(4-fluorophenyl)ethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[2-(4-bromophenyl)ethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[2-(4-trifluoromethylphenyl)ethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[2-(4-trifluoromethoxyphenyl)ethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[2-(4-nitrophenyl)ethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[2-(4-dimethylaminophenyl)ethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[2-(4-acetylaminophenyl)ethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[2-(4-ethoxycarbonylphenyl)ethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[2-(naphth-1-yl)ethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[2-(4-chloronaphth-1-yl)ethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[2-(4-methoxynaphth-1-yl)ethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[2-(4-nitronaphth-1-yl)ethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[2-(4-ethoxycarbonylnaphth-1-yl)ethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[2-(indol-3-yl)ethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[2-(5-chloroindol-3-yl)ethyl)]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[2-(5-nitroindol-3-yl)ethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[2-(5-methoxyindol-3-yl)ethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[2-(5-ethoxycarbonylindol-3-yl)ethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[3-(phenyl)propyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[3-(4-chlorophenyl)propyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[3-(4-fluorophenyl)propyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[3-(4-bromophenyl)propyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[3-(4-methylphenyl)propyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[3-(4-methoxyphenyl)propyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[3-(4-trifluoromethoxyphenyl)propyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[3-(4-trifluoromethylphenyl)propyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[3-(4-nitrophenyl)propyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[3-(4-dimethylaminophenyl)propyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[3-(4-acetamidophenyl)propyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[3-(4-ethoxycarbonylphenyl)propyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[3-(4-phenoxyphenyl)propyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[3-(naphth-1-yl)propyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[3-(4-chloronahth-1-yl)propyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[3-(4-methoxynaphth-1-yl)propyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[3-(4-nitronaphth-1-yl)propyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxol[5,6-a]quinolizinium iodide;
- 13-[3-(4-carbethoxynaphth-1-yl)propyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-(3-indolylpropyl)-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[3-(5-chloroindol-3-yl)propyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[3-(5-nitroindol-3-yl)propyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[3-(5-methoxyindol-3-yl)propyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[3-(5-carbethoxyindol-3-yl)propyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[(1,4-benzodioxan-2-yl)methyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium chloride;
- 13-[2,2-bis(phenyl)ethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[2,2-bis(4-chlorophenyl)ethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[2,2-bis(4-bromophenyl)ethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[2,2-bis(4-fluorophenyl)ethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[2,2-bis(4-methylphenyl)ethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[2,2-bis(4-methoxyphenyl)ethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[3,3-bis(phenyl)propyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[3,3-bis(4-methylphenyl)propyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[3,3-bis(4-methoxyphenyl)propyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[3,3-bis(4-fluorophenyl)propyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[3,3-bis(4-chlorophenyl)propyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[3,3-bis(4-bromophenyl)propyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-benzyloxymethyl-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[2-(phenoxy)ethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[2-(benzyloxy)ethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[3-(phenoxy)propyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[(1,4-benzodioxan-2-yl)methyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[(4-chlorobenzyloxy)methyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[(4-methoxybenzyloxy)methyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[(4-dimethylaminobenzyloxy)methyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[(4-hydroxybenzyloxy)methyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[2-(p-chlorophenoxy)ethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[2-(p-methoxyphenoxy)ethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[2-(p-hydroxyphenoxy)ethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[2-(p-chlorobenzyloxy)ethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[2-(p-methoxybenzyloxy)ethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[2-(p-hydroxybenzyloxy)ethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[3-(p-chlorophenoxy)propyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[3-(p-methoxyphenoxy)propyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[3-(p-hydroxyphenoxy)propyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[2-(diphenylmethyloxy)ethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-diphenylmethyloxymethyl-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-benzylaminocarbonylmethyl-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-phenylaminocarbonylethyl-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-phenylaminocarbonylmethyl-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[(4-pyridyl)aminocarbonylmethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[(1-indolyl)carbonylmethyl)-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[(p-chlorobenzyl)aminocarbonylmethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[(p-methoxybenzyl)aminocarbonylmethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[(p-dimethylaminobenzyl)aminocarbonylmethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[(p-hydroxybenzyl)aminocarbonymethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[(p-chlorophenyl)aminocarbonylmethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[(p-methoxyphenyl)aminocarbonylmethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[(p-dimethylaminophenyl)aminocarbonylmethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[(p-hydroxyphenyl)aminocarbonylmethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[(5-chloroindol-1-yl)carbonylmethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[(5-methoxyindol-1-yl)carbonylmethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[(5-hydroxyindol-1-yl)carbonylmethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[(5-dimethylaminoindol-1-yl)carbonylmethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-benzylcarbonylaminomethyl-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-phenylcarbonylaminomethyl-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[(4-pyridyl)carbonylaminomethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[(p-chlorobenzyl)carbonylaminomethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[(p-methoxybenzyl)carbonylaminomethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[(p-hydroxybenzyl)carbonylaminomethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[(p-chlorophenyl)carbonylaminomethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[(p-methoxyphenyl)carbonylaminomethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide; and
- 13-[(p-hydroxyphenyl)carbonylaminomethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide.
- According to a second object of the present invention, there are provided processes for the preparation of the compounds of the general formula (I).
- A first process comprises reacting a 13-substituted tetrahydroprotoberberine of general formula (II)
- wherein R1, R2, R3, R4, G and n are as previously defined, with such oxidizing agents as represented by halogens, e.g. Br2 or I2, or haloamides and haloimides, e.g N-chloro-, N-bromo- or N-iodosuccinimide to give a compound of the general formula (I) wherein R1, R2, R3, R4, G and n are as previously defined, and X represents the halogen atom derived from the above oxidizing agent used, being said 13-substituted tetrahydroprotoberberines of the general formula (II) obtained as follow:
- i) when G stands for -Z—Ar, wherein Z is a bond or O(CH2)m, or for —Y═(Ar)2, wherein Y is CH or O(CH2)m—CH, reacting a dihydroprotoberberine of general formula (III)
- with an halide of general formulae (IVa) or (IVb)
-
Hal-(CH2)n-Z—Ar (IVa) -
Hal-(CH2)n—Y═ (IVb) - wherein:
- R1, R2, R3, R4, Ar, n and m are as previously defined, Z and Y are as herein above stated, and Hal is an halogen atom such as chlorine, bromine and iodine, to give a 13-substituted iminiumprotoberberine derivative of formula (V)
- wherein R1, R2, R3, R4, n are as previously defined, and G is as herein above stated, and
- reducing the 13-substituted iminiumprotoberberine of formula (V) to obtain a 13-substituted tetrahydroprotoberberine of the general formula (II-i)
- wherein R1, R2, R3, R4, n are as previously defined, and G is as herein above stated;
- ii) when G stands for -Z—Ar, wherein Z is CO—NH(CH2)m, or for —Y═Ar)2, wherein Y is CO—N or CO—NH(CH2)m—CH, reacting a dihydroprotoberberine of the general formula (III) with a haloalkanoic acid ester of formula (VI)
-
Hal-(CH)nCOOR5 (VI) - wherein Hal and n are as previously defined, and R5 represents such radicals as methyl, ethyl, t-butyl, benzyl, 2,2,2-trichloethyl and the like, to obtain an 13-alkylcarboxy acid ester iminiumprotoberberine derivative of formula (VII),
- reducing the 13-substituted iminiumprotoberberine of formula (VII) to obtain the tetrahydroprotoberberine of formula (VIII)
- hydrolyzing or cleaving the ester group of the compound of formula (VIII) to obtain a 13-alkylcarboxy acid tetrahydroprotoberberine derivative of the general formula (IX)
- subjecting the acid compound (IX) so obtained to an amidation reaction with an amine compound of formulae (X), (XI), or (XII)
-
H2N(CH2)m—Ar (X) -
HN(Ar)2 (XI) -
H2N(CH2)m—CH(Ar)2 (XII) - wherein Ar and m are as previously defined to obtain a 13-substituted tetrahydroprotoberberine of the general formula (II-ii)
- wherein R1, R2, R3, R4, n are as previously defined, and G is as herein above stated;
- iii) when G stands for -Z—Ar, wherein Z is NH—CO(CH2)m, or for —Y═(Ar)2, wherein Y is CO—N or NH—CO(CH2)m—CH, obtaining the acyl azido derivative of formula (XIII)
- from the corresponding 13-alkylcarboxy acid tetrahydroprotoberberine derivative of the above general formula (IX), and subjecting the acyl azido derivative of formula (XIII) so obtained to a retro-amidation reaction with an acid compound of formulae (XIV), (XV), or (XVI)
-
HOOC(CH2)m—Ar (XIV) -
HOOCCH(Ar)2 (XV) -
HOOC(CH2)m—CH(Ar)2 (XVI) - wherein Ar and m are as previously defined to obtain a 13-substituted tetrahydroprotoberberine of the general formula (II-iii)
- wherein R1, R2, R3, R4, n are as previously defined, and G is as herein above stated.
- The oxidation of a 13-substituted tetrahydroprotoberberine of general formula (II) to give the compounds of the invention, may be be carried out according to known methods, for instance as described in U.S. Pat. No. 6,030,978 or in J. Nat. Prod. 6, 115 (1998). The reaction may be performed in an organic solvent such as chloroform, ethanol or acetic acid at temperatures ranging from 0 to about 100° C. Preferably the reaction is carried out in chloroform at reflux when N-chlorosuccinimide or N-bromosuccinimide is used. When iodine is employed the preferred solvent is ethanol at reflux. The preferred solvent is acetic acid when bromine is used as oxidizing agent. Preferably the oxidation is carried out with N-chlorosuccinimide or iodine.
- The reaction of a dihydroprotoberberine of general formula (III) with a halide of general formulae (IVa) or (IVb) to give a 13-substituted iminiumprotoberberine derivative of formula (V), wherein G stands for -Z—Ar, wherein Z is a bond or O(CH2)m, or for —Y═(Ar)2, wherein Y is CH or O(CH2)m—CH, and the similar reaction of a dihydroprotoberberine of general formula (III) with a haloalkanoic acid ester of formula (VI) to give a 13-alkylcarboxy acid ester iminiumprotoberberine derivative of formula (VII), may be carried out as generally reported for enamine alkylations. The enamine alkylation, herebelow described, is an analogy process, for example as reported in Bioorganic & Medicinal Chemistry Letters 16, 3913 (2006). The alkylation may be performed in inert organic solvent, for instance acetonitrile, chloroform, dichloromethane or dioxane. Preferably the reaction is carried out in hot acetonitrile in the presence of sodium iodide. In the compounds of formula (IVa) and (IVb) the halogen atom is preferably bromine or iodine.
- The compounds of general formulae (IVa), (IVb) or (VI) are commercially available or known from the literature, or can be prepared by modifications of known chemical procedures which are well within the ordinary skill of one practicing the art of organic synthesis.
- Suitable reaction conditions for the reduction of the iminium compounds of formula (V) and (VII) to obtain the corresponding 13-substituted tetrahydroprotoberberine of formula (II-i) and (VIII), respectively, are sodium or potassium borohydride in a protic solvent, such as methanol, ethanol or isopropanol. Preferably the reduction is carried out in ethanol solution at room temperature using an excess of sodium borohydride. The hydrolysis or the cleavage of the ester group of the ester compound of formula (VII) to obtain a 13-alkylcarboxy acid tetrahydroprotoberberine derivative of formula (IX) may be performed following usual methods and procedures known in organic chemistry for the hydrolysis of methyl, ethyl, t-butyl esters or for the cleavage of benzyl and trichloroethyl esters, respectively.
- The amidation reaction of a compound compound of formula (IX) with an amine of formulae (X), (XI) or (XII) to obtain a compound of general formula (II-i), wherein G stands for -Z—Ar, wherein Z is CO—NH(CH2)m, or for —Y═(Ar)2, wherein Y is CO—N or CO—NH(CH2)m—CH is performed by usual procedures described in organic chemistry. Such condensation agents as dicyclohexylcarbodiimide or 1-(3-dimethylaminopropyl)-3-ethyl carbodiimide hydrochlorides can be used, as described, for instance, in J. Amer. Chem. Soc. 95, 875 (1973). As catalyst, dimethylaminopyridine may be used used. The reaction may be performed in an organic solvent such as dimethylformamide or dichlormethane, at temperatures ranging from 0° C. to about 50° C.
- The amine compounds of general formulae (X), (XI) and (XII) are commercially available or known from the literature, or can be prepared by modifications of known chemical procedures which are well within the ordinary skill of one practicing the art of organic synthesis.
- The retro-amidation reaction of an acyl azido derivative of formula (XIII) with an acid compound of formulae (XIV), (XV), or (XVI) to obtain a compound of general formula (II-iii), wherein G stands for -Z—Ar, wherein Z is NH—CO(CH2)m, or for —Y═(Ar)2, wherein Y is CO—N or NH—CO(CH2)m—CH, is known to proceed through the intermediacy of a reactive isocyanate generated from the acyl azido derivative of formula (XIII) as a precursor (Curtius reaction). Suitable conditions for performing such a retro-amidation reaction are as reported, for instance, in Example 6 of WO92/09574. The acyl azido derivative of formula (XIII) is obtained by the corresponding acid of formula (IX) with methods known in organic chemistry. A preferred method is by the use of diphenyl phosphorazidate (DPPA), as described in Tetrahedron, 30, 2151, 1974.
- The acid compounds of general formulae (XIV), (XV), or (XVI) are commercially available or known from the literature, or can be prepared by modifications of known chemical procedures which are well within the ordinary skill of one practicing the art of organic synthesis.
- In a particular case of the inventive compounds of the general formula (I) where G stands for -Z—Ar, wherein Z is a bond or O(CH2)m, or for —Y═(Ar)2, wherein Y is CH or O(CH2)m—CH, there is provided a second process for the preparation of the compounds of the invention comprising reacting a 8-acetonylprotoberberine of the general formula (XVII), obtained as described, for instance, in U.S. Pat. No. 6,255,317
- with an excess of the halide of the above described general formulae (IVa) or (IVb) to obtain a 13-substituted protoberberine derivative of the general formula (I) wherein R1, R2, R3, R4, and n are as previously described, G is as herein above stated, and X represents Hal in the above described general formulae (IVa) or (IVb). Usually, the reaction is performed in acetonitrile solution at temperatures ranging from room to reflux temperatures. Preferably, the halocompound of formulae (IVa) or (IVb) is used in a large excess (2-10 mol. eq.). When chloro or bromo compounds are used, generally 1-3 mol. eq. of an alkali metal iodide are added to accelerate the reaction.
- According to a third object of the present invention there are provided pharmaceutical compositions containing, as active ingredient, a compound of formula (I) combined with a pharmaceutically acceptable diluent or carrier. Accordingly, a therapeutically effective dose of a compound of formula (I) is combined with an inert carrier. The compositions may be formulated in a conventional manner using common carriers as known to a person skilled in the pharmaceutical art. A preferred carrier is alpha-, beta- or gamma-cyclodextrin.
- As stated, the invention is based on the surprising recognition that the 13-substituted protoberberines of formula (I), in contrast to the prior art compounds derived from protoberberine structure, show a considerable antitumour activities in relevant cancer cell lines. Such a unique anticancer profile has not so far been described in the patent and scientific literature in connection with any one of the prior art protoberberine derivatives.
- For the determination of the in vitro antitumour activities, the compounds of the invention were assayed in a panel of sensible, resistant and refractary tumour cell lines, which are only exemplary for the antitumour activity of the inventive compounds, and are not to be construed as limiting their antitumour activities only to the cell lines set forth herein.
- Cell lines. The 2008 cell line was established from a patient with serous cystadenocarcinoma of the ovary and the cDDP-resistant C13* subline, about 15-fold resistant to cDDP, was derived from the parent 2008 cell line by monthly exposure to cDDP, followed by chronic exposure to step-wise increases in cDDP concentration (Cancer Research 52, 1895, 1992). The cell lines were grown as monolayers in RPMI 1640 medium containing 10% heat-inactivated fetal bovine serum and 50 μg/mL gentamycin sulfate. All cell media and serum were purchased from (Lonza, Verviers, Belgium). Cultures were equilibrated with humidified 5% CO2 in air at 37° C. All studies were performed in Mycoplasma negative cells, as routinely determined with the MycoAlert Mycoplasma detection kit (Lonza, Walkersville, Md., USA).
- The human ovarian cancer cell line A2780 and a platinum-resistant subline selected in vitro by stepwise increases of cisplatin concentration in the medium were from University of Modena and Reggio Emilia. The cisplatin resistant A2780 cells were challenged weekly with 50 uM cisplatin for 1 hr. Both cell lines were maintained in RPMI 1640 medium with 10% (vol/vol) fetal calf serum, penicillin (62.9 mg/L), and streptomycin (100 mg/L) (GIBCO).
- Cell growth assay. Cell growth was determined by a modification of the crystal violet dye assay (Analytical biochemistry, 182, 16 1989). On selected days, after removal of the tissue culture medium, the cell monolayer was fixed with methanol prior to staining with 0.2% crystal violet solution in 20% methanol for at least 30 minutes. After washing several times with distilled water to remove the dye excess, the cells were let to dry. The incorporated dye was solubilized in acidic isopropanol (1N HCl : 2-propanol, 1:10). After appropriate dilution, dye was determined spectrophotometrically at 540 nm. The extracted dye was proportional to cell number. Percentage of cytotoxicity was calculated by comparing the absorbance of cultures exposed to the compounds of the invention to non-exposed (control) cultures. The data are shown in the following Tables 1a and 1b. Percentage of cytotoxicity is here reported as the half maximal inhibitory concentration (IC50), which is a measure of the effectiveness of a compound of the invention in inhibiting cell growth by half with respect to control (100%).
-
TABLE 1a Compound IC50 (uM) at 72 hrs exposure Cell line cDDP 5-FU Berberine Comp Ex NAX012 NAX013 NAX014 NAX018 2008 3.6 10 10 9.2 3.6 6.6 5.8 4 C13* 17 8 6 5 2.2 2.4 1.8 0.66 -
TABLE 1b Compound IC50 (uM) at 72 hrs exposure Cell line cDDP Berberine Comp Ex NAX012 NAX013 NAX014 NAX018 NAX030 A2780 2 4 2.5 0.6 1 1.4 0.4 4.5 A2780/CP 20 2.5 3.3 0.6 1 1 1 2.5 - Cell cultures and treatments. Human tumor cells (HeLa from uterin cervix and HCT116 from colon carcinoma) were grown at 37° C. in humidified atmosphere containing 5% CO2 in D-MEM supplemented with 10% FCS, 4 mM glutamine, 2 mM Na pyruvate, 100 U/mL penicillin and 0.1 mg/mL streptomycin (all reagents were from Celbio, Pero, Italy). HeLa cells are the most widely used human tumor cell line; HCT 116 colon carcinoma cell line has proven to be extremely resistant to conventional chemotherapy. Cells were treated with the compounds of the invention at a fixed dose of 10 uM for 24 h, eventually followed by 24 of recovery in drug free medium. As a positive control of growth inhibition, cells were treated with 10 uM etoposide. Some of the inventive were also assayed at a dose of 1 uM.
- Cell proliferation assays—MTT assay. Cells are seeded in 96 multiwell-plates at the density of 103/100 μl (except fibroblasts that are seeded at the density of 1.5×103/100 μl). Cells are treated 24 h later with the drug for 24 h eventually followed by 24 h of recovery in drug-free medium. At the end of the treatments, 20 μl of CellTiter 96 Non-Radioactive Cell Proliferation Assay (MTT; Promega, Milano, Italy) are added to each well. Plates are then incubated for 4 h at 37° C. in the dark and analyzed with a reader of microplates (Gio. De Vita, Roma, Italy) at 492 nm. Experiments are performed in quadruplicate and repeated three times. Data are expressed in the following Tables 2a-c as the percentage compared to control cells considered as 100%.
-
TABLE 2a Compound at 10 uM Cell line Etoposide Berberine Comp Ex NAX012 NAX013 NAX014 NAX018 NAX019 HeLa 24 h 74.8 121.2 98.0 72.4 74.5 71.9 40.6 62.8 24 h + 24 h 1.0 92.9 74.5 41.3 60.8 45.4 11.3 33.5 HCT 116 24 h 104.2 166.0 20.4 0.0 10.0 49.5 30.6 6.0 24 h + 24 h 96.2 93.3 22.2 34.8 60.2 15.4 13.7 32.1 -
TABLE 2b Compound at 1 uM Cell line Etoposide Berberine Comp Ex NAX014 NAX018 HeLa 24 h 94.3 178.3 139.1 92.1 64.0 24 h + 24 h 59.5 168.3 93.6 59.4 45.8 -
TABLE 2c Compound at 1 uM at 24 h exposure Cell Etopo- Comp line side Berberine Ex NAX012 NAX013 NAX018 HCT 138.8 201.1 119.4 52.1 58.1 68.2 116 -
-
- cDDP: cisplatin; cis-diaminedichloroplatinum
- 5-FU: fluorouracil; 5-fluoro-2,4(1H,3H)-pyrimidinedione
- Etoposide: VP16; 4′-demethylepipodophyllotoxin 9-[4,6-O-ethylidene-beta-D-glucopyranoside]
- Berberine: 9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium chloride
- Comp Ex: 13-benzyl-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide
- NAX012: 13-(3-phenylpropyl)-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide
- NAX013: 13-[2-(4-methoxyphenyl)ethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide
- NAX014: 13-[2-(4-chlorophenyl)ethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide
- NAX018: 13-(3,3-diphenylpropyl)-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide
- NAX019: 13-[2-(indol-3-yl)ethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide
- NAX030: 13-[(5-chloroindol-1-yl)carbonylmethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide
- Accordingly, the claimed compounds are useful for the therapeutic treatments of tumour diseases in humans and other mammals by administration of therapeutically effective quantities of the compound of formula (I) to a subject under treatment for, e. g., leukemias, lymphomas, solid tumours such as sarcomas, breast, ovarian, and cervical carcinomas, bladder and prostate carcinomas, bronchogenic, gastric and hepatic carcinomas, mesotheliomas, brain tumours, glioblastoma and the like. The claimed compounds and compositions and may be administered alone or in combination with one or more additional chemotherapeutic or growth inhibitory agents. Examples of chemotherapeutic agents include alkylating agents such as thiotepa and cyclosphosphamide; alkyl sulfonates such as busulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelamines including altretamine, triethylenemelamine, trietylenephosphoramide, triethylenethiophosphaoramide and trimethylolomelamine; nitrogen mustards such as chlorambucil, chlomaphazine, cholophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard; nitrosureas such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, ranimustine; antibiotics such as aclacinomysins, actinomycin, authramycin, azaserine, bleomycins, cactinomycin, calicheamicin, carabicin, carminomycin, carzinophilin, chromomycins, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin, epirubicin, esorubicin, idarubicin, marcellomycin, mitomycins, mycophenolic acid, nogalamycin, olivomycins, peplomycin, potfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin; anti-metabolites such as methotrexate and 5-fluorouracil (5-FU); folic acid analogues such as denopterin, methotrexate, pteropterin, trimetrexate; purine analogs such as fludarabine, 6-mercaptopurine, thiamiprine, thioguanine; pyrimidine analogs such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine; androgens such as calusterone, dromostanolone propionate, epitiostanol, mepitiostane, testolactone; anti-adrenals such as aminoglutethimide, mitotane, trilostane; folic acid replenisher such as frolinic acid; aceglatone; aldophosphamide glycoside; aminolevulinic acid; amsacrine; bestrabucil; bisantrene; edatraxate; defofamine; demecolcine; diaziquone; elfornithine; elliptinium acetate; etoglucid; gallium nitrate; hydroxyurea; lentinan; lonidamine; mitoguazone; mitoxantrone; mopidamol; nitracrine; pentostatin; phenamet; pirarubicin; podophyllinic acid; 2-ethylhydrazide; procarbazine; PSK(R); razoxane; sizofiran; spirogermanium; tenuazonic acid; triaziquone; 2,2′,2″-trichlorotriethylamine; urethan; vindesine; dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine; arabinoside (“Ara-C”); cyclophosphamide; thiotepa; taxanes, e.g. paclitaxel and docetaxel; chlorambucil; gemcitabine; 6-thioguanine; mercaptopurine; methotrexate; platinum analogs such as cisplatin and carboplatin; vinblastine; platinum; etoposide (VP-16); ifosfamide; mitomycin C; mitoxantrone; vincristine; vinorelbine; navelbine; novantrone; teniposide; daunomycin; aminopterin; xeloda; ibandronate; CPT-11; topoisomerase inhibitor RFS 2000; difluoromethylornithine (DMFO); retinoic acid; esperamicins; capecitabine; and pharmaceutically acceptable salts, acids or derivatives of any of the above. Also included in this definition are anti-hormonal agents that act to regulate or inhibit hormone action on tumors such as anti-estrogens including for example tamoxifen, raloxifene, aromatase inhibiting 4(5)-imidazoles, 4-hydroxytamoxifen, trioxifene, keoxifene, LY117018, onapristone, and toremifene (Fareston); and anti-androgens such as flutamide, nilutamide, bicalutamide, leuprolide, and goserelin.
- Examples of growth inhibitory agents include agents that block cell cycle progression (at a place other than S phase), such as agents that induce G1 arrest and M-phase arrest. Classical M-phase blockers include the vincas (vincristine and vinblastine), taxol, and topo II inhibitors such as doxorubicin, epirubicin, daunorubicin, etoposide, and bleomycin. Those agents that arrest G1 also spill over into S-phase arrest, for example, DNA alkylating agents such as tamoxifen, prednisone, dacarbazine, mechlorethamine, cisplatin, methotrexate, 5-fluorouracil, and ara-C.
- Various delivery systems are known and can be used to administer an agent of the invention, e.g., encapsulation in liposomes, microparticles, microcapsules. Methods of introduction can be enteral or parenteral and include but are not limited to intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, intraocular, and oral routes. The compounds may be administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents. Administration can be systemic or local. Administration can be daily, weekly, or monthly, or in combination with other agents. Pulmonary administration can also be employed, e.g., by use of an inhaler or nebulizer, and formulation with an aerosolizing agent. The amount of the inventive compound that will be effective for its intended therapeutic use can be determined by standard clinical techniques based on the present description. In addition, in vitro assays may optionally be employed to help identify optimal dosage ranges. Generally, suitable dosage ranges for intravenous administration are generally about 1-50 mg/kg body weight, preferably about 5-40 mg/kg body weight, most preferably about 10-20 mg/kg body weight.
- The following examples illustrate the invention without limiting its scope.
- To a solution of berberine hydrochloride (3,718 g, 10 mmol) in pyridine (30 mL) was added portionwise sodium borohydride (450 mg, 12 mmol) and the mixture was stirred at room temperature for 30 min. More sodium borohydride (380 mg, 10 mmol) was added and stirring was continued for 1 h. The reduction was monitored by TLC (DCM-ethyl acetate-methanol 4:4:2). The mixture was poured onto ice water. The precipitate was filtered, the residue washed with water and then dried under vacuum over calcium chloride to give 2.860 g of title compound in about 85 % yield.
- NMR (200 MHz, CDCl3): δ 2.87 (t, J=5.8 Hz, 2H), 3.12 (t, J=5.9 Hz, 2H), 3.84(s, 6H), 4.31 (br s, 2H), 5.94 (s, 2H), 5.95 (s, 1H), 6.58 (brs, 1H), 6.74 (s, 2H), 7.16 (s, 1H).
- Berberine chloride (3.718 g, 10 mmol) was dissolved in 5N sodium hydroxide solution (17 mL, 85 mmol) at room temperature. Then acetone (3.7 mL, 2.90 g, 50 mmol) was added dropwise and the mixture stirred for about 6 h at room temperature. The reaction was monitored by TLC (hexane-diethylamine 9:1). The precipitate was filtered, washed with methanol 80% to neutral pH and then dried under vacuum to give 3.020 g of a white solid (80% yield).
- NMR (200 MHz, DMSO-d6): δ 2.03 (s, 3H), 2.30 (dd, J=4.8/14.4 Hz, 1H), 2.74 (m, 2H), 2.93 (dd, J=6.6/14.4 Hz, 1H), 3.24 (m, 3H), 3.76 (s, 3H), 3.77 (s, 3H), 5.21 (dd, J=4.8/6.6 Hz, 1H), 5.99 (s, 2H), 6.00 (s, 1H), 6.72 (d, J=8.4, 1H), 6.75 (s, 1H), 6.86 (d, J=8.4 Hz, 1H), 7.24 (s, 1H)
- Dry ethyl bromoacetate (30 mL, 270.5 mmol) was added dropwise with stirring to dihydroberberine (2.62 g, 0.78 mmol) at 0° C. under a nitrogen atmosphere. The solution was heated to 100° C. for 1 h to give a suspension. Dry toluene (25 mL) was added to the suspension, the precipitate filtered and then dried to give the unstable iminium salt intermediate (3.78 g, 8.9 mmol) which was dissolved in absolute ethanol (50 mL) and stirred at 0° C. Sodium borohydride (400 mg, 10.5 mmol) was added to the suspension which was then stirred at room temperature for 20 min. More sodium borohydride (400 mg, 10.5 mmol) was added and further stirred for 1 h. The mixture was then concentrated by solvent evaporation in vacuo. Water (200 mL) was added to the crude product and the mixture then extracted with diethyl diethyl ether (3×150 mL). The combined diethyl ether extract was washed with water, dried and evaporated. The crude product was chromotographed on silica gel eluting with dichloromethane to afford the ethyl ester of (9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizin-13-yl)-acetic acid as a yellow solid (2.8 g, 88% yield).
- m.p. 103-104° C.
- NMR (300 Mz, CDCl3): δ 1.15 (t, J=7.2 Hz, 3H), 2.30 (dd, J=15.6, 8.4 Hz, 1H), 2.44 (dd, J=15.6, 8.4 Hz, 1H), 2.50-2.61 (m, 2H), 2.99-3.13 (m, 2H), 3.52 (d, J=16 Hz, 1H), 3.61-3.68 (m, 1H), 3.72 (br s, 1H), 3.85 (s, 6H,), 3.98 (q, J=7 Hz, 2H), 4.10 (d, J=16 Hz, 1H), 5.91 (d, J=1.3 Hz, 1H), 5.92 (d, J=1.3 Hz, 1H), 6.58 (s, 1H), 6.74 (s, 1H), 5.76 (d, J=8.4 Hz, 1H), 7.00 (d, J=8.4 Hz, 1H).
- By proceeding analogously and starting from the appropriate haloalknoic acid ethyl ester of formula (VI), the following compounds were obtained:
- (9,10-Dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizin-13-yl)-propionic acid ethyl ester (13-ethoxycarbonylethyl-tetrahydroberberine).
- To a solution of the ethyl ester compound of Preparative Example 3 (372 mg, 0.88 mmol) in methanol (20 mL) was added a 2% aqueous solution of lithium hydroxide (30 mL) and the mixture heated for 1 h at reflux. The reaction mixture was evaporated, water was added and then acidified to pH 1 with 1N HCl . The precipitate was filtered, washed with water and dried to afford the title compound as a white solid (334 mg, 95%).
- m.p. 202-205° C.
- NMR (300 MHz, CDCl3): δ 2.59-2.85 (m, 4H), 3.18-3.34 (m, 2H), 3.42-3.50 (m, 1H), 3.73 (d, J=15.6 Hz, 1H), 3.87 (s, 3H), 3.88 (s, 3H), 4.06 (d, J=3.3 Hz, 1H), 4.32 (d, J=15.6 Hz, 1H), 5.98 (s, 2H), 6.60 (s, 1H), 6.64 (s, 1H), 6.86 (d, J=8.7 Hz, 1H), 7.00 (d, J=8.7 Hz, 1H).
- By proceeding analogously the following compounds were obtained:
- (9,10-Dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizin-13-yl)-propionic acid (13-carboxyethyl-tetrahydro berberine).
- The title compound was obtained by reacting 8-acetonyl-tetrahydroberberine with benzylbromide as described in Example 1 of U.S. Pat. No. 6,008,356 and U.S. Pat. No. 6,030,978.
- NMR (200 MHz, CDCl3): δ 10.60 (s, 1H), 7.70 (d, 1H), 7.60 (d, 1H), 7.40-7.20 (m, 3H), 7.11 (brd, 2H), 6.85 (s, 1H), 6.95 (s,1H), 6.00 (s, 2H), 5.35-5.20 (m, 2H), 4.68 (s, 2H), 4.38 (s, 3H), 4.00 (s, 2H), 3.25 (t, 2H).
- Preparation of 13-substituted Tetrahydroprotoberberines of the General Formula (II-i)
- To a solution of dihydroberberine (338 mg, 1 mmol) and 2-phenylethylbromide (2.22 g, 12 mmol) in acetonitrile (25 mL) was added sodium iodide (450 mg, 3 mmol) and the resulting mixture was stirred for 16 h at reflux temperature under nitrogen. Then, the mixture was concentrated under vacuum, diluted with water and the unstable iminium salt filtered off and dried.
- To a solution of the above obtained iminium salt in absolute ethanol, sodium borohydride (378 mg, 10 mmol) was added portionwise and the resulting suspension stirred for 45 min at room temperature. More sodium borohydride (302 mg, 8 mmol) was added and the suspension stirred for an additional hour at room temperature. The solvent was evaporated under vacuum, water was added and the mixture extracted with ethyl acetate. The combined organic phases were dried and then evaporated. The residue was chromatographed on silica gel eluting with hexane/ethyl acetate (10-20%) to give the title compound.
- NMR (300 MHz, DMSO-d6): δ 10.55 (s, 1H), 7.65 (d, 1H), 7.55 (d, 1H), 7.20 (m, 3H), 7.10 (brd, 2H), 6.90 (s, 1H), 6.80 (s,1H), 6.05 (s, 2H), 5.25 (m, 2H), 4.65 (m, 4H), 4.40 (s, 3H), 4.10 (s, 3H), 3.20 (t, 2H).
- By proceeding analogously and starting from the appropriate haloalkyl(hetero)aryl compounds of the general formula (IVa, Z is a bond) or haloalkylene(hetero)aryl compounds of the general formula (IVb, Y is CH), the following compounds were obtained:
- 13-[2-(4-chlorophenyl)ethyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[2-(4-methoxyphenyl)ethyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[2-(4-methylphenyl)ethyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[2-(4-fluorophenyl)ethyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[2-(4-bromophenyl)ethyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-3-benzodioxolo[5,6-a]quinolizine;
- 13-[2-(4-trifluoromethylphenyl)ethyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[2-(4-trifluoromethoxyphenyl)ethyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]q quinolizine;
- 13-[2-(4-nitrophenyl)ethyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[2-(4-dimethylaminophenyl)ethyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[2-(4-acetylaminophenyl)ethyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[2-(4-ethoxycarbonylphenyl)ethyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[2-(naphth-1-yl)ethyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[2-(4-chloronaphth-1-yl)ethyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine,
- 13-[2-(4-methoxynaphth-1-yl)ethyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[2-(4-nitronaphth-1-yl)ethyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[2-(4-ethoxycarbonylnaphth-1-yl)ethyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[2-(indol-3-yl)ethyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[2-(5-chloroindol-3-yl)ethyl)]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[2-(5-nitroindol-3-yl)ethyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[2-(5-methoxyindol-3-yl)ethyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[2-(5-ethoxycarbonylindol-3-yl)ethyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[3-(phenyl)propyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[3-(4-chlorophenyl)propyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[3-(4-fluorophenyl)propyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[3-(4-bromophenyl)propyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[3-(4-methylphenyl)propyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[3-(4-methoxyphenyl)propyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[3-(4-trifluoromethoxyphenyl)propyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[3-(4-trifluoromethylphenyl)propyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[3-(4-nitrophenyl)propyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[3-(4-dimethylaminophenyl)propyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[3-(4-acetamidophenyl)propyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[3-(4-ethoxycarbonylphenyl)propyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[3-(4-phenoxyphenyl)propyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[3-(naphth-1-yl)propyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[3-(4-chloronahth-1-yl)propyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[3-(4-methoxynaphth-1-yl)propyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[3-(4-nitronaphth-1-yl)propyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[3-(4-carbethoxynaphth-1-yl)propyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-(3-indolylpropyl)-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[3-(5-chloroindol-3-yl)propyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[3-(5-nitroindol-3-yl)propyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[3-(5-methoxyindol-3-yl)propyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[3-(5-carbethoxyindol-3-yl)propyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[(1,4-benzodioxan-2-yl)methyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[2,2′-bis(phenyl)ethyl)-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[2,2-bis(4-chlorophenyl)ethyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[2,2-bis(4-bromophenyl)ethyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[2,2-bis(4-fluorophenyl)ethyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[2,2-bis(4-methylphenyl)ethyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[2,2-bis(4-methoxyphenyl)ethyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[3,3-bis(phenyl)propyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[3,3-bis(4-methylphenyl)propyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[3,3-bis(4-methoxyphenyl)propyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[3,3-bis(4-fluorophenyl)propyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[3,3-bis(4-chlorophenyl)propyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[3,3-bis(4-bromophenyl)propyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine.
- Dihydroberberine (338 mg, 1 mmol) and benzyl chloromethyl ether (3.44 mg, 15,5 mmol) were dissolved in acetonitrile (25 mL) and then sodium iodide (450 mg, 3 mmol) was added. The resulting suspension was stirred overnight at reflux. The cooled reaction mixture was concentrated under vacuum, diluted with water, the precipitated unstable iminium salt filtered off and dried.
- To a solution of the iminium salt in absolute ethanol (25 mL) sodium borohydride (378 mg, 10 mmol) was added and the resulting mixture stirred for 30 min at room temperature. Then, more sodium borohydride (302 mg, 8 mmol) was added and the mixture stirred for another hour at room temperature. The solvent was evaporated under reduced pressure, water was added and the mixture extracted with ethyl acetate. The combined organic phases were dried and evaporated. The residue was chromatographed on silica gel using hexane/ethyl acetate (10-20%) as eluant to give the title compound.
- NMR (300 MHz, DMSO-d6): δ 9.50 (s, 1H), 7.90 (d, 1H), 7.85 (d, 1H), 7.05-7.60 (m, 5H), 5.80 (s, 2H), 7.4 (s, 1H), 7.35 (s, 1H), 4.80 (m, 2H), 3.9 (s, 3H), 3.85 (s, 3H), 3.2-3.3 (s, 4H)
- By proceeding analogously and starting from the appropriate haloalkyloxyalkyl(hetero)aryl compounds of the general formula (IVa, Z is O(CH2)m, m≧1) or haloalkylene(hetero)aryl compounds of the general formula (IVb, Y is O(CH2)m—CH, m≧0), the following compounds were obtained:
- 13-[2-(benzyloxy)ethyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[(1,4-benzodioxan-2-yl)methyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[(4-chlorobenzyloxy)methyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[(4-methoxybenzyloxy)methyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[(4-dimethylaminobenzyloxy)methyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[(4-hydroxybenzyloxy)methyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine.
- To a solution of dihydroberberine (338 mg, 1 mmol) and 2-phenoxyethylbromide (2.412 g, 12 mmol) in acetonitrile (25 mL) was added sodium iodide (900 mg, 6 mmol) and the resulting mixture was stirred overnight at reflux temperature under a nitrogen atmosphere. Thereafter the mixture was concentrated under vacuum, diluted with water and the unstable iminium salt filtered off and dried.
- The iminium salt was dissolved in absolute ethanol (20 mL), then sodium borohydride (378 mg, 10 mmol) was added and the resulting suspension stirred for 30 min at room temperature. More sodium borohydride (378 mg, 10 mmol) was added and the mixture stirred for further 1 h at room temperature. The solvent was evaporated under vacuum, then water (60 mL) was added and the mixture extracted with ethyl acetate (3×100 mL). The combined organic phases were dried and evaporated to dryness. The residue was submitted to column chromatography using hexane-ethyl acetate (10-25%) as eluant to obtain the title compound.
- NMR (200 MHz, DMSO-d6) δ: 9.9 (s, 1H), 8.3 (d, 1H), 8.2 (d, 1H), 7.6 (d, 1H), 7.5 (d, 1H), 7.1-7.3 (m, 3H), 6.8 (m, 2H), 4.1 (s, 3H), 4.1 (s, 3H), 4.3 (m, 2H), 4.9 (m, 2H), 6.1 (s, 2H), 5.6 (m, 2H), 3.1 (t, 2H).
- By proceeding analogously and starting from the appropriate haloalkyloxy(hetero)aryl compounds of the general formula (IVa, Z is O(CH2)m, m=0), the following compounds were obtained:
- 13-[3-(phenoxy)propyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[2-(p-chlorophenoxy)ethyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[2-(p-methoxyphenoxy)ethyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[2-(p-hydroxyphenoxy)ethyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[3-(p-chlorophenoxy)propyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[3-(p-methoxyphenoxy)propyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[3-(p-hydroxyphenoxy)propyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine.
- A solution of the 13-acetic acid tetrahydroberberine of Preparative Example 4 (334 mg, 0.84 mmol) and benzylamine (180 mg, 1.68 mmol) in DMF (10 mL) was treated with 1-(3-dimethylaminopropyl)-3-ethyl carbodiimide hydrochloride (322 mg, 1.68 mmol) and dimethylaminopyridine (256 mg, 2.1 mmol) and the resulting solution was stirred for 24 h at room temperature. The reaction mixture was poured into ethyl acetate, and the organic phase washed with 10% HCl solution (2×50 ml) and saturated NaHCO3 solution (2×20 ml). The organic phase was dried, concentrated and the residue chromatographed on a silica gel column eluting with hexane:ethyl acetate 8:2 to give the title compound in 75% yield (306 mg).
- NMR (200 MHz, DMSO-d6) δ: 8.1 (m, 1H), 7.2 (m, 3H), 7.1 (m, 2H), 6.8 (d, 1H), 6.7 (s,d,1H), 6.65 (m, 1H), 5.95 (s, 2H), 4.30 (m, 2H), 4.10 (m, 2H), 3.7 (s, 6H), 3.65 (m, 2H), 2.5 (d, 2H), 2.4 (d,2H).
- By proceeding analogously and starting from the appropriate 13-alkanoic acid tetrahydroprotoberberines of the general formula (IX) and the appropriate amine derivatives of the general formulae (X), (XI), and (XII), the following compounds were obtained:
- 13-phenylaminocarbonylethyl-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine; NMR (200 MHz, DMSO-d6): δ 9.6 (s, 1H), 7.5 (d, 2H), 7.25 (d, d, 3H), 7.0 (d, 2H), 6.9 (d, 1H), 6.8 (s, 1H), 6.8 (s, 1H), 6.6 (m, 1H), 4.1 (d, 2H), 3.8 (s, 6H), 3.7 (m, 2H), 2.5 (d, 2H), 2.4 (d, 2H);
- 13-[(4-pyridyl)aminocarbonylmethyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine; NMR (200 MHz, DMSO-d6): δ 10.0 (s, 1H), 8.4 (d, 2H), 7.5 (d, 2H), 7.0 (m, 4H), 6.7 (m, 1H), 6.0 (s, 1H), 5.9 (s, 1H), 4.15 (d, 2H), 3.9 (s, 6H), 3.8 (m, 2H), 2.6 (d, 2H), 2.5 (d, 2H);
- 13-[(1-indolyl)carbonylmethyl)-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[(p-chlorobenzyl)aminocarbonylmethyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[(p-methoxybenzyl)aminocarbonylmethyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[(p-dimethylaminobenzyl)aminocarbonylmethyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[(p-hydroxybenzyl)aminocarbonymethyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[(p-chlorophenyl)aminocarbonylmethyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[(p-methoxyphenyl)aminocarbonylmethyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-obenzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[(p-dimethylaminophenyl)aminocarbonylmethyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[(p-hydroxyphenyl)aminocarbonylmethyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[(5-chloroindol-1-yl)carbonylmethyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[(5-methoxyindol-1-yl)carbonylmethyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[(5-hydroxyindol-1-yl)carbonylmethyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[(5-dimethylaminoindol-1-yl)carbonylmethyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine.
- Triethylamine (1.02 g, 1.02 mmol) and diphenylphosphorylazide (2.75 g, 10 mmol) were added under stirring at room temperature to a suspension of 13-(carboxymethyl)-tetrahydroberberine (3.972 g, 10 mmol) in acetonitrile (30 mL). After 2 h additional stirring at room temperature the mixture was partitioned between chloroform and 5% aqueous sodium bicarbonate. The combined organic phases were dried and evaporated to give 13-(azidocarbonylmethyl)-tetrahydroberberine (3.80 g, 90% yield).
- A stirred suspension of the 13-(azidocarbonylmethyl)-tetrahydroberberine (3.80 g, 9 mmol) so obtained, phenylacetic acid (1.226 g, 9 mmol), and triethylamine (0.911 g, 9 mmol) in benzene was heated at reflux in a nitrogen atmosphere for about 8 h. The reaction mixture was cooled, the precipitate filtered, washed with small portions of benzene and then chromatographed on a silica gel column using hexane—ethyl acetate 8:2 as eluant to give the title compound (3.063 g, 70% yield).
- NMR (200 MHz, DMSO-d6) δ: 8.2 (m,1H), 7.3 (m, 3H), 7.2 (m, 2H), 6.9 (d, 1H), 6,8 (d, 1H), 6.7 (s, 2H), 6.6 (m, 1H), 6.0 (s, 2H), 4.3 (m, 2H), 4.2 (m, 2H), 3,7 (s, 6H), 3.65 (m, 2H), 2.55 (m, 2H), 2.5 (d, 2H).
- By proceeding analogously and starting from the appropriate 13-alkanoic acid tetrahydroprotoberberines of the general formula (IX) and the appropriate acid derivatives of the general formulae (XIV), (XV), and (XVI), the following compounds were obtained:
- 13-phenylcarbonylaminomethyl-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[(4-pyridyl)carbonylaminomethyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[(p-chlorobenzyl)carbonylaminomethyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[(p-methoxybenzyl)carbonylaminomethyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[(p-hydroxybenzyl)carbonylaminomethyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[(p-chlorophenyl)carbonylaminomethyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[(p-methoxyphenyl)carbonylaminomethyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine;
- 13-[(p-hydroxyphenyl)carbonylaminomethyl]-9,10-dimethoxy-5,8,13,13a-tetrahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine.
- To a solution of 13-[(2-(phenyl)ethyl]-tetrahydroberberine (1 mmol, 445 mg) in absolute ethanol (30 mL) was added iodine (762 mg, 3 mmol) and the mixture refluxed for 6 h. More iodine (1.5 mmol, 381 mg) was then added and the mixture refluxed for further 10 h. The excess iodine was decomposed by addition of sodium thiosulfate until the brown solution changed to yellow colour and a yellow precipitate was formed. The solid was filtered off and the filtrate evaporated to dryness. The residue was chromatographed on a silica gel column eluting with 1-3% methanol in dichloromethane to give 512 mg of title compound (90% yield).
- NMR (200 MHz, DMSO-d6) δ: 10.5 (s, 1H), 7.7 (d, 1H), 7.6 (d, 1H), 7.2 (m, 3H), 7.1 (d, 3H), 6.9 (s, 1H), 6.8 (s, 1H), 6.0 (s, 2H), 5.2 (m, 2H), (4.7 (m, 4H), 4.3 (s, 3H), 4.1 (s, 3H), 3.2 (t, 2H).
- By proceeding analogously and starting from the appropriate 13-substituted tetrahydroprotoberberines as prepared as described in the above Examples 1-5, the following compounds of the invention were obtained:
- 13-[2-(4-chlorophenyl)ethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide; NMR (200 MHz, DMSO-d6) δ: 10.02 (s,1H), 9.87 (s, 1H), 9.86 (s,1H), 8.33 (d, 1H), 8.24 (d, 1H), 7.95 (d, 1H), 7.38 (d, 2H), 7.22 (d,2H), 7.05 (s, 2H), 6.16 (s, 2H), 4.12 (s, 3H), 4.11 (s,3H), 4.02 (m, 2H), 3.29 (t, 2H), 2.88 (m, 4H);
- 13-[2-(4-methoxyphenyl)ethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide; NMR (200 MHz, DMSO-d6) δ: 9.86 (s, 1H), 8.32 (d, 1H), 7.85 (d,1H), 7.40 (s,1H), 7.07 (s, 1H), 6.76 (m, 4H), 6.54 (d, 1H), 6.17 (s, 2H), 6.04 (t, 1H), 4.73 (m, 2H), 4.12 (s, 3H), 3.70 (s, 3H), 3.28 (t, 2H), 2.89 (m, 4H);
- 13-[2-(4-methylphenyl)ethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[2-(4-fluorophenyl)ethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[2-(4-bromophenyl)ethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[2-(4-trifluoromethylphenyl)ethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[2-(4-trifluoromethoxyphenyl)ethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[2-(4-nitrophenyl)ethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[2-(4-dimethylaminophenyl)ethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[2-(4-acetylaminophenyl)ethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[2-(4-ethoxycarbonylphenyl)ethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[2-(naphth-1-yl)ethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide; NMR (200 MHz, DMSO-d6) δ: 9.90 (s, 1H), 8.2 (m, 2H), 8.0 (m, 2H), 7.8 (d, 2H), 7.1 (d, 2H), 6.15 (s, 2H), 4.9 (m, 2H), 4.13 (s, 3H), 4.10 (s, 3H), 3.5 (s, 2H), 3.2 (m, 2H);
- 13-[2-(4-chloronaphth-1-yl)ethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[2-(4-methoxynaphth-1-yl)ethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[2-(4-nitronaphth-1-yl)ethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[2-(4-ethoxycarbonylnaphth-1-yl)ethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[2-(indol-3-yl)ethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide; NMR (200 MHz, DMSO-d6) δ: 9.85 (s, 1H), 8.9 (s, 1H), 7.9-8.3 (m, 4H), 6.8-7.4 (m, 8H), 7.8 (d, 11H), 7.7 (d, 1H), 7.3 (s, 1H), 4.15 (s, 3H), 4.10 (s, 3H), 3.1 (d, 2H), 2.5-2.8 (m, 4H);
- 13-[2-(5-chloroindol-3-yl)ethyl)]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[2-(5-nitroindol-3-yl)ethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[2-(5-methoxyindol-3-yl)ethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[2-(5-ethoxycarbonylindol-3-yl)ethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[3-(phenyl)propyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide; NMR (200 MHz, DMSO-d6) δ: 9.88 (s, 1H), 8.19 (d, 1H), 8.20 (d, 1H), 7.70 (m, 1H), 7.29 (s, 1H), 7.16 (s, 1H), 6.18 (s, 2H), 4.80 (m, 2H), 4.00 (s, 3H), 3.10 (t, 2H), 2.50 (m, 4H);
- 13-[3-(4-chlorophenyl)propyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[3-(4-fluorophenyl)propyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[3-(4-bromophenyl)propyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[3-(4-methylphenyl)propyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[3-(4-methoxyphenyl)propyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[3-(4-trifluoromethoxyphenyl)propyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[3-(4-trifluoromethylphenyl)propyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[3-(4-nitrophenyl)propyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[3-(4-dimethylaminophenyl)propyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[3-(4-acetamidophenyl)propyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[3-(4-ethoxycarbonylphenyl)propyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[3-(4-phenoxyphenyl)propyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[3-(naphth-1-yl)propyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[3-(4-chloronaphth-1-yl)propyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[3-(4-methoxynaphth-1-yl)propyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[3-(4-nitronaphth-1-yl)propyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[3-(4-carbethoxynaphth-1-yl)propyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-(3-indolylpropyl)-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[3-(5-chloroindol-3-yl)propyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[3-(5-nitroindol-3-yl)propyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[3-(5-methoxyindol-3-yl)propyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[3-(5-carbethoxyindol-3-yl)propyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[(1,4-benzodioxan-2-yl)methyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium chloride;
- 13-[2,2-bis(phenyl)ethyl)-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[2,2-bis(4-chlorophenyl)ethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[2,2-bis(4-bromophenyl)ethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[2,2-bis(4-fluorophenyl)ethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[2,2-bis(4-methylphenyl)ethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[2,2-bis(4-methoxyphenyl)ethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[3,3-bis(phenyl)propyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide; NMR (200 MHz, DMSO-d6) δ: 9.90 (s, 1H), 8.2 (d, 1H), 8.1 (d, 1H), 7.2 (m, 10H), 7.1 (s, 2H), 6.2 (s, 2H), 4.8 (m, 2H), 4.15 (s, 3H), 4.10 (s, 3H), 4.0 (d, 1H), 3.2 (t, 2H), 2.5 (m, propyl);
- 13-[3,3-bis(4-methylphenyl)propyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[3,3-bis(4-methoxyphenyl)propyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[3,3-bis(4-fluorophenyl)propyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[3,3-bis(4-chlorophenyl)propyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[3,3-bis(4-bromophenyl)propyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-benzyloxymethyl-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide; NMR (200 MHz, DMSO-d6) δ: 9.5 (s, 1H), 7.90 (d, 1H), 7.85 (d, 1H), 7.0-7.6 (m, 5H), 5.8 (s, 2H), 7.4 (s, 1H), 7.3 (s, 1H), 4.8 m, 2H), 3.8 (s, 3H), 3.9 (s, 3H), 3.2 (s, 4H);
- 13-[2-(phenoxy)ethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[2-(benzyloxy)ethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[3-(phenoxy)propyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[(1,4-benzodioxan-2-yl)methyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide; NMR (200 MHz, DMSO-d6) δ: 9.9 (s, 1H), 8.2 (d, 1H), 8.2 (d, 1H), 6.1 (s, 2H), 4.1 (s, 3H), 4.1 (s, 3H), 7.4 (s, 1H), 7.1 (s, 1H), 7.0-7.6 (m, 4H), 5.9-6.0 (m, 4H), 4.9 (m, 2H), 3.1 (t, 2H), 3.5 (d, 2H);
- 13-[(4-chlorobenzyloxy)methyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[(4-methoxybenzyloxy)methyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[(4-dimethylaminobenzyloxy)methyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[(4-hydroxybenzyloxy)methyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[2-(p-chlorophenoxy)ethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[2-(p-methoxyphenoxy)ethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[2-(p-hydroxyphenoxy)ethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[2-(p-chlorobenzyloxy)ethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[2-(p-methoxybenzyloxy)ethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[2-(p-hydroxybenzyloxy)ethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[3-(p-chlorophenoxy)propyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[3-(p-methoxyphenoxy)propyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[3-(p-hydroxyphenoxy)propyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[2-(diphenylmethyloxy)ethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-diphenylmethyloxymethyl-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-benzylaminocarbonylmethyl-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide; NMR (200 MHz, DMSO-d6) δ:10.0 (s, 1H), 9.1 (m, 1H), 8.15 (d, 1H), 7.95 (d, 1H), 7.55-7.10 (m, 9H), 6.10 (s, 1H), 4.8 (m, 2H), 4.45 (d, 2H), 4.30 (d, 2H), 4.10 (s, 3H), 4.08 (s, 3H), 3.50 (d, 2H);
- 13-phenylaminocarbonylmethyl-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide; NMR (200 MHz, DMSO-d6) δ: 10.7 (s, 1H), 10.0 (s, 1H), 8.2 (d, 1H), 8.1 (d, 1H), 7.7 (m, 3H), 7.5 (s, 2H), 7.35 (m, 2H), 7.2 (s, 1H), 7.1 (s, 1H), 6.1 (s, 2H), 4.85 (d, 2H), 4.5 (s, 2H), 4.1 (s, 2H), 4.1 (s, 2H), 3.20 (d, 2H);
- 13-[(4-pyridyl)aminocarbonylmethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide; NMR (200 MHz, DMSO-d6) δ: 11.1 (s, 1H), 10.0 (s, 1H), 8.5 (d, 2H), 8.2 (d, 1H), 8.0 (d, 1H), 7.6 (m, 2H), 7.3 (s, 1H), 7.2 (s, 1H), 6.1 (s, 2H), 4.9 (m, 2H), 4.1 (s, 3H), 4.15 (s, 3H), 3.5 (s, 2H), 3.2 (s, 2H);
- 13-[(1-indolyl)carbonylmethyl)-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[(p-chlorobenzyl)aminocarbonylmethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[(p-methoxybenzyl)aminocarbonylmethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[(p-dimethylaminobenzyl)aminocarbonylmethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[(p-hydroxybenzyl)aminocarbonymethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[(p-chlorophenyl)aminocarbonylmethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[(p-methoxyphenyl)aminocarbonylmethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[(p-dimethylaminophenyl)aminocarbonylmethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[(p-hydroxyphenyl)aminocarbonylmethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[(5-chloroindol-1-yl)carbonylmethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide; NMR (200 MHz, DMSO-d6) δ: 10.0 (s, 1H), 7.9-8.3)m, 4H), 7.8 (d,1H), 7.7 (d, 1H), 7.4 (d, 1H), 7.2 (d, 1H), 6.9-7.1 (m, 1H), 6,1 (s, 1H), 6.2 (s, 1H), 5.3 (s, 2H), 4.9 (m, 2H), 4.15 (s, 3H), 4.10 (3H), 3.3 (m, 2H)
- 13-[(5-methoxyindol-1-yl)carbonylmethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[(5-hydroxyindol-1-yl)carbonylmethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[(5-dimethylaminoindol-1-yl)carbonylmethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-benzylcarbonylaminomethyl-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-phenylcarbonylaminomethyl-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[(4-pyridyl)carbonylaminomethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[(p-chlorobenzyl)carbonylaminomethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[(p-methoxybenzyl)carbonylaminomethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[(p-hydroxybenzyl)carbonylaminomethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[(p-chlorophenyl)carbonylaminomethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide;
- 13-[(p-methoxyphenyl)carbonylaminomethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide; and
- 13-[(p-hydroxyphenyl)carbonylaminomethyl]-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide.
- To a solution of 13-[2-(phenoxy)ethyl]-tetrahydroberberine (446 mg, 1 mmol) in chloroform (25 mL) was added N-chlorosuccinimide (320 mg, 2.4 mmol) and the mixture refluxed for 3 h. The organic phase was washed with water, dried and evaporated under vacuum. The residue was chromatographed on a silica gel column and eluting with DCM—MeOH 1-3% to give 287 mg of title compound (60% yield).
- NMR (200 MHz, DMSO-d6) δ: 9.9 (s, 1H), 8.3 (d, 1H), 8.2 (d, 1H), 7.6 (d, 1H), 7.5 (d, 1H), 7.1-7.3 (m, 3H), 6.8 (m, 2H), 6.1 (s, 2H), 5.6 (m, 2H ), 4.9 m, 2H), 4.3 (m, 2H), 4.1 (s, 3H), 4.05 (s, 3H), 3.1 (t, 2H)
- To 393 mg (1 mmol) of acetonylberberine dissolved in 20 ml of acetonitrile were added 2.985 g (15 mmol) of 3-phenylpropylbromide and 450 mg (3 mmol) of sodium iodide. The reaction mixture was refluxed for 6 h, then concentrated under vacuum and finally purified by column chromatography with dichlorometane-methanol 4% as eluant to give 47 mg of title compound (89% yield).
- NMR (200 MHz, DMSO-d6) δ: 9.88 (s, 1H), 8.19 (d, 1H), 8.20 (d,1H), 7.70 (s,1H), 7.29 (s, 1H), 7.16 (s, 1H), 6.18 (s, 2H), 4.80 (m, 2H), 4.00 (s,3H), 4.20 (s, 3H), 3.10 (t, 2H), 2.50 (m, 4H)
- 0.15 mmol of a compound of formula (I) and 0.38 mmol of beta-cyclodextrin are dissolved in 100 mL of water with stirring for 6 hours. The resulting product is separated by precipitation by cooling the solution at 3° C. or, alternatively, by freeze-drying the solution.
- 2.64 mmol of gamma-cyclodextrin are dissolved in 100 mL of water by applying a gentle heating. To the resulting solution there are added 1.06 mmol of a compound of formula (I) with stirring for 6-12 hours. The product is separated by precipitation by cooling the solution at 3° C. or, alternatively, by freeze-drying the solution.
- Mixtures of a compound of formula (I) and of different amounts of beta-cyclodextrin, or gamma-cyclodextrin are prepared by grinding, followed by sieving (<0.375 mm) and 10 minute of mixing in a turbo-mixer.
Claims (20)
Hal-(CH2)n-Z—Ar (IVa)
(IVa) Hal-(CH2)n—Y═(Ar)2 (IVb)
Hal-(CH)nCOOR5 (VI)
H2N(CH2)m—Ar (X)
(X) HN(Ar)2 (XI)
H2N(CH2)m—CH(Ar)2 (XII)
HOOC(CH2)m—Ar (XIV)
HOOCCH(Ar)2 (XV)
HOOC(CH2)m—CH(Ar)2 (XVI)
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/458,657 US8188109B2 (en) | 2009-07-20 | 2009-07-20 | Benzoquinolizinium salt derivatives as anticancer agents |
PCT/EP2010/059654 WO2011009714A2 (en) | 2009-07-20 | 2010-07-06 | Benzoquinolizinium salt derivatives as anticancer agents |
AU2010275640A AU2010275640A1 (en) | 2009-07-20 | 2010-07-06 | Benzoquinolizinium salt derivatives as anticancer agents |
ES10730174.9T ES2617187T3 (en) | 2009-07-20 | 2010-07-06 | Benzoquinolizinium salt derivatives as anticancer agents |
NZ597916A NZ597916A (en) | 2009-07-20 | 2010-07-06 | Benzoquinolizinium salt derivatives as anticancer agents |
CA2767463A CA2767463A1 (en) | 2009-07-20 | 2010-07-06 | Benzoquinolizinium salt derivatives as anticancer agents |
EP10730174.9A EP2456770B1 (en) | 2009-07-20 | 2010-07-06 | Benzoquinolizinium salt derivatives as anticancer agents |
JP2012520987A JP5778145B2 (en) | 2009-07-20 | 2010-07-06 | Benzoquinolizinium salt derivatives as anticancer agents |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/458,657 US8188109B2 (en) | 2009-07-20 | 2009-07-20 | Benzoquinolizinium salt derivatives as anticancer agents |
Publications (2)
Publication Number | Publication Date |
---|---|
US20110015222A1 true US20110015222A1 (en) | 2011-01-20 |
US8188109B2 US8188109B2 (en) | 2012-05-29 |
Family
ID=42865611
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/458,657 Active 2030-10-13 US8188109B2 (en) | 2009-07-20 | 2009-07-20 | Benzoquinolizinium salt derivatives as anticancer agents |
Country Status (8)
Country | Link |
---|---|
US (1) | US8188109B2 (en) |
EP (1) | EP2456770B1 (en) |
JP (1) | JP5778145B2 (en) |
AU (1) | AU2010275640A1 (en) |
CA (1) | CA2767463A1 (en) |
ES (1) | ES2617187T3 (en) |
NZ (1) | NZ597916A (en) |
WO (1) | WO2011009714A2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102746292A (en) * | 2011-04-18 | 2012-10-24 | 中国医学科学院医药生物技术研究所 | Cyclized berberine derivatives, preparation method and uses thereof |
CN106083842A (en) * | 2016-06-29 | 2016-11-09 | 合肥华方医药科技有限公司 | The Preparation method and use of 9 substituted double-functional group berberinc derivates |
CN114591335A (en) * | 2021-03-29 | 2022-06-07 | 浙江大学 | Indazole compound and preparation method and application thereof |
CN117105930A (en) * | 2023-10-23 | 2023-11-24 | 中国医学科学院医药生物技术研究所 | 3, 13-disubstituted berberine derivative, and preparation method and application thereof |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2477723C2 (en) | 2011-06-16 | 2013-03-20 | Общество С Ограниченной Ответственностью "Фьюжн Фарма" | Protein kinase inhibitor (versions), use thereof for treating oncological diseases and based pharmaceutical composition |
CN103755631B (en) * | 2014-01-07 | 2016-03-02 | 常州工程职业技术学院 | The direct aromatize technique of pyridine derivate |
CN108610342B (en) * | 2018-06-13 | 2020-12-15 | 中南大学 | Novel aza-polycyclic compound and preparation method and application thereof |
CN111349092B (en) * | 2020-04-22 | 2021-03-12 | 山东大学 | Mitochondrial targeting compound and preparation method and application thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6008356A (en) * | 1998-04-24 | 1999-12-28 | Hanwha Corporation | Pharmaceutically available protoberberine salts derivatives, and protoberberine salts derivatives, and protoberberine derivatives and salts thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3920665A (en) | 1972-10-19 | 1975-11-18 | Kanebo Ltd | Berbine compounds |
US3910938A (en) | 1973-01-27 | 1975-10-07 | Kanebo Ltd | Berbine derivatives |
JPS52128234A (en) * | 1976-04-19 | 1977-10-27 | Kanebo Ltd | Anticarcinogens |
IT1243389B (en) | 1990-11-22 | 1994-06-10 | Menarini Farma Ind | POLYAMINE-PYRROLCARBOXIDE DERIVATIVES, PREPARATION PROCESSES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
PL328402A1 (en) * | 1996-02-12 | 1999-01-18 | Rutgers | Analoques of coralline as inhibitors of topoisomerase |
JPH1036263A (en) * | 1996-07-25 | 1998-02-10 | Kureha Chem Ind Co Ltd | Corydaline derivative-containing synthesis inhibitor of protein belonging to hsp27 family |
KR20000021073A (en) | 1998-09-25 | 2000-04-15 | 박원배 | Inhibitors for biosynthesis of cholesterol |
KR20010112798A (en) | 2000-06-15 | 2001-12-22 | 송기원 | Protoberberine derivatives which inhibit activity of the mitogen-activated-protein kinases |
KR100706309B1 (en) * | 2006-02-14 | 2007-04-12 | 한국생명공학연구원 | Berberrubine derivatives having antifungal activities |
CN101153039B (en) | 2006-09-30 | 2010-12-01 | 中国科学院上海药物研究所 | 13, 13a- dihydro berberine derivant and pharmaceutical composition |
US8003795B2 (en) | 2007-06-22 | 2011-08-23 | Cvi Pharmaceuticals Limited | Compounds and compositions for reducing lipid levels |
-
2009
- 2009-07-20 US US12/458,657 patent/US8188109B2/en active Active
-
2010
- 2010-07-06 NZ NZ597916A patent/NZ597916A/en not_active IP Right Cessation
- 2010-07-06 CA CA2767463A patent/CA2767463A1/en not_active Abandoned
- 2010-07-06 JP JP2012520987A patent/JP5778145B2/en active Active
- 2010-07-06 EP EP10730174.9A patent/EP2456770B1/en active Active
- 2010-07-06 AU AU2010275640A patent/AU2010275640A1/en not_active Abandoned
- 2010-07-06 WO PCT/EP2010/059654 patent/WO2011009714A2/en active Application Filing
- 2010-07-06 ES ES10730174.9T patent/ES2617187T3/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6008356A (en) * | 1998-04-24 | 1999-12-28 | Hanwha Corporation | Pharmaceutically available protoberberine salts derivatives, and protoberberine salts derivatives, and protoberberine derivatives and salts thereof |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102746292A (en) * | 2011-04-18 | 2012-10-24 | 中国医学科学院医药生物技术研究所 | Cyclized berberine derivatives, preparation method and uses thereof |
CN106083842A (en) * | 2016-06-29 | 2016-11-09 | 合肥华方医药科技有限公司 | The Preparation method and use of 9 substituted double-functional group berberinc derivates |
CN114591335A (en) * | 2021-03-29 | 2022-06-07 | 浙江大学 | Indazole compound and preparation method and application thereof |
CN117105930A (en) * | 2023-10-23 | 2023-11-24 | 中国医学科学院医药生物技术研究所 | 3, 13-disubstituted berberine derivative, and preparation method and application thereof |
Also Published As
Publication number | Publication date |
---|---|
ES2617187T8 (en) | 2017-08-16 |
NZ597916A (en) | 2013-08-30 |
WO2011009714A2 (en) | 2011-01-27 |
WO2011009714A3 (en) | 2011-09-15 |
ES2617187T3 (en) | 2017-06-15 |
EP2456770B1 (en) | 2016-12-14 |
AU2010275640A1 (en) | 2012-02-16 |
US8188109B2 (en) | 2012-05-29 |
CA2767463A1 (en) | 2011-01-27 |
EP2456770A2 (en) | 2012-05-30 |
JP2012533590A (en) | 2012-12-27 |
AU2010275640A8 (en) | 2012-06-28 |
JP5778145B2 (en) | 2015-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8188109B2 (en) | Benzoquinolizinium salt derivatives as anticancer agents | |
US11535585B2 (en) | Nitrobenzyl derivatives of anti-cancer agents | |
CN106488910B (en) | Inhibitors of KRAS G12C | |
CN102510863B (en) | Pyrazole derivatives | |
Chia et al. | Synthesis and anti-inflammatory structure–activity relationships of thiazine–quinoline–quinones: Inhibitors of the neutrophil respiratory burst in a model of acute gouty arthritis | |
KR100193593B1 (en) | 6,9-bis (substituted amino) benzo [G] isoquinoline-5,10- dione and pharmaceutical composition comprising the same | |
Luo et al. | Isolation, synthesis and bioactivity evaluation of isoquinoline alkaloids from Corydalis hendersonii Hemsl. against gastric cancer in vitro and in vivo | |
JP2003525940A (en) | 1,8-Naphthalimidimidazo [4,5,1-de] acridones having anti-tumor activity | |
EP2556081A2 (en) | A cytosine analogue, a method of preparation of a cytosine analogue, a dna methyltransferase 1 inhibitor, a method for dna methylation inhibition, the use of the analogue in the treatment of diseases associated with deviations from normal dna methylation | |
JP2003520819A (en) | New compounds | |
RU2418795C2 (en) | Dioxolane derivatives for cancer treatment | |
KR20010006453A (en) | 6,7-Disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds | |
CN111333655A (en) | Triazolopyrimidine compound and preparation method and application thereof | |
JP2019521164A (en) | Inhibitors of microbial β-glucuronidase enzymes and uses thereof | |
EP1758904B1 (en) | Flavopereirine derivatives for cancer therapy | |
CN115572247B (en) | Vitamin K 3 Derivatives and medical use thereof | |
CN108137592B (en) | Deuterated compounds and compositions and methods thereof for treating leukemia | |
SK140099A3 (en) | 5,6,7-trisubstituted-4-aminopyridol[2,3-d]pyrimidine compounds | |
CN101703507B (en) | Antineoplastic medicament |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: NAXOSPHARMA S.R.L., ITALY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LOMBARDI, PAOLO;BUZZETTI, FRANCO;ARCAMONE, ANDREA GUIDO;REEL/FRAME:023029/0749 Effective date: 20090714 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2552); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY Year of fee payment: 8 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2553); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY Year of fee payment: 12 |